Unnamed: 0
stringlengths 3
8
| Date
stringlengths 23
23
| Article_title
stringlengths 1
250
| Stock_symbol
stringlengths 1
5
| Url
stringlengths 44
135
| Publisher
stringclasses 1
value | Author
stringclasses 1
value | Article
stringlengths 1
343k
| Lsa_summary
stringlengths 3
53.9k
| Luhn_summary
stringlengths 1
53.9k
| Textrank_summary
stringlengths 1
53.9k
| Lexrank_summary
stringlengths 1
53.9k
| uuid
stringlengths 36
36
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
728400.0
|
2016-02-29 00:00:00 UTC
|
Insiders Bullish on Certain Holdings of DES
|
DES
|
https://www.nasdaq.com/articles/insiders-bullish-certain-holdings-des-2016-02-29
|
nan
|
nan
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 18.4% of holdings on a weighted basis have experienced insider buying within the past six months.
Allegheny Technologies, Inc (Symbol: ATI), which makes up 0.57% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $6,151,972 worth of ATI, making it the #20 largest holding. The table below details the recent insider buying activity observed at ATI:
ATI - last trade: $12.32 - Recent Insider Buys:
And DSW Inc (Symbol: DSW), the #26 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $5,966,527 worth of DSW, which represents approximately 0.55% of the ETF's total assets at last check. The recent insider buying activity observed at DSW is detailed in the table below:
DSW - last trade: $26.46 - Recent Insider Buys:
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 18.4% of holdings on a weighted basis have experienced insider buying within the past six months. Allegheny Technologies, Inc (Symbol: ATI), which makes up 0.57% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ATI: ATI - last trade: $12.32 - Recent Insider Buys: And DSW Inc (Symbol: DSW), the #26 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 2 directors and officers as recently filing Form 4's indicating purchases.
|
Allegheny Technologies, Inc (Symbol: ATI), which makes up 0.57% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ATI: ATI - last trade: $12.32 - Recent Insider Buys: And DSW Inc (Symbol: DSW), the #26 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 2 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 18.4% of holdings on a weighted basis have experienced insider buying within the past six months.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 18.4% of holdings on a weighted basis have experienced insider buying within the past six months. The table below details the recent insider buying activity observed at ATI: ATI - last trade: $12.32 - Recent Insider Buys: And DSW Inc (Symbol: DSW), the #26 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 2 directors and officers as recently filing Form 4's indicating purchases. Allegheny Technologies, Inc (Symbol: ATI), which makes up 0.57% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data.
|
Allegheny Technologies, Inc (Symbol: ATI), which makes up 0.57% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 5 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at ATI: ATI - last trade: $12.32 - Recent Insider Buys: And DSW Inc (Symbol: DSW), the #26 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 2 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 18.4% of holdings on a weighted basis have experienced insider buying within the past six months.
|
b1a23acd-4fee-4f9a-8512-449df81b82ef
|
728401.0
|
2016-02-19 00:00:00 UTC
|
Insiders Pile Into Holdings of DES ETF
|
DES
|
https://www.nasdaq.com/articles/insiders-pile-holdings-des-etf-2016-02-19
|
nan
|
nan
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 20.5% of holdings on a weighted basis have experienced insider buying within the past six months.
Lexmark International, Inc. (Symbol: LXK), which makes up 0.66% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $6,819,948 worth of LXK, making it the #14 largest holding. The table below details the recent insider buying activity observed at LXK:
LXK - last trade: $30.75 - Recent Insider Buys:
And Time Inc (Symbol: TIME), the #20 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $6,057,390 worth of TIME, which represents approximately 0.59% of the ETF's total assets at last check. The recent insider buying activity observed at TIME is detailed in the table below:
TIME - last trade: $14.13 - Recent Insider Buys:
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 20.5% of holdings on a weighted basis have experienced insider buying within the past six months. Lexmark International, Inc. (Symbol: LXK), which makes up 0.66% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at LXK: LXK - last trade: $30.75 - Recent Insider Buys: And Time Inc (Symbol: TIME), the #20 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases.
|
Lexmark International, Inc. (Symbol: LXK), which makes up 0.66% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at LXK: LXK - last trade: $30.75 - Recent Insider Buys: And Time Inc (Symbol: TIME), the #20 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 20.5% of holdings on a weighted basis have experienced insider buying within the past six months.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 20.5% of holdings on a weighted basis have experienced insider buying within the past six months. The table below details the recent insider buying activity observed at LXK: LXK - last trade: $30.75 - Recent Insider Buys: And Time Inc (Symbol: TIME), the #20 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases. Lexmark International, Inc. (Symbol: LXK), which makes up 0.66% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data.
|
Lexmark International, Inc. (Symbol: LXK), which makes up 0.66% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at LXK: LXK - last trade: $30.75 - Recent Insider Buys: And Time Inc (Symbol: TIME), the #20 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 20.5% of holdings on a weighted basis have experienced insider buying within the past six months.
|
5fdd42f0-2bb6-42f0-a35a-565d63b35744
|
728402.0
|
2016-02-11 00:00:00 UTC
|
Strong Insider Buying Found in the Underlying Holdings of DES
|
DES
|
https://www.nasdaq.com/articles/strong-insider-buying-found-underlying-holdings-des-2016-02-11
|
nan
|
nan
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 21.1% of holdings on a weighted basis have experienced insider buying within the past six months.
Pattern Energy Group Inc (Symbol: PEGI), which makes up 0.74% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $7,658,560 worth of PEGI, making it the #9 largest holding. The table below details the recent insider buying activity observed at PEGI:
PEGI - last trade: $15.51 - Recent Insider Buys:
And Joy Global Inc (Symbol: JOY), the #16 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 5 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $5,879,487 worth of JOY, which represents approximately 0.57% of the ETF's total assets at last check. The recent insider buying activity observed at JOY is detailed in the table below:
JOY - last trade: $10.70 - Recent Insider Buys:
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 21.1% of holdings on a weighted basis have experienced insider buying within the past six months. Pattern Energy Group Inc (Symbol: PEGI), which makes up 0.74% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at PEGI: PEGI - last trade: $15.51 - Recent Insider Buys: And Joy Global Inc (Symbol: JOY), the #16 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 5 directors and officers as recently filing Form 4's indicating purchases.
|
Pattern Energy Group Inc (Symbol: PEGI), which makes up 0.74% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at PEGI: PEGI - last trade: $15.51 - Recent Insider Buys: And Joy Global Inc (Symbol: JOY), the #16 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 5 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 21.1% of holdings on a weighted basis have experienced insider buying within the past six months.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 21.1% of holdings on a weighted basis have experienced insider buying within the past six months. The table below details the recent insider buying activity observed at PEGI: PEGI - last trade: $15.51 - Recent Insider Buys: And Joy Global Inc (Symbol: JOY), the #16 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 5 directors and officers as recently filing Form 4's indicating purchases. Pattern Energy Group Inc (Symbol: PEGI), which makes up 0.74% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data.
|
Pattern Energy Group Inc (Symbol: PEGI), which makes up 0.74% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 3 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at PEGI: PEGI - last trade: $15.51 - Recent Insider Buys: And Joy Global Inc (Symbol: JOY), the #16 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 5 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 21.1% of holdings on a weighted basis have experienced insider buying within the past six months.
|
b185789d-b46c-4f3b-9602-37c265561ad7
|
728403.0
|
2016-02-10 00:00:00 UTC
|
Allete, Inc. (ALE) Ex-Dividend Date Scheduled for February 11, 2016
|
DES
|
https://www.nasdaq.com/articles/allete-inc-ale-ex-dividend-date-scheduled-february-11-2016-2016-02-10
|
nan
|
nan
|
Allete, Inc. ( ALE ) will begin trading ex-dividend on February 11, 2016. A cash dividend payment of $0.52 per share is scheduled to be paid on March 01, 2016. Shareholders who purchased ALE prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 2.97% increase over the prior quarter.
The previous trading day's last sale of ALE was $54.65, representing a -3.46% decrease from the 52 week high of $56.61 and a 20.67% increase over the 52 week low of $45.29.
ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). ALE's current earnings per share, an indicator of a company's profitability, is $3.27. Zacks Investment Research reports ALE's forecasted earnings growth in 2015 as 15.72%, compared to an industry average of 1.9%.
For more information on the declaration, record and payment dates, visit the ALE Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ALE through an Exchange Traded Fund [ETF]?
The following ETF(s) have ALE as a top-10 holding:
PowerShares S&P SmallCap Utilities Portfolio ( PSCU )
Victory CEMP US Small Cap High Div Volatility Wtd Index ETF ( CSB )
iShares S&P SmallCap 600 Value ETF ( IJS )
SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is PSCU with an increase of 15.43% over the last 100 days. It also has the highest percent weighting of ALE at 4.85%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) Victory CEMP US Small Cap High Div Volatility Wtd Index ETF ( CSB ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased ALE prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) Victory CEMP US Small Cap High Div Volatility Wtd Index ETF ( CSB ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ).
|
The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) Victory CEMP US Small Cap High Div Volatility Wtd Index ETF ( CSB ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). Shareholders who purchased ALE prior to the ex-dividend date are eligible for the cash dividend payment.
|
ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) Victory CEMP US Small Cap High Div Volatility Wtd Index ETF ( CSB ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). A cash dividend payment of $0.52 per share is scheduled to be paid on March 01, 2016.
|
af1fcb42-1b05-4d3d-bcdb-dbfaf8e02ca1
|
728404.0
|
2016-01-28 00:00:00 UTC
|
Targa Resources, Inc. (TRGP) Ex-Dividend Date Scheduled for January 29, 2016
|
DES
|
https://www.nasdaq.com/articles/targa-resources-inc-trgp-ex-dividend-date-scheduled-january-29-2016-2016-01-28
|
nan
|
nan
|
Targa Resources, Inc. ( TRGP ) will begin trading ex-dividend on January 29, 2016. A cash dividend payment of $0.91 per share is scheduled to be paid on February 09, 2016. Shareholders who purchased TRGP prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 17.42% increase over the same period a year ago.
The previous trading day's last sale of TRGP was $22.49, representing a -79.3% decrease from the 52 week high of $108.63 and a 52.37% increase over the 52 week low of $14.76.
TRGP is a part of the Public Utilities sector, which includes companies such as National Grid Transco, PLC ( NGG ) and Enterprise Products Partners L.P. ( EPD ). TRGP's current earnings per share, an indicator of a company's profitability, is $1.18. Zacks Investment Research reports TRGP's forecasted earnings growth in 2015 as -59.4%, compared to an industry average of -12%.
For more information on the declaration, record and payment dates, visit the TRGP Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to TRGP through an Exchange Traded Fund [ETF]?
The following ETF(s) have TRGP as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an decrease of -8.22% over the last 100 days. It also has the highest percent weighting of TRGP at 0.98%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
TRGP is a part of the Public Utilities sector, which includes companies such as National Grid Transco, PLC ( NGG ) and Enterprise Products Partners L.P. ( EPD ). The following ETF(s) have TRGP as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -8.22% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TRGP is a part of the Public Utilities sector, which includes companies such as National Grid Transco, PLC ( NGG ) and Enterprise Products Partners L.P. ( EPD ). The following ETF(s) have TRGP as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have TRGP as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). TRGP is a part of the Public Utilities sector, which includes companies such as National Grid Transco, PLC ( NGG ) and Enterprise Products Partners L.P. ( EPD ). The top-performing ETF of this group is DES with an decrease of -8.22% over the last 100 days.
|
TRGP is a part of the Public Utilities sector, which includes companies such as National Grid Transco, PLC ( NGG ) and Enterprise Products Partners L.P. ( EPD ). The following ETF(s) have TRGP as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -8.22% over the last 100 days.
|
d05739bb-def2-45e1-9d83-8e167e081c61
|
728405.0
|
2016-01-22 00:00:00 UTC
|
Cal-Maine Foods, Inc. (CALM) Ex-Dividend Date Scheduled for January 25, 2016
|
DES
|
https://www.nasdaq.com/articles/cal-maine-foods-inc-calm-ex-dividend-date-scheduled-january-25-2016-2016-01-22
|
nan
|
nan
|
Cal-Maine Foods, Inc. ( CALM ) will begin trading ex-dividend on January 25, 2016. A cash dividend payment of $0.751 per share is scheduled to be paid on February 11, 2016. Shareholders who purchased CALM prior to the ex-dividend date are eligible for the cash dividend payment. This represents an -23.6% decrease from the prior quarter.
The previous trading day's last sale of CALM was $48.91, representing a -22.67% decrease from the 52 week high of $63.25 and a 43.73% increase over the 52 week low of $34.03.
CALM is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and Altria Group ( MO ). CALM's current earnings per share, an indicator of a company's profitability, is $5.71. Zacks Investment Research reports CALM's forecasted earnings growth in 2016 as 126.43%, compared to an industry average of 3.8%.
For more information on the declaration, record and payment dates, visit the CALM Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CALM through an Exchange Traded Fund [ETF]?
The following ETF(s) have CALM as a top-10 holding:
PowerShares S&P SmallCap Consumer Staples Portfolio ( PSCC )
WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS )
WisdomTree Trust SmallCap Dividend Fund ( DES )
Guggenheim S&P Smallcap 600 Pure Growth ETF ( RZG )
PowerShares Russell 2000 Equal Weight Portfolio ( EQWS ).
The top-performing ETF of this group is PSCC with an decrease of -3.48% over the last 100 days. It also has the highest percent weighting of CALM at 5.44%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CALM is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and Altria Group ( MO ). The following ETF(s) have CALM as a top-10 holding: PowerShares S&P SmallCap Consumer Staples Portfolio ( PSCC ) WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim S&P Smallcap 600 Pure Growth ETF ( RZG ) PowerShares Russell 2000 Equal Weight Portfolio ( EQWS ). Shareholders who purchased CALM prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have CALM as a top-10 holding: PowerShares S&P SmallCap Consumer Staples Portfolio ( PSCC ) WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim S&P Smallcap 600 Pure Growth ETF ( RZG ) PowerShares Russell 2000 Equal Weight Portfolio ( EQWS ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CALM is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and Altria Group ( MO ).
|
The following ETF(s) have CALM as a top-10 holding: PowerShares S&P SmallCap Consumer Staples Portfolio ( PSCC ) WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim S&P Smallcap 600 Pure Growth ETF ( RZG ) PowerShares Russell 2000 Equal Weight Portfolio ( EQWS ). CALM is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and Altria Group ( MO ). Shareholders who purchased CALM prior to the ex-dividend date are eligible for the cash dividend payment.
|
CALM is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and Altria Group ( MO ). The following ETF(s) have CALM as a top-10 holding: PowerShares S&P SmallCap Consumer Staples Portfolio ( PSCC ) WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim S&P Smallcap 600 Pure Growth ETF ( RZG ) PowerShares Russell 2000 Equal Weight Portfolio ( EQWS ). A cash dividend payment of $0.751 per share is scheduled to be paid on February 11, 2016.
|
7ea6d521-a3a5-4e9f-b9be-0ffe0693f563
|
728406.0
|
2015-12-24 00:00:00 UTC
|
Covanta Holding Corporation (CVA) Ex-Dividend Date Scheduled for December 28, 2015
|
DES
|
https://www.nasdaq.com/articles/covanta-holding-corporation-cva-ex-dividend-date-scheduled-december-28-2015-2015-12-24
|
nan
|
nan
|
Covanta Holding Corporation ( CVA ) will begin trading ex-dividend on December 28, 2015. A cash dividend payment of $0.25 per share is scheduled to be paid on January 07, 2016. Shareholders who purchased CVA prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 6th quarter that CVA has paid the same dividend. At the current stock price of $16.25, the dividend yield is 6.15%.
The previous trading day's last sale of CVA was $16.25, representing a -29.46% decrease from the 52 week high of $23.04 and a 18.74% increase over the 52 week low of $13.69.
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). CVA's current earnings per share, an indicator of a company's profitability, is -$.11. Zacks Investment Research reports CVA's forecasted earnings growth in 2015 as -52.99%, compared to an industry average of 16.3%.
For more information on the declaration, record and payment dates, visit the CVA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CVA through an Exchange Traded Fund [ETF]?
The following ETF(s) have CVA as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an decrease of -3.22% over the last 100 days. It also has the highest percent weighting of CVA at 1.08%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The following ETF(s) have CVA as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -3.22% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The following ETF(s) have CVA as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have CVA as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The top-performing ETF of this group is DES with an decrease of -3.22% over the last 100 days.
|
The following ETF(s) have CVA as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The top-performing ETF of this group is DES with an decrease of -3.22% over the last 100 days.
|
482beff1-3351-4044-811e-2aafca294f37
|
728407.0
|
2015-12-09 00:00:00 UTC
|
UIL Holdings Corporation (UIL) Ex-Dividend Date Scheduled for December 10, 2015
|
DES
|
https://www.nasdaq.com/articles/uil-holdings-corporation-uil-ex-dividend-date-scheduled-december-10-2015-2015-12-09
|
nan
|
nan
|
UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on December 10, 2015. A cash dividend payment of $0.432 per share is scheduled to be paid on January 04, 2016. Shareholders who purchased UIL prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 38th quarter that UIL has paid the same dividend. At the current stock price of $47.82, the dividend yield is 3.61%.
The previous trading day's last sale of UIL was $47.82, representing a -8.91% decrease from the 52 week high of $52.50 and a 16.1% increase over the 52 week low of $41.19.
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). UIL's current earnings per share, an indicator of a company's profitability, is $2.12. Zacks Investment Research reports UIL's forecasted earnings growth in 2015 as 6.08%, compared to an industry average of 2.1%.
For more information on the declaration, record and payment dates, visit the UIL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to UIL through an Exchange Traded Fund [ETF]?
The following ETF(s) have UIL as a top-10 holding:
PowerShares S&P SmallCap Utilities Portfolio ( PSCU )
WisdomTree Trust SmallCap Dividend Fund ( DES )
Vanguard S&P Small-Cap 600 Value ETF ( VIOV )
iShares S&P SmallCap 600 Value ETF ( IJS )
SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ).
The top-performing ETF of this group is PSCU with an increase of 9.14% over the last 100 days. It also has the highest percent weighting of UIL at 8.92%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Vanguard S&P Small-Cap 600 Value ETF ( VIOV ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ). Shareholders who purchased UIL prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Vanguard S&P Small-Cap 600 Value ETF ( VIOV ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ).
|
The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Vanguard S&P Small-Cap 600 Value ETF ( VIOV ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on December 10, 2015.
|
The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Vanguard S&P Small-Cap 600 Value ETF ( VIOV ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). A cash dividend payment of $0.432 per share is scheduled to be paid on January 04, 2016.
|
7d29d747-5e54-4aae-ad31-a1b8858270bb
|
728408.0
|
2015-11-25 00:00:00 UTC
|
NRG Yield, Inc. (NYLD) Ex-Dividend Date Scheduled for November 27, 2015
|
DES
|
https://www.nasdaq.com/articles/nrg-yield-inc-nyld-ex-dividend-date-scheduled-november-27-2015-2015-11-25
|
nan
|
nan
|
NRG Yield, Inc. ( NYLD ) will begin trading ex-dividend on November 27, 2015. A cash dividend payment of $0.215 per share is scheduled to be paid on December 15, 2015. Shareholders who purchased NYLD prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 2.38% increase over the prior quarter. At the current stock price of $15.29, the dividend yield is 5.62%.
The previous trading day's last sale of NYLD was $15.29, representing a -45.61% decrease from the 52 week high of $28.11 and a 41.71% increase over the 52 week low of $10.79.
NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ).
For more information on the declaration, record and payment dates, visit the NYLD Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to NYLD through an Exchange Traded Fund [ETF]?
The following ETF(s) have NYLD as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES )
Guggenheim Russell 2000 Equal Weight ETF ( EWRS ).
The top-performing ETF of this group is DES with an decrease of -3.38% over the last 100 days. It also has the highest percent weighting of NYLD at 0.45%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). The top-performing ETF of this group is DES with an decrease of -3.38% over the last 100 days.
|
The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ).
|
The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The top-performing ETF of this group is DES with an decrease of -3.38% over the last 100 days.
|
The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The top-performing ETF of this group is DES with an decrease of -3.38% over the last 100 days.
|
6f8ef6e7-3a0b-4420-af07-c80dc9d606f7
|
728409.0
|
2015-11-23 00:00:00 UTC
|
Lexmark International, Inc. (LXK) Ex-Dividend Date Scheduled for November 24, 2015
|
DES
|
https://www.nasdaq.com/articles/lexmark-international-inc-lxk-ex-dividend-date-scheduled-november-24-2015-2015-11-23
|
nan
|
nan
|
Lexmark International, Inc. ( LXK ) will begin trading ex-dividend on November 24, 2015. A cash dividend payment of $0.36 per share is scheduled to be paid on December 11, 2015. Shareholders who purchased LXK prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 7th quarter that LXK has paid the same dividend. At the current stock price of $35.43, the dividend yield is 4.06%.
The previous trading day's last sale of LXK was $35.43, representing a -25.71% decrease from the 52 week high of $47.69 and a 30.16% increase over the 52 week low of $27.22.
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). LXK's current earnings per share, an indicator of a company's profitability, is -$.94. Zacks Investment Research reports LXK's forecasted earnings growth in 2015 as -14.85%, compared to an industry average of -6%.
For more information on the declaration, record and payment dates, visit the LXK Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to LXK through an Exchange Traded Fund [ETF]?
The following ETF(s) have LXK as a top-10 holding:
WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an decrease of -4.87% over the last 100 days. DGRS has the highest percent weighting of LXK at 1.57%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -4.87% over the last 100 days.
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ).
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The top-performing ETF of this group is DES with an decrease of -4.87% over the last 100 days.
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The top-performing ETF of this group is DES with an decrease of -4.87% over the last 100 days.
|
63ec31b6-3bdc-4ec5-9e6f-442644037adb
|
728410.0
|
2015-11-11 00:00:00 UTC
|
Allete, Inc. (ALE) Ex-Dividend Date Scheduled for November 12, 2015
|
DES
|
https://www.nasdaq.com/articles/allete-inc-ale-ex-dividend-date-scheduled-november-12-2015-2015-11-11
|
nan
|
nan
|
Allete, Inc. ( ALE ) will begin trading ex-dividend on November 12, 2015. A cash dividend payment of $0.505 per share is scheduled to be paid on December 01, 2015. Shareholders who purchased ALE prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ALE has paid the same dividend. At the current stock price of $51.31, the dividend yield is 3.94%.
The previous trading day's last sale of ALE was $51.31, representing a -14.1% decrease from the 52 week high of $59.73 and a 13.29% increase over the 52 week low of $45.29.
ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). ALE's current earnings per share, an indicator of a company's profitability, is $3.27. Zacks Investment Research reports ALE's forecasted earnings growth in 2015 as 13.63%, compared to an industry average of 1.4%.
For more information on the declaration, record and payment dates, visit the ALE Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ALE through an Exchange Traded Fund [ETF]?
The following ETF(s) have ALE as a top-10 holding:
PowerShares S&P SmallCap Utilities Portfolio ( PSCU )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is PSCU with an increase of 10.39% over the last 100 days. It also has the highest percent weighting of ALE at 4.78%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased ALE prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ).
|
The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). Shareholders who purchased ALE prior to the ex-dividend date are eligible for the cash dividend payment.
|
ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). A cash dividend payment of $0.505 per share is scheduled to be paid on December 01, 2015.
|
c383b52a-47b4-4484-8488-f9d5b88c845b
|
728411.0
|
2015-11-11 00:00:00 UTC
|
West Corporation (WSTC) Ex-Dividend Date Scheduled for November 12, 2015
|
DES
|
https://www.nasdaq.com/articles/west-corporation-wstc-ex-dividend-date-scheduled-november-12-2015-2015-11-11
|
nan
|
nan
|
West Corporation ( WSTC ) will begin trading ex-dividend on November 12, 2015. A cash dividend payment of $0.225 per share is scheduled to be paid on November 25, 2015. Shareholders who purchased WSTC prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 11th quarter that WSTC has paid the same dividend. At the current stock price of $25.97, the dividend yield is 3.47%.
The previous trading day's last sale of WSTC was $25.97, representing a -27.82% decrease from the 52 week high of $35.98 and a 19.13% increase over the 52 week low of $21.80.
WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). WSTC's current earnings per share, an indicator of a company's profitability, is $2.65. Zacks Investment Research reports WSTC's forecasted earnings growth in 2015 as -8.88%, compared to an industry average of -7.2%.
For more information on the declaration, record and payment dates, visit the WSTC Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to WSTC through an Exchange Traded Fund [ETF]?
The following ETF(s) have WSTC as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an decrease of -6.59% over the last 100 days. It also has the highest percent weighting of WSTC at 0.6%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -6.59% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The top-performing ETF of this group is DES with an decrease of -6.59% over the last 100 days.
|
The top-performing ETF of this group is DES with an decrease of -6.59% over the last 100 days. WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
f2887875-482a-4ac6-a058-24e8fe68e7be
|
728412.0
|
2015-11-04 00:00:00 UTC
|
PBF Energy Inc. (PBF) Ex-Dividend Date Scheduled for November 05, 2015
|
DES
|
https://www.nasdaq.com/articles/pbf-energy-inc-pbf-ex-dividend-date-scheduled-november-05-2015-2015-11-04
|
nan
|
nan
|
PBF Energy Inc. ( PBF ) will begin trading ex-dividend on November 05, 2015. A cash dividend payment of $0.3 per share is scheduled to be paid on November 24, 2015. Shareholders who purchased PBF prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 12th quarter that PBF has paid the same dividend. At the current stock price of $35.24, the dividend yield is 3.41%.
The previous trading day's last sale of PBF was $35.24, representing a -4.58% decrease from the 52 week high of $36.93 and a 53.95% increase over the 52 week low of $22.89.
PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). PBF's current earnings per share, an indicator of a company's profitability, is -$.28. Zacks Investment Research reports PBF's forecasted earnings growth in 2015 as -15.46%, compared to an industry average of -1.7%.
For more information on the declaration, record and payment dates, visit the PBF Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to PBF through an Exchange Traded Fund [ETF]?
The following ETF(s) have PBF as a top-10 holding:
WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS )
WisdomTree Trust SmallCap Dividend Fund ( DES )
ProShares Ultra Oil & Gas ( DIG ).
The top-performing ETF of this group is DES with an decrease of -4.35% over the last 100 days. DGRS has the highest percent weighting of PBF at 2.02%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). The top-performing ETF of this group is DES with an decrease of -4.35% over the last 100 days.
|
The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). The top-performing ETF of this group is DES with an decrease of -4.35% over the last 100 days.
|
The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). The top-performing ETF of this group is DES with an decrease of -4.35% over the last 100 days.
|
PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Quality Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). The top-performing ETF of this group is DES with an decrease of -4.35% over the last 100 days.
|
be3b17b6-deb2-416c-af7b-b7c33cd6d086
|
728413.0
|
2015-10-06 00:00:00 UTC
|
WGL Holdings Inc (WGL) Ex-Dividend Date Scheduled for October 07, 2015
|
DES
|
https://www.nasdaq.com/articles/wgl-holdings-inc-wgl-ex-dividend-date-scheduled-october-07-2015-2015-10-06
|
nan
|
nan
|
WGL Holdings Inc ( WGL ) will begin trading ex-dividend on October 07, 2015. A cash dividend payment of $0.4625 per share is scheduled to be paid on November 01, 2015. Shareholders who purchased WGL prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that WGL has paid the same dividend. At the current stock price of $60.2, the dividend yield is 3.07%.
The previous trading day's last sale of WGL was $60.2, representing a -0.12% decrease from the 52 week high of $60.28 and a 41.31% increase over the 52 week low of $42.60.
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). WGL's current earnings per share, an indicator of a company's profitability, is $3.33. Zacks Investment Research reports WGL's forecasted earnings growth in 2015 as 12.31%, compared to an industry average of 1.8%.
For more information on the declaration, record and payment dates, visit the WGL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to WGL through an Exchange Traded Fund [ETF]?
The following ETF(s) have WGL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an decrease of -6.95% over the last 100 days. It also has the highest percent weighting of WGL at 0.69%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -6.95% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The top-performing ETF of this group is DES with an decrease of -6.95% over the last 100 days.
|
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -6.95% over the last 100 days.
|
ec79449d-1418-4bef-a11c-093d282ebb23
|
728414.0
|
2015-09-11 00:00:00 UTC
|
UIL Holdings Corporation (UIL) Ex-Dividend Date Scheduled for September 14, 2015
|
DES
|
https://www.nasdaq.com/articles/uil-holdings-corporation-uil-ex-dividend-date-scheduled-september-14-2015-2015-09-11
|
nan
|
nan
|
UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on September 14, 2015. A cash dividend payment of $0.432 per share is scheduled to be paid on October 01, 2015. Shareholders who purchased UIL prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 37th quarter that UIL has paid the same dividend. At the current stock price of $47.22, the dividend yield is 3.66%.
The previous trading day's last sale of UIL was $47.22, representing a -10.06% decrease from the 52 week high of $52.50 and a 33.65% increase over the 52 week low of $35.33.
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). UIL's current earnings per share, an indicator of a company's profitability, is $2.07. Zacks Investment Research reports UIL's forecasted earnings growth in 2015 as 5.97%, compared to an industry average of 1.7%.
For more information on the declaration, record and payment dates, visit the UIL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to UIL through an Exchange Traded Fund [ETF]?
The following ETF(s) have UIL as a top-10 holding:
PowerShares S&P SmallCap Utilities Portfolio ( PSCU )
WisdomTree Trust SmallCap Dividend Fund ( DES )
Vanguard S&P Small-Cap 600 Value ETF ( VIOV )
iShares S&P SmallCap 600 Value ETF ( IJS )
SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ).
The top-performing ETF of this group is PSCU with an decrease of -8.27% over the last 100 days. It also has the highest percent weighting of UIL at 8.92%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Vanguard S&P Small-Cap 600 Value ETF ( VIOV ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ). Zacks Investment Research reports UIL's forecasted earnings growth in 2015 as 5.97%, compared to an industry average of 1.7%.
|
The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Vanguard S&P Small-Cap 600 Value ETF ( VIOV ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ).
|
The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Vanguard S&P Small-Cap 600 Value ETF ( VIOV ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on September 14, 2015.
|
The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Vanguard S&P Small-Cap 600 Value ETF ( VIOV ) iShares S&P SmallCap 600 Value ETF ( IJS ) SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value ( SLYV ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). A cash dividend payment of $0.432 per share is scheduled to be paid on October 01, 2015.
|
262e8132-8271-4bff-aea0-a55f4065e250
|
728415.0
|
2015-09-04 00:00:00 UTC
|
Theravance, Inc. (THRX) Ex-Dividend Date Scheduled for September 08, 2015
|
DES
|
https://www.nasdaq.com/articles/theravance-inc-thrx-ex-dividend-date-scheduled-september-08-2015-2015-09-04
|
nan
|
nan
|
Theravance, Inc. ( THRX ) will begin trading ex-dividend on September 08, 2015. A cash dividend payment of $0.25 per share is scheduled to be paid on September 30, 2015. Shareholders who purchased THRX prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 5th quarter that THRX has paid the same dividend. At the current stock price of $15.93, the dividend yield is 6.28%.
The previous trading day's last sale of THRX was $15.93, representing a -28.47% decrease from the 52 week high of $22.27 and a 50.57% increase over the 52 week low of $10.58.
THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). THRX's current earnings per share, an indicator of a company's profitability, is -$.49. Zacks Investment Research reports THRX's forecasted earnings growth in 2015 as 79.09%, compared to an industry average of 8.2%.
For more information on the declaration, record and payment dates, visit the THRX Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to THRX through an Exchange Traded Fund [ETF]?
The following ETF(s) have THRX as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an decrease of -10.86% over the last 100 days. It also has the highest percent weighting of THRX at 1.17%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). The following ETF(s) have THRX as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -10.86% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). The following ETF(s) have THRX as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have THRX as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). The top-performing ETF of this group is DES with an decrease of -10.86% over the last 100 days.
|
The top-performing ETF of this group is DES with an decrease of -10.86% over the last 100 days. THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). The following ETF(s) have THRX as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
d319c971-286e-4e49-86f1-2033dfe54d79
|
728416.0
|
2015-08-27 00:00:00 UTC
|
NRG Yield, Inc. (NYLD) Ex-Dividend Date Scheduled for August 28, 2015
|
DES
|
https://www.nasdaq.com/articles/nrg-yield-inc-nyld-ex-dividend-date-scheduled-august-28-2015-2015-08-27
|
nan
|
nan
|
NRG Yield, Inc. ( NYLD ) will begin trading ex-dividend on August 28, 2015. A cash dividend payment of $0.21 per share is scheduled to be paid on September 15, 2015. Shareholders who purchased NYLD prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 5% increase over the prior quarter. At the current stock price of $15.92, the dividend yield is 5.28%.
The previous trading day's last sale of NYLD was $15.92, representing a -43.37% decrease from the 52 week high of $28.11 and a 4.53% increase over the 52 week low of $15.23.
NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ).
For more information on the declaration, record and payment dates, visit the NYLD Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to NYLD through an Exchange Traded Fund [ETF]?
The following ETF(s) have NYLD as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES )
Guggenheim Russell 2000 Equal Weight ETF ( EWRS ).
The top-performing ETF of this group is DES with an decrease of -12.07% over the last 100 days. It also has the highest percent weighting of NYLD at 0.45%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). The top-performing ETF of this group is DES with an decrease of -12.07% over the last 100 days.
|
The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ).
|
The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an decrease of -12.07% over the last 100 days.
|
The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an decrease of -12.07% over the last 100 days.
|
a2e36435-725d-4b44-92e2-7398229fe311
|
728417.0
|
2015-08-19 00:00:00 UTC
|
West Corporation (WSTC) Ex-Dividend Date Scheduled for August 20, 2015
|
DES
|
https://www.nasdaq.com/articles/west-corporation-wstc-ex-dividend-date-scheduled-august-20-2015-2015-08-19
|
nan
|
nan
|
West Corporation ( WSTC ) will begin trading ex-dividend on August 20, 2015. A cash dividend payment of $0.225 per share is scheduled to be paid on September 03, 2015. Shareholders who purchased WSTC prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 10th quarter that WSTC has paid the same dividend. At the current stock price of $26.33, the dividend yield is 3.42%.
The previous trading day's last sale of WSTC was $26.33, representing a -26.82% decrease from the 52 week high of $35.98 and a 9.62% increase over the 52 week low of $24.02.
WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). WSTC's current earnings per share, an indicator of a company's profitability, is $2.26. Zacks Investment Research reports WSTC's forecasted earnings growth in 2015 as -8.96%, compared to an industry average of 7.4%.
For more information on the declaration, record and payment dates, visit the WSTC Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to WSTC through an Exchange Traded Fund [ETF]?
The following ETF(s) have WSTC as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an decrease of -3.31% over the last 100 days. It also has the highest percent weighting of WSTC at 0.6%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -3.31% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The top-performing ETF of this group is DES with an decrease of -3.31% over the last 100 days.
|
The top-performing ETF of this group is DES with an decrease of -3.31% over the last 100 days. WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
b101fe48-c48e-4c0d-8fe1-b772c0a6583d
|
728418.0
|
2015-08-11 00:00:00 UTC
|
Allete, Inc. (ALE) Ex-Dividend Date Scheduled for August 12, 2015
|
DES
|
https://www.nasdaq.com/articles/allete-inc-ale-ex-dividend-date-scheduled-august-12-2015-2015-08-11
|
nan
|
nan
|
Allete, Inc. ( ALE ) will begin trading ex-dividend on August 12, 2015. A cash dividend payment of $0.505 per share is scheduled to be paid on September 01, 2015. Shareholders who purchased ALE prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that ALE has paid the same dividend. At the current stock price of $50.69, the dividend yield is 3.99%.
The previous trading day's last sale of ALE was $50.69, representing a -15.13% decrease from the 52 week high of $59.73 and a 14.71% increase over the 52 week low of $44.19.
ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). ALE's current earnings per share, an indicator of a company's profitability, is $3.01. Zacks Investment Research reports ALE's forecasted earnings growth in 2015 as 9.25%, compared to an industry average of 3.6%.
For more information on the declaration, record and payment dates, visit the ALE Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ALE through an Exchange Traded Fund [ETF]?
The following ETF(s) have ALE as a top-10 holding:
PowerShares S&P SmallCap Utilities Portfolio ( PSCU )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is PSCU with an decrease of -1.18% over the last 100 days. It also has the highest percent weighting of ALE at 4.78%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased ALE prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ).
|
The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). Shareholders who purchased ALE prior to the ex-dividend date are eligible for the cash dividend payment.
|
ALE is a part of the Public Utilities sector, which includes companies such as Duke Energy Corporation ( DUK ) and Exelon Corporation ( EXCU ). The following ETF(s) have ALE as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). A cash dividend payment of $0.505 per share is scheduled to be paid on September 01, 2015.
|
518701de-7006-483f-8cf5-c52dd374e291
|
728419.0
|
2015-08-05 00:00:00 UTC
|
Insiders Buy the Holdings of DES ETF
|
DES
|
https://www.nasdaq.com/articles/insiders-buy-holdings-des-etf-2015-08-05
|
nan
|
nan
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 12.3% of holdings on a weighted basis have experienced insider buying within the past six months.
Mobile Mini, Inc. (Symbol: MINI), which makes up 0.25% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $3,161,657 worth of MINI, making it the #110 largest holding. The table below details the recent insider buying activity observed at MINI:
MINI - last trade: $35.42 - Recent Insider Buys:
And Sabra Health Care REIT Inc (Symbol: SBRA), the #121 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $3,045,839 worth of SBRA, which represents approximately 0.24% of the ETF's total assets at last check. The recent insider buying activity observed at SBRA is detailed in the table below:
SBRA - last trade: $27.05 - Recent Insider Buys:
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 12.3% of holdings on a weighted basis have experienced insider buying within the past six months. Mobile Mini, Inc. (Symbol: MINI), which makes up 0.25% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at MINI: MINI - last trade: $35.42 - Recent Insider Buys: And Sabra Health Care REIT Inc (Symbol: SBRA), the #121 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases.
|
Mobile Mini, Inc. (Symbol: MINI), which makes up 0.25% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at MINI: MINI - last trade: $35.42 - Recent Insider Buys: And Sabra Health Care REIT Inc (Symbol: SBRA), the #121 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 12.3% of holdings on a weighted basis have experienced insider buying within the past six months.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 12.3% of holdings on a weighted basis have experienced insider buying within the past six months. The table below details the recent insider buying activity observed at MINI: MINI - last trade: $35.42 - Recent Insider Buys: And Sabra Health Care REIT Inc (Symbol: SBRA), the #121 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases. Mobile Mini, Inc. (Symbol: MINI), which makes up 0.25% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data.
|
Mobile Mini, Inc. (Symbol: MINI), which makes up 0.25% of the WisdomTree SmallCap Dividend Fund ( DES ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at MINI: MINI - last trade: $35.42 - Recent Insider Buys: And Sabra Health Care REIT Inc (Symbol: SBRA), the #121 largest holding among components of the WisdomTree SmallCap Dividend Fund ( DES ), shows 3 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund ( DES ) shows an impressive 12.3% of holdings on a weighted basis have experienced insider buying within the past six months.
|
ab11f54a-f457-4478-af2f-a558b972e34d
|
728420.0
|
2015-08-05 00:00:00 UTC
|
PBF Energy Inc. (PBF) Ex-Dividend Date Scheduled for August 06, 2015
|
DES
|
https://www.nasdaq.com/articles/pbf-energy-inc-pbf-ex-dividend-date-scheduled-august-06-2015-2015-08-05
|
nan
|
nan
|
PBF Energy Inc. ( PBF ) will begin trading ex-dividend on August 06, 2015. A cash dividend payment of $0.3 per share is scheduled to be paid on August 25, 2015. Shareholders who purchased PBF prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 11th quarter that PBF has paid the same dividend. At the current stock price of $30.97, the dividend yield is 3.87%.
The previous trading day's last sale of PBF was $30.97, representing a -10.54% decrease from the 52 week high of $34.62 and a 47.34% increase over the 52 week low of $21.02.
PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). PBF's current earnings per share, an indicator of a company's profitability, is $.83. Zacks Investment Research reports PBF's forecasted earnings growth in 2015 as -19.09%, compared to an industry average of 8.2%.
For more information on the declaration, record and payment dates, visit the PBF Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to PBF through an Exchange Traded Fund [ETF]?
The following ETF(s) have PBF as a top-10 holding:
WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS )
WisdomTree Trust SmallCap Dividend Fund ( DES )
ProShares Ultra Oil & Gas ( DIG ).
The top-performing ETF of this group is DGRS with an decrease of -3.62% over the last 100 days. It also has the highest percent weighting of PBF at 2.02%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). Shareholders who purchased PBF prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). PBF Energy Inc. ( PBF ) will begin trading ex-dividend on August 06, 2015.
|
The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). PBF Energy Inc. ( PBF ) will begin trading ex-dividend on August 06, 2015.
|
PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). PBF Energy Inc. ( PBF ) will begin trading ex-dividend on August 06, 2015.
|
cdb28f83-5226-4336-89b6-45811a6d2a99
|
728421.0
|
2015-07-27 00:00:00 UTC
|
WisdomTree SmallCap Dividend Fund Getting Very Oversold
|
DES
|
https://www.nasdaq.com/articles/wisdomtree-smallcap-dividend-fund-getting-very-oversold-2015-07-27
|
nan
|
nan
|
In trading on Monday, shares of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) entered into oversold territory, changing hands as low as $67.41 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In the case of WisdomTree SmallCap Dividend Fund, the RSI reading has hit 29.1 - by comparison, the RSI reading for the S&P 500 is currently 41.1. A bullish investor could look at DES's 29.1 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side.
Looking at a chart of one year performance (below), DES's low point in its 52 week range is $63.50 per share, with $72.99 as the 52 week high point - that compares with a last trade of $67.67. WisdomTree SmallCap Dividend Fund shares are currently trading off about 0.6% on the day.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A bullish investor could look at DES's 29.1 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. In trading on Monday, shares of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) entered into oversold territory, changing hands as low as $67.41 per share. Looking at a chart of one year performance (below), DES's low point in its 52 week range is $63.50 per share, with $72.99 as the 52 week high point - that compares with a last trade of $67.67.
|
In trading on Monday, shares of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) entered into oversold territory, changing hands as low as $67.41 per share. A bullish investor could look at DES's 29.1 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Looking at a chart of one year performance (below), DES's low point in its 52 week range is $63.50 per share, with $72.99 as the 52 week high point - that compares with a last trade of $67.67.
|
In trading on Monday, shares of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) entered into oversold territory, changing hands as low as $67.41 per share. A bullish investor could look at DES's 29.1 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Looking at a chart of one year performance (below), DES's low point in its 52 week range is $63.50 per share, with $72.99 as the 52 week high point - that compares with a last trade of $67.67.
|
In trading on Monday, shares of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) entered into oversold territory, changing hands as low as $67.41 per share. A bullish investor could look at DES's 29.1 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Looking at a chart of one year performance (below), DES's low point in its 52 week range is $63.50 per share, with $72.99 as the 52 week high point - that compares with a last trade of $67.67.
|
2f9b4717-24f7-475c-8359-6a8e7af9edc7
|
728422.0
|
2015-07-20 00:00:00 UTC
|
WisdomTree SmallCap Dividend Fund -- Insider Buying Index Registering 12.6%
|
DES
|
https://www.nasdaq.com/articles/wisdomtree-smallcap-dividend-fund-insider-buying-index-registering-126-2015-07-20
|
nan
|
nan
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund (Symbol: DES) shows an impressive 12.6% of holdings on a weighted basis have experienced insider buying within the past six months.
Harsco Corp. (Symbol: HSC), which makes up 0.49% of the WisdomTree SmallCap Dividend Fund (Symbol: DES), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $6,184,017 worth of HSC, making it the #32 largest holding. The table below details the recent insider buying activity observed at HSC:
HSC - last trade: $15.65 - Recent Insider Buys:
And Applied Industrial Technologies, Inc. (Symbol: AIT), the #85 largest holding among components of the WisdomTree SmallCap Dividend Fund (Symbol: DES), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $3,736,602 worth of AIT, which represents approximately 0.30% of the ETF's total assets at last check. The recent insider buying activity observed at AIT is detailed in the table below:
AIT - last trade: $39.78 - Recent Insider Buys:
10 ETFs With Stocks That Insiders Are Buying »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund (Symbol: DES) shows an impressive 12.6% of holdings on a weighted basis have experienced insider buying within the past six months. Harsco Corp. (Symbol: HSC), which makes up 0.49% of the WisdomTree SmallCap Dividend Fund (Symbol: DES), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at HSC: HSC - last trade: $15.65 - Recent Insider Buys: And Applied Industrial Technologies, Inc. (Symbol: AIT), the #85 largest holding among components of the WisdomTree SmallCap Dividend Fund (Symbol: DES), shows 2 directors and officers as recently filing Form 4's indicating purchases.
|
Harsco Corp. (Symbol: HSC), which makes up 0.49% of the WisdomTree SmallCap Dividend Fund (Symbol: DES), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at HSC: HSC - last trade: $15.65 - Recent Insider Buys: And Applied Industrial Technologies, Inc. (Symbol: AIT), the #85 largest holding among components of the WisdomTree SmallCap Dividend Fund (Symbol: DES), shows 2 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund (Symbol: DES) shows an impressive 12.6% of holdings on a weighted basis have experienced insider buying within the past six months.
|
A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund (Symbol: DES) shows an impressive 12.6% of holdings on a weighted basis have experienced insider buying within the past six months. The table below details the recent insider buying activity observed at HSC: HSC - last trade: $15.65 - Recent Insider Buys: And Applied Industrial Technologies, Inc. (Symbol: AIT), the #85 largest holding among components of the WisdomTree SmallCap Dividend Fund (Symbol: DES), shows 2 directors and officers as recently filing Form 4's indicating purchases. Harsco Corp. (Symbol: HSC), which makes up 0.49% of the WisdomTree SmallCap Dividend Fund (Symbol: DES), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data.
|
Harsco Corp. (Symbol: HSC), which makes up 0.49% of the WisdomTree SmallCap Dividend Fund (Symbol: DES), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at HSC: HSC - last trade: $15.65 - Recent Insider Buys: And Applied Industrial Technologies, Inc. (Symbol: AIT), the #85 largest holding among components of the WisdomTree SmallCap Dividend Fund (Symbol: DES), shows 2 directors and officers as recently filing Form 4's indicating purchases. A look at the weighted underlying holdings of the WisdomTree SmallCap Dividend Fund (Symbol: DES) shows an impressive 12.6% of holdings on a weighted basis have experienced insider buying within the past six months.
|
3658fe25-393b-44e7-9a48-9dbfdee008ba
|
728423.0
|
2015-07-20 00:00:00 UTC
|
Small-Cap Dividend ETFs Target Quality, Cut Risk
|
DES
|
https://www.nasdaq.com/articles/small-cap-dividend-etfs-target-quality-cut-risk-2015-07-20
|
nan
|
nan
|
H istorically low interest rates have polished the appeal of dividend equity ETFs. But with interest rates widely expected to rise by year-end, what can investors expect? Dividend-paying firms could be hard hit when the Federal Reserve normalizes policy. With stable cash flows, they typically don't get the same boost that nondividend payers do from an improving economy .
But in a rising rate environment, dividend growth ETFs should fare better than dividend yield strategies, panelists on a Charles Schwab media call on dividend equity investing noted Friday.
"Historically, there is not that cyclicality as in high yield," said Simeon Hyman, ProShares' head of investment strategy. "They don't have that bond sensitivity associated with them." But dividend equity investing has a hidden bias, the panelists said. Most dividend ETFs focus on large caps. There are almost twice as many dividend-paying stocks in large caps as in small.
Many investors associate small caps with growth and potentially higher returns, not dividends, Hyman said. With a dividend ETF strategy , investors can have both.
ProShares says that its four dividend growth ETFs "curate" firms from well-known indexes with the longest track records of growing dividends. One ETF, launched in February, focuses on small caps.
ProShares Russell 2000 Dividend Growers ( SMDV ) invests in 55 names that raised dividends in each of the past 10 years. Holdings include payments processorCass Information Systems ( CASS ),West Pharmaceutical Services ( WST ) and grains distributorAndersons ( ANDE ). These small caps are firms of higher quality, based on balance sheets, earnings and debt levels, than peers offering the highest dividend yield. SMDV has $5 million in assets and a 0.4% expense ratio.
The $1.28 billionWisdomTree SmallCap Dividend ( DES ), meanwhile, weights holdings by dividends, focusing on quality rather than high yield alone. DES is up 0.9% in 2015. It's more diversified and less costly than SMDV. It yields 2.9%.
Small caps can be risky. The potential for higher gains can come at the cost of violent price swings.
But small-cap dividend growers are less volatile than stocks that don't pay dividends or that pay but don't grow dividends, Ned Davis Research data shows. They have lower drawdowns; that is, they don't lose as much when the market declines. "You can have your cake and eat it too," Hyman said. " Investors can participate in small-cap growth with higher quality names and less volatility."
On Schwab's ETF platform, dividend ETFs holding large- and midcap stocks saw net outflow in the first half of 2015.
"This offset the positive flow we saw going into small-cap dividend ETFs," said Heather Fischer, a Schwab vice president.
Small caps outperformed recently and could shine when rates rise. They adapt more nimbly when economic currents shift.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The $1.28 billionWisdomTree SmallCap Dividend ( DES ), meanwhile, weights holdings by dividends, focusing on quality rather than high yield alone. DES is up 0.9% in 2015. Many investors associate small caps with growth and potentially higher returns, not dividends, Hyman said.
|
The $1.28 billionWisdomTree SmallCap Dividend ( DES ), meanwhile, weights holdings by dividends, focusing on quality rather than high yield alone. DES is up 0.9% in 2015. But in a rising rate environment, dividend growth ETFs should fare better than dividend yield strategies, panelists on a Charles Schwab media call on dividend equity investing noted Friday.
|
The $1.28 billionWisdomTree SmallCap Dividend ( DES ), meanwhile, weights holdings by dividends, focusing on quality rather than high yield alone. DES is up 0.9% in 2015. But in a rising rate environment, dividend growth ETFs should fare better than dividend yield strategies, panelists on a Charles Schwab media call on dividend equity investing noted Friday.
|
The $1.28 billionWisdomTree SmallCap Dividend ( DES ), meanwhile, weights holdings by dividends, focusing on quality rather than high yield alone. DES is up 0.9% in 2015. But in a rising rate environment, dividend growth ETFs should fare better than dividend yield strategies, panelists on a Charles Schwab media call on dividend equity investing noted Friday.
|
331eb4ed-a7de-4740-9240-55ce4aa1de84
|
728424.0
|
2015-06-12 00:00:00 UTC
|
Vector Group Ltd. (VGR) Ex-Dividend Date Scheduled for June 15, 2015
|
DES
|
https://www.nasdaq.com/articles/vector-group-ltd-vgr-ex-dividend-date-scheduled-june-15-2015-2015-06-12
|
nan
|
nan
|
Vector Group Ltd. ( VGR ) will begin trading ex-dividend on June 15, 2015. A cash dividend payment of $0.4 per share is scheduled to be paid on June 30, 2015. Shareholders who purchased VGR prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 48th quarter that VGR has paid the same dividend. At the current stock price of $22.37, the dividend yield is 7.15%.
The previous trading day's last sale of VGR was $22.37, representing a -3.99% decrease from the 52 week high of $23.30 and a 17.38% increase over the 52 week low of $19.06.
VGR is a part of the Consumer Non-Durables sector. VGR's current earnings per share, an indicator of a company's profitability, is $.51. Zacks Investment Research reports VGR's forecasted earnings growth in 2015 as 23.33%, compared to an industry average of 4.9%.
For more information on the declaration, record and payment dates, visit the VGR Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to VGR through an Exchange Traded Fund [ETF]?
The following ETF(s) have VGR as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES )
ProShares Russell 2000 Dividend Growers ETF ( SMDV ).
The top-performing ETF of this group is DES with an increase of 2.95% over the last 100 days. It also has the highest percent weighting of VGR at 1.34%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The following ETF(s) have VGR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Russell 2000 Dividend Growers ETF ( SMDV ). The top-performing ETF of this group is DES with an increase of 2.95% over the last 100 days. Shareholders who purchased VGR prior to the ex-dividend date are eligible for the cash dividend payment.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The following ETF(s) have VGR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Russell 2000 Dividend Growers ETF ( SMDV ). The top-performing ETF of this group is DES with an increase of 2.95% over the last 100 days.
|
The following ETF(s) have VGR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Russell 2000 Dividend Growers ETF ( SMDV ). The top-performing ETF of this group is DES with an increase of 2.95% over the last 100 days. Shareholders who purchased VGR prior to the ex-dividend date are eligible for the cash dividend payment.
|
The top-performing ETF of this group is DES with an increase of 2.95% over the last 100 days. The following ETF(s) have VGR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Russell 2000 Dividend Growers ETF ( SMDV ). A cash dividend payment of $0.4 per share is scheduled to be paid on June 30, 2015.
|
bbb5320d-9563-4537-9e35-48dd55c02ab5
|
728425.0
|
2015-06-10 00:00:00 UTC
|
UIL Holdings Corporation (UIL) Ex-Dividend Date Scheduled for June 11, 2015
|
DES
|
https://www.nasdaq.com/articles/uil-holdings-corporation-uil-ex-dividend-date-scheduled-june-11-2015-2015-06-10
|
nan
|
nan
|
UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on June 11, 2015. A cash dividend payment of $0.432 per share is scheduled to be paid on July 01, 2015. Shareholders who purchased UIL prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 36th quarter that UIL has paid the same dividend. At the current stock price of $48.91, the dividend yield is 3.53%.
The previous trading day's last sale of UIL was $48.91, representing a -6.84% decrease from the 52 week high of $52.50 and a 42.43% increase over the 52 week low of $34.34.
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). UIL's current earnings per share, an indicator of a company's profitability, is $1.95. Zacks Investment Research reports UIL's forecasted earnings growth in 2015 as 6.86%, compared to an industry average of 6.4%.
For more information on the declaration, record and payment dates,
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). Shareholders who purchased UIL prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports UIL's forecasted earnings growth in 2015 as 6.86%, compared to an industry average of 6.4%.
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). A cash dividend payment of $0.432 per share is scheduled to be paid on July 01, 2015. Shareholders who purchased UIL prior to the ex-dividend date are eligible for the cash dividend payment.
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on June 11, 2015. Shareholders who purchased UIL prior to the ex-dividend date are eligible for the cash dividend payment.
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). A cash dividend payment of $0.432 per share is scheduled to be paid on July 01, 2015. Shareholders who purchased UIL prior to the ex-dividend date are eligible for the cash dividend payment.
|
fa4ab726-5876-40ab-a2d3-48536668e214
|
728426.0
|
2015-06-09 00:00:00 UTC
|
Theravance, Inc. (THRX) Ex-Dividend Date Scheduled for June 10, 2015
|
DES
|
https://www.nasdaq.com/articles/theravance-inc-thrx-ex-dividend-date-scheduled-june-10-2015-2015-06-09
|
nan
|
nan
|
Theravance, Inc. ( THRX ) will begin trading ex-dividend on June 10, 2015. A cash dividend payment of $0.25 per share is scheduled to be paid on June 30, 2015. Shareholders who purchased THRX prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that THRX has paid the same dividend. At the current stock price of $18.06, the dividend yield is 5.54%.
The previous trading day's last sale of THRX was $18.06, representing a -43.21% decrease from the 52 week high of $31.80 and a 70.7% increase over the 52 week low of $10.58.
THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). THRX's current earnings per share, an indicator of a company's profitability, is -$.99. Zacks Investment Research reports THRX's forecasted earnings growth in 2015 as 74.55%, compared to an industry average of 8.1%.
For more information on the declaration, record and payment dates, visit the THRX Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to THRX through an Exchange Traded Fund [ETF]?
The following ETF(s) have THRX as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 1.83% over the last 100 days. It also has the highest percent weighting of THRX at 1.17%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). The following ETF(s) have THRX as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 1.83% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). The following ETF(s) have THRX as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have THRX as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). The top-performing ETF of this group is DES with an increase of 1.83% over the last 100 days.
|
The top-performing ETF of this group is DES with an increase of 1.83% over the last 100 days. THRX is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). The following ETF(s) have THRX as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
893eef59-9ccf-4591-a03c-146b88e49883
|
728427.0
|
2015-05-27 00:00:00 UTC
|
NRG Yield, Inc. (NYLD) Ex-Dividend Date Scheduled for May 28, 2015
|
DES
|
https://www.nasdaq.com/articles/nrg-yield-inc-nyld-ex-dividend-date-scheduled-may-28-2015-2015-05-27
|
nan
|
nan
|
NRG Yield, Inc. ( NYLD ) will begin trading ex-dividend on May 28, 2015. A cash dividend payment of $0.2 per share is scheduled to be paid on June 15, 2015. Shareholders who purchased NYLD prior to the ex-dividend date are eligible for the cash dividend payment. At the current stock price of $24.9, the dividend yield is 3.21%.
The previous trading day's last sale of NYLD was $24.9, representing a -2.34% decrease from the 52 week high of $25.50 and a 7.93% increase over the 52 week low of $23.07.
NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ).
For more information on the declaration, record and payment dates, visit the NYLD Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to NYLD through an Exchange Traded Fund [ETF]?
The following ETF(s) have NYLD as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES )
Guggenheim Russell 2000 Equal Weight ETF ( EWRS ).
The top-performing ETF of this group is EWRS with an decrease of -0.48% over the last 100 days. DES has the highest percent weighting of NYLD at 0.45%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). DES has the highest percent weighting of NYLD at 0.45%.
|
The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ).
|
The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). DES has the highest percent weighting of NYLD at 0.45%.
|
The following ETF(s) have NYLD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) Guggenheim Russell 2000 Equal Weight ETF ( EWRS ). NYLD is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). DES has the highest percent weighting of NYLD at 0.45%.
|
a0ccb9bd-3677-440f-a627-cd4a09e411f5
|
728428.0
|
2015-05-26 00:00:00 UTC
|
Lexmark International, Inc. (LXK) Ex-Dividend Date Scheduled for May 27, 2015
|
DES
|
https://www.nasdaq.com/articles/lexmark-international-inc-lxk-ex-dividend-date-scheduled-may-27-2015-2015-05-26
|
nan
|
nan
|
Lexmark International, Inc. ( LXK ) will begin trading ex-dividend on May 27, 2015. A cash dividend payment of $0.36 per share is scheduled to be paid on June 12, 2015. Shareholders who purchased LXK prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 5th quarter that LXK has paid the same dividend. At the current stock price of $45.85, the dividend yield is 3.14%.
The previous trading day's last sale of LXK was $45.85, representing a -11.44% decrease from the 52 week high of $51.77 and a 23.32% increase over the 52 week low of $37.18.
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). LXK's current earnings per share, an indicator of a company's profitability, is $1.09. Zacks Investment Research reports LXK's forecasted earnings growth in 2015 as -10.89%, compared to an industry average of -7.1%.
For more information on the declaration, record and payment dates, visit the LXK Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to LXK through an Exchange Traded Fund [ETF]?
The following ETF(s) have LXK as a top-10 holding:
WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DGRS with an increase of 0.34% over the last 100 days. It also has the highest percent weighting of LXK at 1.57%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Zacks Investment Research reports LXK's forecasted earnings growth in 2015 as -10.89%, compared to an industry average of -7.1%.
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ).
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). Shareholders who purchased LXK prior to the ex-dividend date are eligible for the cash dividend payment.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Lexmark International, Inc. ( LXK ) will begin trading ex-dividend on May 27, 2015.
|
486f97c2-457d-4fcc-9b9e-1c4b4bed3870
|
728429.0
|
2015-05-19 00:00:00 UTC
|
Nu Skin Enterprises, Inc. (NUS) Ex-Dividend Date Scheduled for May 20, 2015
|
DES
|
https://www.nasdaq.com/articles/nu-skin-enterprises-inc-nus-ex-dividend-date-scheduled-may-20-2015-2015-05-19
|
nan
|
nan
|
Nu Skin Enterprises, Inc. ( NUS ) will begin trading ex-dividend on May 20, 2015. A cash dividend payment of $0.35 per share is scheduled to be paid on June 10, 2015. Shareholders who purchased NUS prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 1.45% increase over the same period a year ago. At the current stock price of $51.82, the dividend yield is 2.7%.
The previous trading day's last sale of NUS was $51.82, representing a -33.31% decrease from the 52 week high of $77.70 and a 35.94% increase over the 52 week low of $38.12.
NUS is a part of the Health Care sector, which includes companies such as McKesson Corporation ( MCK ) and Cardinal Health, Inc. ( CAH ). NUS's current earnings per share, an indicator of a company's profitability, is $2.81. Zacks Investment Research reports NUS's forecasted earnings growth in 2015 as -5.15%, compared to an industry average of -6.1%.
For more information on the declaration, record and payment dates, visit the NUS Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to NUS through an Exchange Traded Fund [ETF]?
The following ETF(s) have NUS as a top-10 holding:
WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS )
WisdomTree Trust SmallCap Dividend Fund ( DES )
Direxion Daily Retail Bull 3X Shares ETF ( RETL ).
The top-performing ETF of this group is RETL with an increase of 29.67% over the last 100 days. DGRS has the highest percent weighting of NUS at 2.05%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
NUS is a part of the Health Care sector, which includes companies such as McKesson Corporation ( MCK ) and Cardinal Health, Inc. ( CAH ). The following ETF(s) have NUS as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Direxion Daily Retail Bull 3X Shares ETF ( RETL ). Shareholders who purchased NUS prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have NUS as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Direxion Daily Retail Bull 3X Shares ETF ( RETL ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. NUS is a part of the Health Care sector, which includes companies such as McKesson Corporation ( MCK ) and Cardinal Health, Inc. ( CAH ).
|
The following ETF(s) have NUS as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Direxion Daily Retail Bull 3X Shares ETF ( RETL ). NUS is a part of the Health Care sector, which includes companies such as McKesson Corporation ( MCK ) and Cardinal Health, Inc. ( CAH ). Shareholders who purchased NUS prior to the ex-dividend date are eligible for the cash dividend payment.
|
NUS is a part of the Health Care sector, which includes companies such as McKesson Corporation ( MCK ) and Cardinal Health, Inc. ( CAH ). The following ETF(s) have NUS as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) Direxion Daily Retail Bull 3X Shares ETF ( RETL ). Shareholders who purchased NUS prior to the ex-dividend date are eligible for the cash dividend payment.
|
e47e452d-9894-44ed-839a-b81a73397a7b
|
728430.0
|
2015-05-13 00:00:00 UTC
|
West Corporation (WSTC) Ex-Dividend Date Scheduled for May 14, 2015
|
DES
|
https://www.nasdaq.com/articles/west-corporation-wstc-ex-dividend-date-scheduled-may-14-2015-2015-05-13
|
nan
|
nan
|
West Corporation ( WSTC ) will begin trading ex-dividend on May 14, 2015. A cash dividend payment of $0.225 per share is scheduled to be paid on May 28, 2015. Shareholders who purchased WSTC prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 9th quarter that WSTC has paid the same dividend. At the current stock price of $30.76, the dividend yield is 2.93%.
The previous trading day's last sale of WSTC was $30.76, representing a -14.51% decrease from the 52 week high of $35.98 and a 28.92% increase over the 52 week low of $23.86.
WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). WSTC's current earnings per share, an indicator of a company's profitability, is $2.24. Zacks Investment Research reports WSTC's forecasted earnings growth in 2015 as -9.89%, compared to an industry average of 1.5%.
For more information on the declaration, record and payment dates, visit the WSTC Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to WSTC through an Exchange Traded Fund [ETF]?
The following ETF(s) have WSTC as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 3.38% over the last 100 days. It also has the highest percent weighting of WSTC at 0.6%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 3.38% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The top-performing ETF of this group is DES with an increase of 3.38% over the last 100 days.
|
The top-performing ETF of this group is DES with an increase of 3.38% over the last 100 days. WSTC is a part of the Miscellaneous sector, which includes companies such as Alibaba Group Holding Limited ( BABA ) and Visa Inc. ( V ). The following ETF(s) have WSTC as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
2a9f59a4-acb9-43c6-b04a-36fb378d2cf4
|
728431.0
|
2015-05-06 00:00:00 UTC
|
PBF Energy Inc. (PBF) Ex-Dividend Date Scheduled for May 07, 2015
|
DES
|
https://www.nasdaq.com/articles/pbf-energy-inc-pbf-ex-dividend-date-scheduled-may-07-2015-2015-05-06
|
nan
|
nan
|
PBF Energy Inc. ( PBF ) will begin trading ex-dividend on May 07, 2015. A cash dividend payment of $0.3 per share is scheduled to be paid on May 27, 2015. Shareholders who purchased PBF prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 10th quarter that PBF has paid the same dividend. At the current stock price of $27.6, the dividend yield is 4.35%.
The previous trading day's last sale of PBF was $27.6, representing a -20.28% decrease from the 52 week high of $34.62 and a 31.3% increase over the 52 week low of $21.02.
PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). PBF's current earnings per share, an indicator of a company's profitability, is -$.45. Zacks Investment Research reports PBF's forecasted earnings growth in 2015 as -13.5%, compared to an industry average of -.1%.
For more information on the declaration, record and payment dates, visit the PBF Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to PBF through an Exchange Traded Fund [ETF]?
The following ETF(s) have PBF as a top-10 holding:
WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS )
WisdomTree Trust SmallCap Dividend Fund ( DES )
ProShares Ultra Oil & Gas ( DIG ).
The top-performing ETF of this group is DIG with an increase of 8.47% over the last 100 days. DGRS has the highest percent weighting of PBF at 2.02%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). Shareholders who purchased PBF prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ).
|
The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). PBF Energy Inc. ( PBF ) will begin trading ex-dividend on May 07, 2015.
|
PBF is a part of the Energy sector, which includes companies such as Exxon Mobil Corporation ( XOM ) and Chevron Corporation ( CVX ). The following ETF(s) have PBF as a top-10 holding: WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ) ProShares Ultra Oil & Gas ( DIG ). PBF Energy Inc. ( PBF ) will begin trading ex-dividend on May 07, 2015.
|
5e9b03c1-2359-47c4-b065-612ec470ef31
|
728432.0
|
2015-04-07 00:00:00 UTC
|
WGL Holdings Inc (WGL) Ex-Dividend Date Scheduled for April 08, 2015
|
DES
|
https://www.nasdaq.com/articles/wgl-holdings-inc-wgl-ex-dividend-date-scheduled-april-08-2015-2015-04-07
|
nan
|
nan
|
WGL Holdings Inc ( WGL ) will begin trading ex-dividend on April 08, 2015. A cash dividend payment of $0.4625 per share is scheduled to be paid on May 01, 2015. Shareholders who purchased WGL prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 5.11% increase over the prior quarter. At the current stock price of $57.2, the dividend yield is 3.23%.
The previous trading day's last sale of WGL was $57.2, representing a -3.18% decrease from the 52 week high of $59.08 and a 51.44% increase over the 52 week low of $37.77.
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). WGL's current earnings per share, an indicator of a company's profitability, is $2.97. Zacks Investment Research reports WGL's forecasted earnings growth in 2015 as 6.06%, compared to an industry average of .9%.
For more information on the declaration, record and payment dates, visit the WGL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to WGL through an Exchange Traded Fund [ETF]?
The following ETF(s) have WGL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 3.28% over the last 100 days. It also has the highest percent weighting of WGL at 0.69%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 3.28% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The top-performing ETF of this group is DES with an increase of 3.28% over the last 100 days.
|
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 3.28% over the last 100 days.
|
4a2b28c1-a928-41a5-9bb2-2dca975a9b63
|
728433.0
|
2015-03-23 00:00:00 UTC
|
Will the Lure of Dividends Lead Small Cap ETFs Higher? - ETF News And Commentary
|
DES
|
https://www.nasdaq.com/articles/will-the-lure-of-dividends-lead-small-cap-etfs-higher-etf-news-and-commentary-2015-03-23
|
nan
|
nan
|
U.S. small cap ETFs space saw a great start this year courtesy of steady U.S. economic growth, especially compared to the other parts of the developed world. The economy's growth rate moderated to 2.2% in Q4 from an impressive 5% in Q3 and 4.6% in Q2 of 2014, yet investors pinned their hope on sustained recovery.
Normally, smaller companies pick up faster than the larger ones in a growing economy. Since these pint-sized securities usually focus more on the domestic market, they are less ruffled by international worries than their globally exposed larger counterparts. As a result, small-caps are leading the way this year, with iShares S&P Small-Cap 600 Growth ETF (IJT) having added more than 6% in the year-to-date frame (as of March 18).
In such a situation, the Fed came up with a caution stance on domestic growth. The central bank also slashed the U.S. economic growth projection (considering the central tendency method) for 2015 from 2.6−3% (guided in December) to 2.3−2.7%. The growth projections for 2016 and 2017 were also cut to 2.3−2.7% and 2.0−2.4%, respectively, from 2.5−3% and 2.3−2.5%.
Plus, the Fed seeks further stabilization in the labor market and inflation numbers before taking a decision of hiking interest rates. While a strong possibility of delayed rate hike should spur the small-cap ETFs space, moderation in economic growth is no less a threat. In such a situation, a value or dividend play could soothe investors' nerves to some extent.
Small-Cap Dividends on the Rise
Per Financial Times , dividend initiations or increments have prevailed among the small-cap U.S. companies over the last 15 months. More than 50% of the 600 companies in the small-cap index pay out a dividend now. The figure lags the S&P 500 by 15 bps but surpasses its mid-cap counterparts by 12 bps.
Over the last 20 years ending December 2014, dividend issues in the S&P Small Cap 600 index grew about 22.3% compared to a 3.4% decline in the S&P 500 index. As per S&P Dow Jones indices , at the current level, '202 issues will pay more than they paid in 2014; 255 paid more in 2014 than 2013 and 139 paid more in 2013 than 2012'.
In such a backdrop, small-caps with a tilt toward value notion and dividend focus might seem intriguing ideas. Below, we have highlighted some of the small cap high yield ETFs that are outperforming in the small cap space and could be ones to watch in the months ahead (read: Investor Guide to Small-Cap Value ETFs ).
SmallCap Dividend Fund ( DES )
DES looks to track the performance of the WisdomTree SmallCap Dividend Index. The fund is one of the popular choices in the small-cap value space with about $1.21 billion in AUM. It is a low cost (38 bps) option in the small-cap value ETF space.
Holding more than 700 stocks in its basket, the product puts about 10% of its total assets in the top 10 holdings, suggesting low concentration risk. Sector wise, this ETF is heavy on financials (24.9%) followed by industrials (15.7%) and consumer discretionary (15.6%).
The fund has lost about 0.4% in the YTD time frame, though it was up about 2.3% in the last one week (as of March 18, 2015). DES has a yield of 2.45% per annum. The fund carries a Medium risk outlook along with a Zacks ETF Rank #3 (Hold).
PowerShares S&P SmallCap Utilities Portfolio (PSCU)
The utility sector in any case is known for high dividend payouts and stability. Only one glitch associated with the sector is the rising rate concern. However, with this very concern now apparently taking a pause due to a backward shift in the timing of interest rate hike, the utility sector should perform well this year (read: 3 Best Performing Small Cap Sector ETFs of 2014 ).
A good way to play this trend is with PSCU, which follows the S&P Small Cap 600 Utilities Index. This fund added 2.4% in the last five trading sessions (as of March 18, 2015). The ETF has accumulated $42.6 million in its asset base while volume is paltry at 5,000 shares a day, suggesting additional cost in the form of a wide bid/ask spread beyond the expense ratio of 0.29%.
Holding 20 stocks, the product is concentrated on the top 10. The dividend yield of the fund was 2.39% (as of March 18, 2015). PSCU has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook.
S&P SmallCap Low Volatility Portfolio (XSLV)
The fund seeks to match the price and performance of the S&P SmallCap 600 Low Volatility Index. This product is appropriate for investors looking to participate in U.S. small cap market growth while limiting portfolio volatility (read: Can Small Cap Low Volatility ETFs Continue Their Hot Streak? ).
The fund is well spread out across various components as each security holds less than 1.43% of total assets. However, the product is heavily dependent on the financial sector at 55.1%, with industrials and utilities also taking double-digit exposure. The fund puts about $77.3 million of assets in 120 holdings. The fund was up 3.9% in the last five trading sessions (as of March 18, 2015). The fund had a dividend yield of 2.38% (as of the same date).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ISHARS-SP SC GR (IJT): ETF Research Reports
WISDMTR-SC DIV (DES): ETF Research Reports
PWRSH-SP SC UTL (PSCU): ETF Research Reports
PWRSH-SP SC LVP (XSLV): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
SmallCap Dividend Fund ( DES ) DES looks to track the performance of the WisdomTree SmallCap Dividend Index. DES has a yield of 2.45% per annum. Click to get this free report ISHARS-SP SC GR (IJT): ETF Research Reports WISDMTR-SC DIV (DES): ETF Research Reports PWRSH-SP SC UTL (PSCU): ETF Research Reports PWRSH-SP SC LVP (XSLV): ETF Research Reports To read this article on Zacks.com click here.
|
Click to get this free report ISHARS-SP SC GR (IJT): ETF Research Reports WISDMTR-SC DIV (DES): ETF Research Reports PWRSH-SP SC UTL (PSCU): ETF Research Reports PWRSH-SP SC LVP (XSLV): ETF Research Reports To read this article on Zacks.com click here. SmallCap Dividend Fund ( DES ) DES looks to track the performance of the WisdomTree SmallCap Dividend Index. DES has a yield of 2.45% per annum.
|
Click to get this free report ISHARS-SP SC GR (IJT): ETF Research Reports WISDMTR-SC DIV (DES): ETF Research Reports PWRSH-SP SC UTL (PSCU): ETF Research Reports PWRSH-SP SC LVP (XSLV): ETF Research Reports To read this article on Zacks.com click here. SmallCap Dividend Fund ( DES ) DES looks to track the performance of the WisdomTree SmallCap Dividend Index. DES has a yield of 2.45% per annum.
|
SmallCap Dividend Fund ( DES ) DES looks to track the performance of the WisdomTree SmallCap Dividend Index. DES has a yield of 2.45% per annum. Click to get this free report ISHARS-SP SC GR (IJT): ETF Research Reports WISDMTR-SC DIV (DES): ETF Research Reports PWRSH-SP SC UTL (PSCU): ETF Research Reports PWRSH-SP SC LVP (XSLV): ETF Research Reports To read this article on Zacks.com click here.
|
fd5a9188-27ba-4efd-a30d-50e322dd877c
|
728434.0
|
2015-03-19 00:00:00 UTC
|
Medtronic Up on Positive Preclinical Drug-Filled Stent Results - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/medtronic-up-on-positive-preclinical-drug-filled-stent-results-analyst-blog-2015-03-19
|
nan
|
nan
|
In an attempt to expand its interventional cardiology products portfolio, Medtronic plcMDT recently revealed preclinical outcomes of its latest, groundbreaking Drug-Filled Stent (DFS), demonstrating the device's safety and efficiency, at the 64 th Annual Scientific Session of the American College of Cardiology (ACC).
Following the news release, shares of this medical technology giant have risen 1.5% to eventually close at $77.61 yesterday.
The preclinical results validated Medtronic's DFS as a unique, next-generation stent device that allows controlled yet effective, polymer free drug elution over a desired period of time, directly into the arterial wall of coronary heart patients. The device was also found to minimize the chance of any diameter stenosis event and rapidly achieve complete stent coverage, accompanied by zero inflammation and adverse vascular responses.
Buoyed by the positive data, management plans to start a clinical trial - a first of its kind - involving the study of Medtronic's novel DFS, over the coming months. This 100-patient global study will analyze late lumen loss utilizing quantitative coronary angiography, at multiple sites in Australia and Brazil.
According to management, physicians face multiple complications while treating coronary patients with both bioabsorbable polymers and polymer-free technologies. Medtronic's primary purpose behind developing the novel internally-loaded DFS was to address these issues.
Management was pleased to declare that the preclinical outcomes confirm the ability of the polymer-free DFS to control drug release by eliminating any possibility of inflammation caused by polymer degradation.
Evidently, second-generation drug eluting stent (DES) technologies have delivered clinically superior outcomes in comparison to first generation DES in a broad spectrum of patient anatomies. Controlled polymer-free drug elution allows further optimized treatment option, both in the short and the long run.
Remarkably, Medtronic's DFS is based on the proven platform of Medtronic's first generation Resolute Integrity DES and the second-generation Resolute Onyx DES that incorporates the CoreWire Technology - which offers advanced visibility during the stenting procedure.
Currently, Medtronic's DFS is available for investigational use only and has not been approved for commercial use.
In the third quarter of fiscal 2015, Medtronic launched its second-generation Resolute Onyx DES in the international market. The device is seeks to provide improved drug deliverability without compromising radial and longitudinal strength, thus enhancing the efficiency of stenting procedures.
We believe the aforementioned news adds yet another milestone to Medtronic's ever-expanding interventional cardiology portfolio. We expect this development to help expand the company's shares in the global coronary stent market, which, according to CNBC, is expected to grow at a CAGR of 4.54% over the period 2013-2018.
Currently, the stock carries a Zacks Rank #2 (Buy). Some other top-ranked medical products stocks are Abaxis, Inc. ABAX , LeMaitre Vascular, Inc. LMAT and Phibro Animal Health Corp. PAHC . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
ABAXIS INC (ABAX): Free Stock Analysis Report
LEMAITRE VASCLR (LMAT): Free Stock Analysis Report
PHIBRO ANIMAL (PAHC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The preclinical results validated Medtronic's DFS as a unique, next-generation stent device that allows controlled yet effective, polymer free drug elution over a desired period of time, directly into the arterial wall of coronary heart patients. Evidently, second-generation drug eluting stent (DES) technologies have delivered clinically superior outcomes in comparison to first generation DES in a broad spectrum of patient anatomies. Remarkably, Medtronic's DFS is based on the proven platform of Medtronic's first generation Resolute Integrity DES and the second-generation Resolute Onyx DES that incorporates the CoreWire Technology - which offers advanced visibility during the stenting procedure.
|
The preclinical results validated Medtronic's DFS as a unique, next-generation stent device that allows controlled yet effective, polymer free drug elution over a desired period of time, directly into the arterial wall of coronary heart patients. Evidently, second-generation drug eluting stent (DES) technologies have delivered clinically superior outcomes in comparison to first generation DES in a broad spectrum of patient anatomies. Remarkably, Medtronic's DFS is based on the proven platform of Medtronic's first generation Resolute Integrity DES and the second-generation Resolute Onyx DES that incorporates the CoreWire Technology - which offers advanced visibility during the stenting procedure.
|
The preclinical results validated Medtronic's DFS as a unique, next-generation stent device that allows controlled yet effective, polymer free drug elution over a desired period of time, directly into the arterial wall of coronary heart patients. Remarkably, Medtronic's DFS is based on the proven platform of Medtronic's first generation Resolute Integrity DES and the second-generation Resolute Onyx DES that incorporates the CoreWire Technology - which offers advanced visibility during the stenting procedure. Evidently, second-generation drug eluting stent (DES) technologies have delivered clinically superior outcomes in comparison to first generation DES in a broad spectrum of patient anatomies.
|
The preclinical results validated Medtronic's DFS as a unique, next-generation stent device that allows controlled yet effective, polymer free drug elution over a desired period of time, directly into the arterial wall of coronary heart patients. Evidently, second-generation drug eluting stent (DES) technologies have delivered clinically superior outcomes in comparison to first generation DES in a broad spectrum of patient anatomies. Remarkably, Medtronic's DFS is based on the proven platform of Medtronic's first generation Resolute Integrity DES and the second-generation Resolute Onyx DES that incorporates the CoreWire Technology - which offers advanced visibility during the stenting procedure.
|
20794ff4-0f7f-4663-99d1-f4f71b5a811c
|
728435.0
|
2015-03-16 00:00:00 UTC
|
Medtronic Starts US DES Trial for Small Vessel CAD Patients - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/medtronic-starts-us-des-trial-for-small-vessel-cad-patients-analyst-blog-2015-03-16
|
nan
|
nan
|
Medical technology giant Medtronic plcMDT recently initiated the Resolute Onyx Clinical Program in the U.S. This study aims at estimating the clinical efficacy of the company's Resolute Onyx drug eluting stent (DES) in patients who suffer from coronary artery disease.
The study is in line with Medtronic's attempts to offer advanced solutions for unmet medical needs in cardiovascular diseases facilitated by the joint efforts of improved biologics and therapy delivery devices.
In its initial phase, this study will consider patients who have small blood vessels and hence require a 2.0 mm sized stent. Notably, before this trial, most patients with narrow blood vessels were considered untreatable with a DES.
According to Medtronic's management, one of the toughest challenges that a healthcare provider in the interventional cardiology market face is that of treating coronary artery disease (CAD) patients with small blood vessels. Unfortunately, such a medical condition is rather common in diabetic patients who suffer from heart ailments, and this patient population is rapidly increasing every year across the globe.
Medtronic's Resolute Onyx DES - a next-generation coronary stent that has been developed on the proven clinical performance and superior deliverability of Medtronic's well-acclaimed Resolute Integrity DES - incorporates the CoreWire Technology, which offers advanced visibility during the stenting procedure.
The device also helps in providing improved deliverability without compromising radial and longitudinal strength. This enhances the efficiency of stent implanting (stenting) procedures.
Currently, the Resolute Onyx DES is not available for commercial purposes in the U.S. However, it is available in the European countries that approve the CE Mark, which the device received in Nov 2014. The company is currently seeing healthy uptake of this device in these countries.
With the Resolute Onyx Clinical Program off to a start, management expects to highlight the technological advancements that allow Resolute Onyx DES to enable physicians to increase procedural efficiency and enhanced deliverability in stenting procedures, involving a wide range of vessel sizes.
In the last reported fiscal third quarter, with respect to its broader Coronary product portfolio, the company has been experiencing the continued rollout of its new NC Euphora Noncompliant PTCA Balloon family, as well as strong sequential growth in U.S. revenues from its FFR co-promotion alliance with Acist Medical Systems.
In Feb 2015, Medtronic launched the Euphora Semicompliant Balloon Dilatation Catheter in countries that recognize the CE mark. It is not yet commercially available in the U.S.
We believe such back-to-back achievements in the global coronary market will allow Medtronic to expand its share in there, going forward. In particular, we expect the domestic coronary market to ride high on the back of the Resolute Onyx DES, once it becomes available in the U.S.
Currently, the stock carries a Zacks Rank #2 (Buy). Some other top-ranked medical products stocks are Abaxis, Inc. ABAX , LeMaitre Vascular, Inc. LMAT and Phibro Animal Health Corp. PAHC . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
ABAXIS INC (ABAX): Free Stock Analysis Report
LEMAITRE VASCLR (LMAT): Free Stock Analysis Report
PHIBRO ANIMAL (PAHC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
This study aims at estimating the clinical efficacy of the company's Resolute Onyx drug eluting stent (DES) in patients who suffer from coronary artery disease. Notably, before this trial, most patients with narrow blood vessels were considered untreatable with a DES. Medtronic's Resolute Onyx DES - a next-generation coronary stent that has been developed on the proven clinical performance and superior deliverability of Medtronic's well-acclaimed Resolute Integrity DES - incorporates the CoreWire Technology, which offers advanced visibility during the stenting procedure.
|
This study aims at estimating the clinical efficacy of the company's Resolute Onyx drug eluting stent (DES) in patients who suffer from coronary artery disease. Notably, before this trial, most patients with narrow blood vessels were considered untreatable with a DES. Medtronic's Resolute Onyx DES - a next-generation coronary stent that has been developed on the proven clinical performance and superior deliverability of Medtronic's well-acclaimed Resolute Integrity DES - incorporates the CoreWire Technology, which offers advanced visibility during the stenting procedure.
|
Medtronic's Resolute Onyx DES - a next-generation coronary stent that has been developed on the proven clinical performance and superior deliverability of Medtronic's well-acclaimed Resolute Integrity DES - incorporates the CoreWire Technology, which offers advanced visibility during the stenting procedure. With the Resolute Onyx Clinical Program off to a start, management expects to highlight the technological advancements that allow Resolute Onyx DES to enable physicians to increase procedural efficiency and enhanced deliverability in stenting procedures, involving a wide range of vessel sizes. This study aims at estimating the clinical efficacy of the company's Resolute Onyx drug eluting stent (DES) in patients who suffer from coronary artery disease.
|
This study aims at estimating the clinical efficacy of the company's Resolute Onyx drug eluting stent (DES) in patients who suffer from coronary artery disease. Medtronic's Resolute Onyx DES - a next-generation coronary stent that has been developed on the proven clinical performance and superior deliverability of Medtronic's well-acclaimed Resolute Integrity DES - incorporates the CoreWire Technology, which offers advanced visibility during the stenting procedure. Notably, before this trial, most patients with narrow blood vessels were considered untreatable with a DES.
|
72400947-e7d4-4fb7-b206-46aed708821e
|
728436.0
|
2015-02-04 00:00:00 UTC
|
Boston Scientific Tops Q4 Earnings, Revenues Miss Mark - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/boston-scientific-tops-q4-earnings-revenues-miss-mark-analyst-blog-2015-02-04
|
nan
|
nan
|
BostonScientific Corporation ( BSX ) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 15 cents in the fourth quarter of 2014, 15.4% ahead of the year-ago adjusted number.
However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 22 cents, 4.8% ahead of both the year-ago adjusted number and the Zacks Consensus Estimate. The figure coincides with the upper end of the company's adjusted EPS guidance range of 20-22 cents.
Without these adjustments, the company reported net income of $87 million or EPS of 6 cents in the quarter, down from the year-ago net income of $108 million or EPS of 8 cents, respectively.
For full year 2014, Boston Scientific reported adjusted earnings (considering certain one-time adjustments including amortization expense) of 84 cents per share, reflecting a year-
|
The figure coincides with the upper end of the company's adjusted EPS guidance range of 20-22 cents. Without these adjustments, the company reported net income of $87 million or EPS of 6 cents in the quarter, down from the year-ago net income of $108 million or EPS of 8 cents, respectively. For full year 2014, Boston Scientific reported adjusted earnings (considering certain one-time adjustments including amortization expense) of 84 cents per share, reflecting a year-
|
The figure coincides with the upper end of the company's adjusted EPS guidance range of 20-22 cents. BostonScientific Corporation ( BSX ) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 15 cents in the fourth quarter of 2014, 15.4% ahead of the year-ago adjusted number. However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 22 cents, 4.8% ahead of both the year-ago adjusted number and the Zacks Consensus Estimate.
|
The figure coincides with the upper end of the company's adjusted EPS guidance range of 20-22 cents. BostonScientific Corporation ( BSX ) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 15 cents in the fourth quarter of 2014, 15.4% ahead of the year-ago adjusted number. However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 22 cents, 4.8% ahead of both the year-ago adjusted number and the Zacks Consensus Estimate.
|
The figure coincides with the upper end of the company's adjusted EPS guidance range of 20-22 cents. BostonScientific Corporation ( BSX ) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 15 cents in the fourth quarter of 2014, 15.4% ahead of the year-ago adjusted number. Without these adjustments, the company reported net income of $87 million or EPS of 6 cents in the quarter, down from the year-ago net income of $108 million or EPS of 8 cents, respectively.
|
2447b9d2-e114-4710-972a-4c7c4d24e1b8
|
728437.0
|
2015-01-06 00:00:00 UTC
|
WGL Holdings Inc (WGL) Ex-Dividend Date Scheduled for January 07, 2015
|
DES
|
https://www.nasdaq.com/articles/wgl-holdings-inc-wgl-ex-dividend-date-scheduled-january-07-2015-2015-01-06
|
nan
|
nan
|
WGL Holdings Inc ( WGL ) will begin trading ex-dividend on January 07, 2015. A cash dividend payment of $0.44 per share is scheduled to be paid on February 01, 2015. Shareholders who purchased WGL stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that WGL has paid the same dividend.
The previous trading day's last sale of WGL was $53.51, representing a -5.78% decrease from the 52 week high of $56.79 and a 51.35% increase over the 52 week low of $35.36.
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Cheniere Energy Partners, LP ( CQP ). WGL's current earnings per share, an indicator of a company's profitability, is $2.05. Zacks Investment Research reports WGL's forecasted earnings growth in 2015 as 4.1%, compared to an industry average of -9.2%.
For more information on the declaration, record and payment dates, visit the WGL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to WGL through an Exchange Traded Fund [ETF]?
The following ETF(s) have WGL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 3.28% over the last 100 days. It also has the highest percent weighting of WGL at 0.89%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Cheniere Energy Partners, LP ( CQP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 3.28% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Cheniere Energy Partners, LP ( CQP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Cheniere Energy Partners, LP ( CQP ). The top-performing ETF of this group is DES with an increase of 3.28% over the last 100 days.
|
The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Cheniere Energy Partners, LP ( CQP ). The top-performing ETF of this group is DES with an increase of 3.28% over the last 100 days.
|
7aacd752-cb00-4332-aed0-a03a591ccd77
|
728438.0
|
2014-12-19 00:00:00 UTC
|
Covanta Holding Corporation (CVA) Ex-Dividend Date Scheduled for December 22, 2014
|
DES
|
https://www.nasdaq.com/articles/covanta-holding-corporation-cva-ex-dividend-date-scheduled-december-22-2014-2014-12-19
|
nan
|
nan
|
Covanta Holding Corporation ( CVA ) will begin trading ex-dividend on December 22, 2014. A cash dividend payment of $0.25 per share is scheduled to be paid on January 02, 2015. Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 51.52% increase over the same period a year ago. At the current stock price of $21.9, the dividend yield is 4.57%.
The previous trading day's last sale of CVA was $21.9, representing a -13.59% decrease from the 52 week high of $25.35 and a 33.37% increase over the 52 week low of $16.42.
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). CVA's current earnings per share, an indicator of a company's profitability, is $.22. Zacks Investment Research reports CVA's forecasted earnings growth in 2014 as 15.79%, compared to an industry average of 38.4%.
For more information on the declaration, record and payment dates, visit the CVA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CVA through an Exchange Traded Fund [ETF]?
The following ETF(s) have CVA as a top-10 holding:
iShares S&P Global Clean Energy Index Fund ( ICLN )
First Trust RBA American Industrial Renaissance ETF ( AIRR )
Market Vectors Environment Index ETF Fund ( EVX )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 4.1% over the last 100 days. ICLN has the highest percent weighting of CVA at 5.24%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 4.1% over the last 100 days.
|
The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ).
|
The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The top-performing ETF of this group is DES with an increase of 4.1% over the last 100 days.
|
The top-performing ETF of this group is DES with an increase of 4.1% over the last 100 days. CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
46eb7b1a-e95d-447e-9b64-2234e703f4e1
|
728439.0
|
2014-12-12 00:00:00 UTC
|
UIL Holdings Corporation (UIL) Ex-Dividend Date Scheduled for December 15, 2014
|
DES
|
https://www.nasdaq.com/articles/uil-holdings-corporation-uil-ex-dividend-date-scheduled-december-15-2014-2014-12-12
|
nan
|
nan
|
UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on December 15, 2014. A cash dividend payment of $0.432 per share is scheduled to be paid on January 02, 2015. Shareholders who purchased UIL stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 34th quarter that UIL has paid the same dividend. At the current stock price of $43.35, the dividend yield is 3.99%.
The previous trading day's last sale of UIL was $43.35, representing a -0.85% decrease from the 52 week high of $43.72 and a 26.24% increase over the 52 week low of $34.34.
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). UIL's current earnings per share, an indicator of a company's profitability, is $2.08. Zacks Investment Research reports UIL's forecasted earnings growth in 2014 as -5.19%, compared to an industry average of 1.1%.
For more information on the declaration, record and payment dates, visit the UIL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to UIL through an Exchange Traded Fund [ETF]?
The following ETF(s) have UIL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 1.33% over the last 100 days. It also has the highest percent weighting of UIL at 0.9%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 1.33% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The top-performing ETF of this group is DES with an increase of 1.33% over the last 100 days.
|
The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Southern Company ( SO ). The top-performing ETF of this group is DES with an increase of 1.33% over the last 100 days.
|
8b85d288-d432-4899-942a-191f7d0b4a53
|
728440.0
|
2014-12-02 00:00:00 UTC
|
PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for December 03, 2014
|
DES
|
https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-december-03-2014-2014-12-02
|
nan
|
nan
|
PDL BioPharma, Inc. ( PDLI ) will begin trading ex-dividend on December 03, 2014. A cash dividend payment of $0.15 per share is scheduled to be paid on December 12, 2014. Shareholders who purchased PDLI stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 16th quarter that PDLI has paid the same dividend. At the current stock price of $8.08, the dividend yield is 7.43%.
The previous trading day's last sale of PDLI was $8.08, representing a -21.25% decrease from the 52 week high of $10.26 and a 11.91% increase over the 52 week low of $7.22.
PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ). PDLI's current earnings per share, an indicator of a company's profitability, is $1.96.
For more information on the declaration, record and payment dates, visit the PDLI Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to PDLI through an Exchange Traded Fund [ETF]?
The following ETF(s) have PDLI as a top-10 holding:
First Trust DJ Global Select Dividend ( FGD )
WisdomTree SmallCap Earnings Fund ( EES )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 0.09% over the last 100 days. FGD has the highest percent weighting of PDLI at 1.45%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ). The following ETF(s) have PDLI as a top-10 holding: First Trust DJ Global Select Dividend ( FGD ) WisdomTree SmallCap Earnings Fund ( EES ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 0.09% over the last 100 days.
|
The following ETF(s) have PDLI as a top-10 holding: First Trust DJ Global Select Dividend ( FGD ) WisdomTree SmallCap Earnings Fund ( EES ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ).
|
The following ETF(s) have PDLI as a top-10 holding: First Trust DJ Global Select Dividend ( FGD ) WisdomTree SmallCap Earnings Fund ( EES ) WisdomTree Trust SmallCap Dividend Fund ( DES ). PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ). The top-performing ETF of this group is DES with an increase of 0.09% over the last 100 days.
|
The following ETF(s) have PDLI as a top-10 holding: First Trust DJ Global Select Dividend ( FGD ) WisdomTree SmallCap Earnings Fund ( EES ) WisdomTree Trust SmallCap Dividend Fund ( DES ). PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ). The top-performing ETF of this group is DES with an increase of 0.09% over the last 100 days.
|
085255c0-0ee5-41a8-be7a-96d2d59447f1
|
728441.0
|
2014-11-25 00:00:00 UTC
|
Compass Minerals International, Inc. (CMP) Ex-Dividend Date Scheduled for November 26, 2014
|
DES
|
https://www.nasdaq.com/articles/compass-minerals-international-inc-cmp-ex-dividend-date-scheduled-november-26-2014-2014-11
|
nan
|
nan
|
Compass Minerals International, Inc. ( CMP ) will begin trading ex-dividend on November 26, 2014. A cash dividend payment of $0.6 per share is scheduled to be paid on December 15, 2014. Shareholders who purchased CMP stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that CMP has paid the same dividend. At the current stock price of $90.09, the dividend yield is 2.66%.
The previous trading day's last sale of CMP was $90.09, representing a -7.6% decrease from the 52 week high of $97.50 and a 27.71% increase over the 52 week low of $70.54.
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ). CMP's current earnings per share, an indicator of a company's profitability, is $5.8. Zacks Investment Research reports CMP's forecasted earnings growth in 2014 as 16.4%, compared to an industry average of -1.8%.
For more information on the declaration, record and payment dates, visit the CMP Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CMP through an Exchange Traded Fund [ETF]?
The following ETF(s) have CMP as a top-10 holding:
First Trust RBA Quality Income ETF ( QINC )
WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is QINC with an increase of 3.83% over the last 100 days. It also has the highest percent weighting of CMP at 2.13%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ). The following ETF(s) have CMP as a top-10 holding: First Trust RBA Quality Income ETF ( QINC ) WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased CMP stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have CMP as a top-10 holding: First Trust RBA Quality Income ETF ( QINC ) WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ).
|
The following ETF(s) have CMP as a top-10 holding: First Trust RBA Quality Income ETF ( QINC ) WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ). Shareholders who purchased CMP stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ). The following ETF(s) have CMP as a top-10 holding: First Trust RBA Quality Income ETF ( QINC ) WisdomTree U.S. SmallCap Dividend Growth Fund ( DGRS ) WisdomTree Trust SmallCap Dividend Fund ( DES ). A cash dividend payment of $0.6 per share is scheduled to be paid on December 15, 2014.
|
ea38962e-f016-4d71-8fa4-3521262aac2b
|
728442.0
|
2014-11-18 00:00:00 UTC
|
Medtronic (MDT) Posts In Line Earnings, Revenues Beat in Q2 - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/medtronic-mdt-posts-in-line-earnings-revenues-beat-in-q2-analyst-blog-2014-11-18
|
nan
|
nan
|
Medtronic Inc. 's ( MDT ) second-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 96 cents, up 5.5% year over year, after adjusting for certain one-time items including a special charge related to an after-tax charitable cash donation made to the Medtronic Foundation and acquisition-related items primarily associated with the pending Covidien plc ( COV ) acquisition. However, adjusted EPS remained in line with the Zacks Consensus Estimate.
However, the company's reported net income of $828 million or 83 cents a share were down 8.2% and 6.7%, respectively, on a year-over-year basis.
|
Medtronic Inc. 's ( MDT ) second-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 96 cents, up 5.5% year over year, after adjusting for certain one-time items including a special charge related to an after-tax charitable cash donation made to the Medtronic Foundation and acquisition-related items primarily associated with the pending Covidien plc ( COV ) acquisition. However, adjusted EPS remained in line with the Zacks Consensus Estimate. However, the company's reported net income of $828 million or 83 cents a share were down 8.2% and 6.7%, respectively, on a year-over-year basis.
|
Medtronic Inc. 's ( MDT ) second-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 96 cents, up 5.5% year over year, after adjusting for certain one-time items including a special charge related to an after-tax charitable cash donation made to the Medtronic Foundation and acquisition-related items primarily associated with the pending Covidien plc ( COV ) acquisition. However, adjusted EPS remained in line with the Zacks Consensus Estimate. However, the company's reported net income of $828 million or 83 cents a share were down 8.2% and 6.7%, respectively, on a year-over-year basis.
|
Medtronic Inc. 's ( MDT ) second-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 96 cents, up 5.5% year over year, after adjusting for certain one-time items including a special charge related to an after-tax charitable cash donation made to the Medtronic Foundation and acquisition-related items primarily associated with the pending Covidien plc ( COV ) acquisition. However, adjusted EPS remained in line with the Zacks Consensus Estimate. However, the company's reported net income of $828 million or 83 cents a share were down 8.2% and 6.7%, respectively, on a year-over-year basis.
|
Medtronic Inc. 's ( MDT ) second-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 96 cents, up 5.5% year over year, after adjusting for certain one-time items including a special charge related to an after-tax charitable cash donation made to the Medtronic Foundation and acquisition-related items primarily associated with the pending Covidien plc ( COV ) acquisition. However, adjusted EPS remained in line with the Zacks Consensus Estimate. However, the company's reported net income of $828 million or 83 cents a share were down 8.2% and 6.7%, respectively, on a year-over-year basis.
|
5b3aa2f7-f56d-41df-9608-2bddcc588d86
|
728443.0
|
2014-11-11 00:00:00 UTC
|
Diebold, Incorporated (DBD) Ex-Dividend Date Scheduled for November 12, 2014
|
DES
|
https://www.nasdaq.com/articles/diebold-incorporated-dbd-ex-dividend-date-scheduled-november-12-2014-2014-11-11
|
nan
|
nan
|
Diebold, Incorporated ( DBD ) will begin trading ex-dividend on November 12, 2014. A cash dividend payment of $0.2875 per share is scheduled to be paid on December 05, 2014. Shareholders who purchased DBD stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 8th quarter that DBD has paid the same dividend. At the current stock price of $36.02, the dividend yield is 3.19%.
The previous trading day's last sale of DBD was $36.02, representing a -13.1% decrease from the 52 week high of $41.45 and a 22.73% increase over the 52 week low of $29.35.
DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). DBD's current earnings per share, an indicator of a company's profitability, is $.65. Zacks Investment Research reports DBD's forecasted earnings growth in 2014 as 30.64%, compared to an industry average of 5.1%.
For more information on the declaration, record and payment dates, visit the DBD Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to DBD through an Exchange Traded Fund [ETF]?
The following ETF(s) have DBD as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 1.26% over the last 100 days. It also has the highest percent weighting of DBD at 0.82%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 1.26% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). The top-performing ETF of this group is DES with an increase of 1.26% over the last 100 days.
|
DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 1.26% over the last 100 days.
|
03373a76-2197-48f2-bbc2-e728443921fd
|
728444.0
|
2014-10-22 00:00:00 UTC
|
Boston Scientific Earnings, Revenues in Line; View Up - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/boston-scientific-earnings-revenues-in-line-view-up-analyst-blog-2014-10-22
|
nan
|
nan
|
BostonScientific ( BSX ) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 13 cents in the third quarter of 2014, 30% ahead of the year-ago adjusted number.
However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 20 cents, 17.6% ahead of the year-ago adjusted number. This coincides with the upper end of the company's adjusted EPS guidance range of 18-20 cents and is on par with the Zacks Consensus Estimate.
Without these adjustments, the company reported net income of $43 million or EPS of 3 cents in the quarter, a huge increase from the year-ago net loss of $5 million or breakeven earnings a share, respectively.
Boston Scientific Corporation - Earnings Surprise | FindTheBest
Revenues in the third quarter registered a 6.4% increase year over year (7% growth at constant exchange rate or CER, excluding divested business) to $1.846 billion. The figure exceeded the Zacks Consensus Estimate of $1.822 billion. Earlier, the company had provided third quarter revenue expectation in the range of $1.79-$1.84 billion.
Segment Analysis
Boston Scientific currently has three global reportable segments comprising Cardiovascular, Rhythm Management and MedSurg.
The company generates maximum revenues from Cardiovascular, which comprises Interventional Cardiology and Peripheral Interventions. Sales in these sub-segments were $508 million (up 8% year over year at CER) and $215 million (up 9%), respectively, during the quarter.
Global sales of coronary stent system (within Interventional Cardiology) were $298 million, up 7.6%. The improvement in drug-eluting stents (DES) performance that increased 9.2% to $286 million was partially offset by the poor bare-metal stents performance that plunged 20% to $12 million.
The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. CRM reflected sales improvement of 4% to $480 million at CER.
Worldwide sales from pacemakers (within CRM) dropped 1.5% to $132 million, while defibrillators increased 5.5% to $348 million.
Electrophysiology sales surged a massive 57% year over year at CER to $54 million.
Over the recent past, the company has been targeting new product launches to revive the sales of the beleaguered Interventional Cardiology and CRM segments. The improved performance in these core segments in the reported quarter, proved beyond doubt that the measures undertaken are working effectively to counter the ongoing challenges.
Other segments like Endoscopy, Urology/Women's Health and Neuromodulation (coming under the MedSurg broader group) recorded sales of $336 million (up 7% at CER), $137 million (up 5%) and $115 million (no growth), respectively.
Margins
Gross margin was down 40 basis points (bps) year over year to 70.2%. Adjusted operating margin contracted 112 bps to 17.4% in the quarter. During the reported quarter, selling, general and administrative expenses increased 12.6% to $741 million while research and development expenses dropped 2.3% to $212 million. Royalty expense also plunged 25% to $21 million.
Balance Sheet
Boston Scientific exited the third quarter with cash and cash equivalents of $246 million, up from $217 million at the end of fiscal 2013, and had long-term debt of $4.25 billion. The company generated operating cash flow of $346 million in the quarter.
Guidance
Boston Scientific increased the lower end of its 2014 adjusted EPS guidance to the range of 81-83 cents from the earlier guided 79-83 cents (considering all one-time items including amortized expense). Estimated revenues, on the other hand, have been narrowed to $7.370-$7.420 billion (growth of 3% to 4% on an operational basis) from the earlier guidance of $7.325-$7.425 billion (growth of 3% to 5%). The current Zacks Consensus Estimate for EPS of 82 cents and revenues of $7.394 billion coincide with the company's outlook.
For the fourth quarter of 2014, adjusted earnings are expected to remain in the band of 20-22 cents per share while the company predicts revenues within $1.875−$1.925 million. The Zacks Consensus Estimate for EPS stands at 21 cents, while that for revenues is $1.919 billion.
Our Take
Despite challenging economic conditions, a competitive environment, pressure on margins and currency headwinds, Boston Scientific posted a decent third-quarter 2014, in line with our estimates on both the earnings and revenue front. The companyhas managed to post an impressive performance with balanced growth across all its segments. Moreover, the improved guidance for 2014 also helps us to rely on the sustainability of this growth performance.
We are also optimistic about the recent update on the company's growth objectives. Boston Scientific is focusing on strategic initiatives like portfolio expansion, restructuring initiatives which include the 2014 restructuring plan, focus on emerging markets and share repurchases.
Moreover, Boston Scientific has a strong pipeline of products under development, the launch of which should drive the top line. We are, at the same time, encouraged by the focus on emerging markets, especially India and China.
We take a note that recently the company closed the acquisition of the Interventional Division of Bayer AG which it expects to boost growth in peripheral atherectomy and thrombectomy categories.
Currently, Boston Scientific retains a Zacks Rank #3 (Hold). Some of the better-placed Medical Product stocks are Abaxis, Inc. ( ABAX ), Alere Inc. ( ALR ) and ICU Medical, Inc. ( ICUI ), all carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
ABAXIS INC (ABAX): Free Stock Analysis Report
ALERE INC (ALR): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Our Take Despite challenging economic conditions, a competitive environment, pressure on margins and currency headwinds, Boston Scientific posted a decent third-quarter 2014, in line with our estimates on both the earnings and revenue front. This coincides with the upper end of the company's adjusted EPS guidance range of 18-20 cents and is on par with the Zacks Consensus Estimate. The improvement in drug-eluting stents (DES) performance that increased 9.2% to $286 million was partially offset by the poor bare-metal stents performance that plunged 20% to $12 million.
|
This coincides with the upper end of the company's adjusted EPS guidance range of 18-20 cents and is on par with the Zacks Consensus Estimate. The improvement in drug-eluting stents (DES) performance that increased 9.2% to $286 million was partially offset by the poor bare-metal stents performance that plunged 20% to $12 million. The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.
|
This coincides with the upper end of the company's adjusted EPS guidance range of 18-20 cents and is on par with the Zacks Consensus Estimate. The improvement in drug-eluting stents (DES) performance that increased 9.2% to $286 million was partially offset by the poor bare-metal stents performance that plunged 20% to $12 million. The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.
|
This coincides with the upper end of the company's adjusted EPS guidance range of 18-20 cents and is on par with the Zacks Consensus Estimate. The improvement in drug-eluting stents (DES) performance that increased 9.2% to $286 million was partially offset by the poor bare-metal stents performance that plunged 20% to $12 million. The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.
|
bd7cdb7e-d4cb-4a3e-be99-c79f7f8176b8
|
728445.0
|
2014-10-08 00:00:00 UTC
|
Investor Guide to Small-Cap Value ETFs - ETF News And Commentary
|
DES
|
https://www.nasdaq.com/articles/investor-guide-to-small-cap-value-etfs-etf-news-and-commentary-2014-10-08
|
nan
|
nan
|
The U.S. stock markets are in decent shape since the second quarter of the year with the S&P 500 hovering near the 2,000 mark for the first time. Two other benchmark indices including Dow Jones and Nasdaq also clocked solid gains during this phase.
The U.S. economy advanced 4.6 % in the second quarter indicating the best clip after the fourth quarter of 2011 thanks to improved activities both at corporate and household levels. Most of the economic indicators released recently, be it consumer confidence, manufacturing, inflation and job-less data, were relatively upbeat.
Investors should note that while faster growth is setting in the U.S., foreign markets were sluggish with the Euro zone buckling under the pressure of deflationary concerns, China still showing soft economic numbers and Japan seeing deceleration in growth pace.
Why Small-Cap Value ETFs?
This economic trend should stage a proper backdrop for small-cap U.S. stocks. Normally, smaller companies pick up faster than the larger ones in a growing economy. Since these pint-sized securities usually focus more on the domestic market, they are less ruffled by international worries than their globally exposed larger counterparts. This is especially true as a pile of woes hit a number of developing and emerging nations this year and next year.
Having said this, we emphasize value picks in the small-cap spectrum. Small-caps have the potential to offer good returns in a trending market, but these are often blamed for increasing volatility. Thus, investors seeking equity appreciation with a lower level of risk should look for value notion in the small-cap space (read: Endure Market Volatility with These ETFs ).
This is especially true given that the Fed will end its asset repurchase program this October and there is a strong chance that the short-term interest rates will be hiked mid next year. However, the Fed has not made it official till now and has instead reiterated that it will keep the rates low for a 'considerable time'. But, all seem to be convinced that sooner or later, the U.S. economy will soon see the end of a prolonged low-rate environment.
Though the U.S. economy is on the right track, a sudden tightening in the Fed policy might cause some disruptions in the market activities. Also, as the markets are hovering around lofty levels, many perceive that the U.S. equities as slightly over-valued currently.
In such a backdrop, value investing will be an intriguing option as this investment pattern takes into account under-priced securities. These stocks normally have low P/E, P/B ratios and high dividend yields. In short, small-cap value ETFs have the potential to offer investors both capital appreciation and low volatility (read: 3 Ultra Cheap ETFs for Value Investors ).
Small caps are presently exhibiting a losing streak. However, losses were less acute in the value ETF pack. Below, we have highlighted some of the top performing small cap value ETFs that are outperforming in the small cap space and could be ones to watch in the months ahead.
Vanguard Small-Cap Value ETF (VBR)
This fund provides exposure to the value segment of the U.S. small cap market by tracking the CRSP US Small Cap Value Index. It holds a large basket of 819 stocks, which is widely spread across individual securities as none of these has more than 0.5% of assets.
In terms of sector exposure, financials dominate the portfolio at 28.2%, followed by industrials (20.8%) and consumer services (13.1%). The ETF is quite popular with AUM of more than $4.53 billion and trades in good average daily volume of about 125,000 shares. It is one of the low cost choices in the small cap space, charging 9 bps in fees per year from investors.
The fund has added about 2.3% so far this year (as of October 3, 2014) versus 4.7% loss incurred by the biggest small-cap value ETF iShares Russell 2000 Value ETF ( IWN ). VBR has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook. VBR has a dividend yield of 1.83% (read: 3 Small Cap Value ETFs Poised to Outperform ).
iShares Morningstar Small-Cap Value ETF (JKL)
JKL is designed to track the performance of the Morningstar Small Value Index. The fund invests about $378 million of assets in its 130-securities portfolio. No single firm makes up more than 0.88% of the portfolio.
Only 7.45% focus on the top-10 holdings suggests extremely low concentration risk. As such, we have a 'Medium' risk outlook for JKL in the near term (see Create a Diversified Portfolio Using ETFs ).
The choice charges investors only 0.30% for this exposure which makes it a reasonable one in the space. In terms of sector exposure, financials (15%), industrials (9.5%) and consumer services (5.2%) rule the product.
The fund has returned about 0.9% so far this year. JKL has a yield of 1.99% per annum. This product also carries a Zacks ETF Rank #2 (Buy).
SmallCap Dividend Fund (DES)
DES looks to track the performance of the WisdomTree SmallCap Dividend Index. The fund is one of the popular choices in the small-cap value space with about $988 million in AUM. It is a low cost (38 bps) option in the small-cap value ETF space.
Holding more than 600 stocks in its basket, the product puts more than 10% of its total assets in the top 10 holdings, suggesting low concentration risk. Sector wise, this ETF is heavy on financials (26.4%) followed by industrials (17.93%) and utilities (12.6%).
The fund has lost about 2.6% in the YTD time frame. DES has a yield of 2.81% per annum. The fund carries a Medium risk outlook along with a Zacks ETF Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
VIPERS-SC VALUE (VBR): ETF Research Reports
ISHARS-MO SC VL (JKL): ETF Research Reports
WISDMTR-SC DIV (DES): ETF Research Reports
ISHARS-RS 2K VL (IWN): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Vanguard Small-Cap Value ETF (VBR) This fund provides exposure to the value segment of the U.S. small cap market by tracking the CRSP US Small Cap Value Index. The ETF is quite popular with AUM of more than $4.53 billion and trades in good average daily volume of about 125,000 shares. iShares Morningstar Small-Cap Value ETF (JKL) JKL is designed to track the performance of the Morningstar Small Value Index.
|
iShares Morningstar Small-Cap Value ETF (JKL) JKL is designed to track the performance of the Morningstar Small Value Index. Click to get this free report VIPERS-SC VALUE (VBR): ETF Research Reports ISHARS-MO SC VL (JKL): ETF Research Reports WISDMTR-SC DIV (DES): ETF Research Reports ISHARS-RS 2K VL (IWN): ETF Research Reports To read this article on Zacks.com click here. Vanguard Small-Cap Value ETF (VBR) This fund provides exposure to the value segment of the U.S. small cap market by tracking the CRSP US Small Cap Value Index.
|
Vanguard Small-Cap Value ETF (VBR) This fund provides exposure to the value segment of the U.S. small cap market by tracking the CRSP US Small Cap Value Index. Click to get this free report VIPERS-SC VALUE (VBR): ETF Research Reports ISHARS-MO SC VL (JKL): ETF Research Reports WISDMTR-SC DIV (DES): ETF Research Reports ISHARS-RS 2K VL (IWN): ETF Research Reports To read this article on Zacks.com click here. The ETF is quite popular with AUM of more than $4.53 billion and trades in good average daily volume of about 125,000 shares.
|
Vanguard Small-Cap Value ETF (VBR) This fund provides exposure to the value segment of the U.S. small cap market by tracking the CRSP US Small Cap Value Index. The ETF is quite popular with AUM of more than $4.53 billion and trades in good average daily volume of about 125,000 shares. iShares Morningstar Small-Cap Value ETF (JKL) JKL is designed to track the performance of the Morningstar Small Value Index.
|
e9776af6-f09b-49a1-b18f-b12ef3d5dde4
|
728446.0
|
2014-10-07 00:00:00 UTC
|
WGL Holdings Inc (WGL) Ex-Dividend Date Scheduled for October 08, 2014
|
DES
|
https://www.nasdaq.com/articles/wgl-holdings-inc-wgl-ex-dividend-date-scheduled-october-08-2014-2014-10-07
|
nan
|
nan
|
WGL Holdings Inc ( WGL ) will begin trading ex-dividend on October 08, 2014. A cash dividend payment of $0.44 per share is scheduled to be paid on November 01, 2014. Shareholders who purchased WGL stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that WGL has paid the same dividend. At the current stock price of $43.06, the dividend yield is 4.09%.
The previous trading day's last sale of WGL was $43.06, representing a -5.67% decrease from the 52 week high of $45.65 and a 21.79% increase over the 52 week low of $35.36.
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). WGL's current earnings per share, an indicator of a company's profitability, is $.31. Zacks Investment Research reports WGL's forecasted earnings growth in 2014 as 10.22%, compared to an industry average of 8.3%.
For more information on the declaration, record and payment dates, visit the WGL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to WGL through an Exchange Traded Fund [ETF]?
The following ETF(s) have WGL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an decrease of -2.51% over the last 100 days. It also has the highest percent weighting of WGL at 0.89%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -2.51% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The top-performing ETF of this group is DES with an decrease of -2.51% over the last 100 days.
|
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -2.51% over the last 100 days.
|
c7b320dd-6093-40d2-9d86-cbfe03a2b239
|
728447.0
|
2014-09-24 00:00:00 UTC
|
Covanta Holding Corporation (CVA) Ex-Dividend Date Scheduled for September 25, 2014
|
DES
|
https://www.nasdaq.com/articles/covanta-holding-corporation-cva-ex-dividend-date-scheduled-september-25-2014-2014-09-24
|
nan
|
nan
|
Covanta Holding Corporation ( CVA ) will begin trading ex-dividend on September 25, 2014. A cash dividend payment of $0.25 per share is scheduled to be paid on October 06, 2014. Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 38.89% increase over the prior quarter. At the current stock price of $21.48, the dividend yield is 4.66%.
The previous trading day's last sale of CVA was $21.48, representing a -1.15% decrease from the 52 week high of $21.73 and a 30.82% increase over the 52 week low of $16.42.
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). CVA's current earnings per share, an indicator of a company's profitability, is $.39. Zacks Investment Research reports CVA's forecasted earnings growth in 2014 as 11.84%, compared to an industry average of 33.9%.
For more information on the declaration, record and payment dates, visit the CVA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CVA through an Exchange Traded Fund [ETF]?
The following ETF(s) have CVA as a top-10 holding:
iShares S&P Global Clean Energy Index Fund ( ICLN )
First Trust RBA American Industrial Renaissance ETF ( AIRR )
Market Vectors Environment Index ETF Fund ( EVX )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is ICLN with an increase of 3.64% over the last 100 days. It also has the highest percent weighting of CVA at 5.24%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ).
|
The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
f143dd84-cdb8-4e99-b722-b1cdedfb8359
|
728448.0
|
2014-09-22 00:00:00 UTC
|
Portland General Electric Company (POR) Ex-Dividend Date Scheduled for September 23, 2014
|
DES
|
https://www.nasdaq.com/articles/portland-general-electric-company-por-ex-dividend-date-scheduled-september-23-2014-2014-09
|
nan
|
nan
|
Portland General Electric Company ( POR ) will begin trading ex-dividend on September 23, 2014. A cash dividend payment of $0.28 per share is scheduled to be paid on October 15, 2014. Shareholders who purchased POR stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 1.82% increase over the same period a year ago. At the current stock price of $33.09, the dividend yield is 3.38%.
The previous trading day's last sale of POR was $33.09, representing a -4.75% decrease from the 52 week high of $34.74 and a 18.94% increase over the 52 week low of $27.82.
POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). POR's current earnings per share, an indicator of a company's profitability, is $2.15. Zacks Investment Research reports POR's forecasted earnings growth in 2014 as 5.25%, compared to an industry average of .7%.
For more information on the declaration, record and payment dates, visit the POR Dividend History page. Our
|
POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). Shareholders who purchased POR stock prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports POR's forecasted earnings growth in 2014 as 5.25%, compared to an industry average of .7%.
|
POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). Portland General Electric Company ( POR ) will begin trading ex-dividend on September 23, 2014. Shareholders who purchased POR stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). Shareholders who purchased POR stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of POR was $33.09, representing a -4.75% decrease from the 52 week high of $34.74 and a 18.94% increase over the 52 week low of $27.82.
|
POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). Portland General Electric Company ( POR ) will begin trading ex-dividend on September 23, 2014. Shareholders who purchased POR stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
877ac768-de2c-4730-bcc3-0b793d351018
|
728449.0
|
2014-09-17 00:00:00 UTC
|
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/abbott-labs-abt-to-initiate-new-trial-on-absorb-analyst-blog-2014-09-17
|
nan
|
nan
|
Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.
Abbott Labs ( ABT ) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
The trial will evaluate whether Absorb is more cost-effective and offers a higher quality of life than other metallic drug eluting stent (DES).
The randomized heart stent trial will measure angina (chest pain) as the primary endpoint at one year. The other primary endpoint of the ABSORB IV trial is to assess the long-term clinical safety and performance based on the change in target lesion failure (TLF) from one to five years.
Abbott Labs plans to consolidate data from the ABSORB IV trial with that from the ABSORB III trial to create a population of more than 5,000 patients studied in the U.S.
Earlier, Abbott Labs released positive one-year results from the randomized, controlled trial ABSORB II. The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb heart device to Abbott Labs' Xience family of DES in patients suffering from coronary artery disease (CAD).
Data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina compared to those treated with the Xience family of DES.
We note that Absorb obtained the CE mark in Europe in Jan 2011 but is yet to be approved in the U.S.
The vascular business is an important part of Abbott Labs' product portfolio that generated sales of $1.5 billion in the first half of 2014. Of the total vascular sales, approximately $738 million came from the DES and BVS product portfolio. The continued rollout of Absorb and Xience Xpedition along with new products such as Supera stents will further strengthen the company's vascular portfolio in 2014.
Abbott Labs currently carries a Zacks Rank #2 (Buy). Investors may also consider stocks like Allergan ( AGN ), Gilead Sciences ( GILD ) and Shire ( SHPG ). While Allegan and Gilead Sciences carry a Zacks Rank #1 (Strong Buy), Shire is a Zacks Rank #2 stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The trial will evaluate whether Absorb is more cost-effective and offers a higher quality of life than other metallic drug eluting stent (DES). The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb heart device to Abbott Labs' Xience family of DES in patients suffering from coronary artery disease (CAD). Data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina compared to those treated with the Xience family of DES.
|
The trial will evaluate whether Absorb is more cost-effective and offers a higher quality of life than other metallic drug eluting stent (DES). The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb heart device to Abbott Labs' Xience family of DES in patients suffering from coronary artery disease (CAD). Data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina compared to those treated with the Xience family of DES.
|
The trial will evaluate whether Absorb is more cost-effective and offers a higher quality of life than other metallic drug eluting stent (DES). The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb heart device to Abbott Labs' Xience family of DES in patients suffering from coronary artery disease (CAD). Data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina compared to those treated with the Xience family of DES.
|
The trial will evaluate whether Absorb is more cost-effective and offers a higher quality of life than other metallic drug eluting stent (DES). The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb heart device to Abbott Labs' Xience family of DES in patients suffering from coronary artery disease (CAD). Data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina compared to those treated with the Xience family of DES.
|
284d7080-ffc7-4fe4-b0ef-d3fbe125e2fc
|
728450.0
|
2014-09-15 00:00:00 UTC
|
Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/abbott-labs-presents-positive-one-year-data-on-absorb-analyst-blog-2014-09-15
|
nan
|
nan
|
Abbott Laboratories ( ABT ) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb.
The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD).
The data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina (chest pain) compared to those treated with the Xience family of DES.
We note that Absorb obtained the CE mark in Europe in Jan 2011 but is yet to be approved in the U.S.
The vascular portfolio of Abbott Labs boasts of DES such as the Xience series and Absorb.
The portfolio has been further strengthened by a number of recent favorable updates. In Mar 2014, the FDA approved the company's Supera peripheral stent system for the treatment of patients with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD).
The vascular business is an important part of Abbott Labs' product portfolio generating sales of $1.5 billion in the first half of 2014. Of the total vascular sales, approximately $738 million came from the DES and BVS product portfolio. The continued rollout of Absorb and Xience Xpedition along with new products such as Supera stents will further strengthen Abbott Labs' vascular portfolio in 2014.
We remind investors that Abbott Labs became a diversified medical products company focusing on branded generic pharmaceutical, medical devices, diagnostic and nutritional businesses following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc. ( ABBV ), in Jan 2013.
Abbott Labs currently carries a Zacks Rank #2 (Buy). Investors may also consider stocks like Allergan ( AGN ) and Gilead Sciences ( GILD ). Both carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD). The data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina (chest pain) compared to those treated with the Xience family of DES. The vascular portfolio of Abbott Labs boasts of DES such as the Xience series and Absorb.
|
The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD). The data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina (chest pain) compared to those treated with the Xience family of DES. The vascular portfolio of Abbott Labs boasts of DES such as the Xience series and Absorb.
|
The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD). The data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina (chest pain) compared to those treated with the Xience family of DES. The vascular portfolio of Abbott Labs boasts of DES such as the Xience series and Absorb.
|
The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD). The vascular portfolio of Abbott Labs boasts of DES such as the Xience series and Absorb. The data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina (chest pain) compared to those treated with the Xience family of DES.
|
39235335-900d-4bd6-b887-3da5c1f578e5
|
728451.0
|
2014-09-12 00:00:00 UTC
|
UIL Holdings Corporation (UIL) Ex-Dividend Date Scheduled for September 15, 2014
|
DES
|
https://www.nasdaq.com/articles/uil-holdings-corporation-uil-ex-dividend-date-scheduled-september-15-2014-2014-09-12
|
nan
|
nan
|
UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on September 15, 2014. A cash dividend payment of $0.432 per share is scheduled to be paid on October 01, 2014. Shareholders who purchased UIL stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 33rd quarter that UIL has paid the same dividend. At the current stock price of $37.83, the dividend yield is 4.57%.
The previous trading day's last sale of UIL was $37.83, representing a -7.01% decrease from the 52 week high of $40.68 and a 10.16% increase over the 52 week low of $34.34.
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). UIL's current earnings per share, an indicator of a company's profitability, is $1.96. Zacks Investment Research reports UIL's forecasted earnings growth in 2014 as -4.44%, compared to an industry average of -.3%.
For more information on the declaration, record and payment dates, visit the UIL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to UIL through an Exchange Traded Fund [ETF]?
The following ETF(s) have UIL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 1.93% over the last 100 days. It also has the highest percent weighting of UIL at 0.9%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 1.93% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an increase of 1.93% over the last 100 days.
|
The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an increase of 1.93% over the last 100 days.
|
32d781fa-2281-4453-93bc-e3c657133631
|
728452.0
|
2014-08-28 00:00:00 UTC
|
MKS Instruments (MKSI) Passes Through 2% Yield Mark
|
DES
|
https://www.nasdaq.com/articles/mks-instruments-mksi-passes-through-2-yield-mark-2014-08-28
|
nan
|
nan
|
Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of MKS Instruments, Inc. (Symbol: MKSI) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.66), with the stock changing hands as low as $32.91 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the iShares Russell 3000 ETF ( IWV ) back on 5/31/2000 - you would have paid $78.27 per share. Fast forward to 5/31/2012 and each share was worth $77.79 on that date, a loss of $0.48 or 0.6% decrease over twelve years. But now consider that you collected a whopping $10.77 per share in dividends over the same period, increasing your return to 13.15%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.0%; so by comparison collecting a yield above 2% would appear considerably attractive if that yield is sustainable. MKS Instruments, Inc. (Symbol: MKSI) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of MKS Instruments, Inc., looking at the history chart for MKSI below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield.
According to the ETF Finder at ETF Channel, MKSI makes up 355.84% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday.
Click here to find out which 9 other dividend stocks just recently went on sale »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, MKSI makes up 355.84% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday. Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of MKS Instruments, Inc. (Symbol: MKSI) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.66), with the stock changing hands as low as $32.91 on the day. MKS Instruments, Inc. (Symbol: MKSI) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets.
|
According to the ETF Finder at ETF Channel, MKSI makes up 355.84% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday. Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of MKS Instruments, Inc. (Symbol: MKSI) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.66), with the stock changing hands as low as $32.91 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
|
According to the ETF Finder at ETF Channel, MKSI makes up 355.84% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday. Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of MKS Instruments, Inc. (Symbol: MKSI) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.66), with the stock changing hands as low as $32.91 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
|
According to the ETF Finder at ETF Channel, MKSI makes up 355.84% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday. Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of MKS Instruments, Inc. (Symbol: MKSI) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.66), with the stock changing hands as low as $32.91 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
|
49614ae2-52b2-4250-8e66-44780e7e0600
|
728453.0
|
2014-08-27 00:00:00 UTC
|
Medtronic Reports Strong Sales On New Products And Robust U.S. Performance
|
DES
|
https://www.nasdaq.com/articles/medtronic-reports-strong-sales-new-products-and-robust-us-performance-2014-08-27
|
nan
|
nan
|
Medtronic ( MDT ) recently reported its fiscal first quarter results, with operational revenue growth of 4% year-over-year (y-o-y) to about $4.27 billion, driven by growing acceptance of new products and robust sales in the U.S. as well as emerging markets. The company's largest divisions, Cardiac Rhythm Disease Management (CRDM) and Cardiovascular, continued to grow in low single digits driven by sales growth of about 60% in Atrial Fibrillation ( AF ) and 10% in the pacemaker business. Other businesses such as Neuromodulation, Surgical Technologies and Diabetes also registered robust revenue growth, which offset declines in the Spinal division. International sales accounted for 45% of total revenues for the medical device maker, driven by 11% y-o-y growth in emerging markets.
The company's gross margin for the quarter was 74.4% on an operational basis, on the back of certain unfavorable price adjustments in Japan and expenses related to addressing product quality issues in Neuromodulation and Diabetes. Excluding the impact of these adjustments, the company stated that its gross margin could have been higher by about 40 basis points. For fiscal 2015, the company expects gross margins to be in the range of 74.5-75% on a constant currency basis due to the ongoing quality improvement expenses. In itsearnings call Medtronic also reiterated its intent to buy healthcare and medical supplies major Covidien ( COV ) in a cash-and-stock deal valued at close to $43 billion. The company said that is was "fully committed" to complete the strategically important and financially attractive deal by the fourth quarter of calender year 2014 or early 2015. (( Press release , Medtronic, Aug 19 2014))
Our price estimate for Medtronic's stock is currently around $60 , implying a discount of about 5% to the market price.
See our full analysis for Medtronic Inc.
CRDM Reports Steady Sales Growth
Cardiac Rhythm Disease Management (CRDM), primarily consisting of defibrillators and pacemakers, is Medtronic's largest division, accounting for about 30% of total sales. During Q1 FY 2015, operational sales in the division grew by 4% y-o-y to $1.25 billion as solid growth in Pacemakers (reported as Low Power) and Atrial Fibrillation ( AF ) offset declining implantable cardioverter defibrillator (ICD, reported as High Power) sales. Weak demand in the U.S. ICD market offset Medtronic's relatively better performance in international markets, where its sales grew by 1% y-o-y driven by growing adoption of the Attain Performa quadripolar lead in Europe and Japan. Following the growing acceptance of its Attain Performa quadripolar (APQ) lead in Japan in the last two quarters, the company expects to launch this product in the U.S. in the next few weeks.
Growing acceptance of the Reveal LINQ system contributed to sales growth in the diagnostics business. In the AF division, sales grew 30% on a constant currency basis on account of solid growth of the Arctic Front CryoAblation System and launch of the Pulmonary Vein Ablation Catheter (PVAC) Gold system. Going forward, we expect sluggish U.S. sales to offset international market gains in the overall CRDM business. Medtronic'sglobal marketshare is unlikely to improve significantly unless its performance in the U.S. improves.
CoreValve TAVR and Drug Eluting Stents Drive Cardiovascular Sales
The Cardiovascular division, consisting of the Coronary, Structural Heart and Endovascular businesses, offers products such as stents, heart valves and renal denervation systems for treating hypertension. The Cardiovascular division, contributing over 20% of edtronic's sales, grew over 3% y-o-y, registering sales of about $1 billion in the fiscal first quarter. Sales of drug eluting stents ( DES ) increased 2% on an operational basis to $279 million, driven by strong global sales of the company's Resolute Integrity DES.
The Structural Heart business reported 8% sales growth, as the CoreValve Transcatheter Aortic Valve (TAVR) system continued its strong performance in international markets as well as the U.S. Following its recent settlement with Edwards regarding a patent infringement issue, Medtronic should be looking to ramp up its training facilities and further improve sales in the lucrative U.S. TAVR market.
Diabetes Sales Soar, Spine Continues to Suffer
Sales in the Diabetes division grew 12% y-o-y to $416 million, driven by solid uptake of the company's MiniMed 530G system (with Enlite CGM sensor). The company states that MiniMed is the only system in the market which has a built-in automatic control mechanism to start/stop insulin delivery in the blood based on pre-determined insulin levels. Medtronic estimates that this product could drive sales significantly in the near term as it expands internationally focusing on the type-2 diabetes market.
Spine revenue declined 3% y-o-y to $743 million on account of declining sales in the Core spine business, Balloon Kyphoplasty Procedures (BKP) and Bone Morphogenetic Proteins (BMP) products. Spinal sales are expected to get a boost in the coming quarters as the company launches its recently approved Prestige LP next-generation cervical disc in the U.S. market and overhauls its anterior cervical plate portfolio this year.
Emerging Markets Remain Key
Emerging markets contributed about 28% of overall international revenues and saw robust growth of 11% y-o-y to $539 million. In emerging markets, Africa and the Middle East were again strong performers, with revenues growing 30%. However, there were strong headwinds in China and India, where sales declined in high single digits owing to challenges in distribution channels and inventory rebalancing.
The company expects sales from emerging markets, including Asia-Pacific, Latin America and South Asia, to continue to grow in the mid teens as it works on optimizing its business channels and establishes sustainable and broader business partnerships with national governments. The medical device major expects emerging markets to contribute 150 to 200 basis points to its overall sales growth in fiscal 2015.
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Sales of drug eluting stents ( DES ) increased 2% on an operational basis to $279 million, driven by strong global sales of the company's Resolute Integrity DES. Medtronic ( MDT ) recently reported its fiscal first quarter results, with operational revenue growth of 4% year-over-year (y-o-y) to about $4.27 billion, driven by growing acceptance of new products and robust sales in the U.S. as well as emerging markets. The company's largest divisions, Cardiac Rhythm Disease Management (CRDM) and Cardiovascular, continued to grow in low single digits driven by sales growth of about 60% in Atrial Fibrillation ( AF ) and 10% in the pacemaker business.
|
Sales of drug eluting stents ( DES ) increased 2% on an operational basis to $279 million, driven by strong global sales of the company's Resolute Integrity DES. The company's largest divisions, Cardiac Rhythm Disease Management (CRDM) and Cardiovascular, continued to grow in low single digits driven by sales growth of about 60% in Atrial Fibrillation ( AF ) and 10% in the pacemaker business. See our full analysis for Medtronic Inc. CRDM Reports Steady Sales Growth Cardiac Rhythm Disease Management (CRDM), primarily consisting of defibrillators and pacemakers, is Medtronic's largest division, accounting for about 30% of total sales.
|
Sales of drug eluting stents ( DES ) increased 2% on an operational basis to $279 million, driven by strong global sales of the company's Resolute Integrity DES. Medtronic ( MDT ) recently reported its fiscal first quarter results, with operational revenue growth of 4% year-over-year (y-o-y) to about $4.27 billion, driven by growing acceptance of new products and robust sales in the U.S. as well as emerging markets. During Q1 FY 2015, operational sales in the division grew by 4% y-o-y to $1.25 billion as solid growth in Pacemakers (reported as Low Power) and Atrial Fibrillation ( AF ) offset declining implantable cardioverter defibrillator (ICD, reported as High Power) sales.
|
Sales of drug eluting stents ( DES ) increased 2% on an operational basis to $279 million, driven by strong global sales of the company's Resolute Integrity DES. Medtronic ( MDT ) recently reported its fiscal first quarter results, with operational revenue growth of 4% year-over-year (y-o-y) to about $4.27 billion, driven by growing acceptance of new products and robust sales in the U.S. as well as emerging markets. The company's largest divisions, Cardiac Rhythm Disease Management (CRDM) and Cardiovascular, continued to grow in low single digits driven by sales growth of about 60% in Atrial Fibrillation ( AF ) and 10% in the pacemaker business.
|
bacbef52-035d-4743-8ed0-ec1853997d89
|
728454.0
|
2014-08-26 00:00:00 UTC
|
Compass Minerals International, Inc. (CMP) Ex-Dividend Date Scheduled for August 27, 2014
|
DES
|
https://www.nasdaq.com/articles/compass-minerals-international-inc-cmp-ex-dividend-date-scheduled-august-27-2014-2014-08
|
nan
|
nan
|
Compass Minerals International, Inc. ( CMP ) will begin trading ex-dividend on August 27, 2014. A cash dividend payment of $0.6 per share is scheduled to be paid on September 12, 2014. Shareholders who purchased CMP stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that CMP has paid the same dividend. At the current stock price of $88.37, the dividend yield is 2.72%.
The previous trading day's last sale of CMP was $88.37, representing a -9.36% decrease from the 52 week high of $97.50 and a 25.28% increase over the 52 week low of $70.54.
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Martin Marietta Materials, Inc. ( MLM ). CMP's current earnings per share, an indicator of a company's profitability, is $3.66. Zacks Investment Research reports CMP's forecasted earnings growth in 2014 as 19.61%, compared to an industry average of 1.9%.
For more information on the declaration, record and payment dates, visit the CMP Dividend History page. Our
|
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Martin Marietta Materials, Inc. ( MLM ). Shareholders who purchased CMP stock prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports CMP's forecasted earnings growth in 2014 as 19.61%, compared to an industry average of 1.9%.
|
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Martin Marietta Materials, Inc. ( MLM ). A cash dividend payment of $0.6 per share is scheduled to be paid on September 12, 2014. Shareholders who purchased CMP stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Martin Marietta Materials, Inc. ( MLM ). Shareholders who purchased CMP stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that CMP has paid the same dividend.
|
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Martin Marietta Materials, Inc. ( MLM ). Compass Minerals International, Inc. ( CMP ) will begin trading ex-dividend on August 27, 2014. A cash dividend payment of $0.6 per share is scheduled to be paid on September 12, 2014.
|
fdab75a4-1332-4fa2-b67c-aeca32f29cd9
|
728455.0
|
2014-08-26 00:00:00 UTC
|
Lexmark International, Inc. (LXK) Ex-Dividend Date Scheduled for August 27, 2014
|
DES
|
https://www.nasdaq.com/articles/lexmark-international-inc-lxk-ex-dividend-date-scheduled-august-27-2014-2014-08-26
|
nan
|
nan
|
Lexmark International, Inc. ( LXK ) will begin trading ex-dividend on August 27, 2014. A cash dividend payment of $0.36 per share is scheduled to be paid on September 12, 2014. Shareholders who purchased LXK stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 20% increase over the same period a year ago. At the current stock price of $49.97, the dividend yield is 2.88%.
The previous trading day's last sale of LXK was $49.97, representing a -3.48% decrease from the 52 week high of $51.77 and a 53.42% increase over the 52 week low of $32.57.
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). LXK's current earnings per share, an indicator of a company's profitability, is $3.06. Zacks Investment Research reports LXK's forecasted earnings growth in 2014 as -2.86%, compared to an industry average of 3.7%.
For more information on the declaration, record and payment dates, visit the LXK Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to LXK through an Exchange Traded Fund [ETF]?
The following ETF(s) have LXK as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an decrease of -0.78% over the last 100 days. It also has the highest percent weighting of LXK at 0.98%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -0.78% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The top-performing ETF of this group is DES with an decrease of -0.78% over the last 100 days.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an decrease of -0.78% over the last 100 days.
|
8cc04cb9-a218-481b-9e90-5e19a064d1a3
|
728456.0
|
2014-08-22 00:00:00 UTC
|
Reminder - Schweitzer-Mauduit International (SWM) Goes Ex-Dividend Soon
|
DES
|
https://www.nasdaq.com/articles/reminder-schweitzer-mauduit-international-swm-goes-ex-dividend-soon-2014-08-22
|
nan
|
nan
|
Looking at the universe of stocks we cover at Dividend Channel , on 8/26/14, Schweitzer-Mauduit International, Inc. (Symbol: SWM) will trade ex-dividend, for its quarterly dividend of $0.36, payable on 9/25/14. As a percentage of SWM's recent stock price of $42.58, this dividend works out to approximately 0.85%, so look for shares of Schweitzer-Mauduit International, Inc. to trade 0.85% lower - all else being equal - when SWM shares open for trading on 8/26/14.
In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from SWM is likely to continue, and whether the current estimated yield of 3.38% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of SWM shares, versus its 200 day moving average:
Looking at the chart above, SWM's low point in its 52 week range is $38.88 per share, with $63.53 as the 52 week high point - that compares with a last trade of $42.58.
According to the ETF Finder at ETF Channel, SWM makes up 368.08% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Friday.
In Friday trading, Schweitzer-Mauduit International, Inc. shares are currently down about 0.6% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, SWM makes up 368.08% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Friday. As a percentage of SWM's recent stock price of $42.58, this dividend works out to approximately 0.85%, so look for shares of Schweitzer-Mauduit International, Inc. to trade 0.85% lower - all else being equal - when SWM shares open for trading on 8/26/14. In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from SWM is likely to continue, and whether the current estimated yield of 3.38% on annualized basis is a reasonable expectation of annual yield going forward.
|
According to the ETF Finder at ETF Channel, SWM makes up 368.08% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Friday. Looking at the universe of stocks we cover at Dividend Channel , on 8/26/14, Schweitzer-Mauduit International, Inc. (Symbol: SWM) will trade ex-dividend, for its quarterly dividend of $0.36, payable on 9/25/14. In Friday trading, Schweitzer-Mauduit International, Inc. shares are currently down about 0.6% on the day.
|
According to the ETF Finder at ETF Channel, SWM makes up 368.08% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Friday. Looking at the universe of stocks we cover at Dividend Channel , on 8/26/14, Schweitzer-Mauduit International, Inc. (Symbol: SWM) will trade ex-dividend, for its quarterly dividend of $0.36, payable on 9/25/14. As a percentage of SWM's recent stock price of $42.58, this dividend works out to approximately 0.85%, so look for shares of Schweitzer-Mauduit International, Inc. to trade 0.85% lower - all else being equal - when SWM shares open for trading on 8/26/14.
|
According to the ETF Finder at ETF Channel, SWM makes up 368.08% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Friday. Looking at the universe of stocks we cover at Dividend Channel , on 8/26/14, Schweitzer-Mauduit International, Inc. (Symbol: SWM) will trade ex-dividend, for its quarterly dividend of $0.36, payable on 9/25/14. As a percentage of SWM's recent stock price of $42.58, this dividend works out to approximately 0.85%, so look for shares of Schweitzer-Mauduit International, Inc. to trade 0.85% lower - all else being equal - when SWM shares open for trading on 8/26/14.
|
978d68fa-38e5-42cb-b665-9e31b5023cf1
|
728457.0
|
2014-08-21 00:00:00 UTC
|
ARCP Makes Bullish Cross Above Critical Moving Average
|
DES
|
https://www.nasdaq.com/articles/arcp-makes-bullish-cross-above-critical-moving-average-2014-08-21
|
nan
|
nan
|
In trading on Thursday, shares of American Realty Capital Properties Inc (Symbol: ARCP) crossed above their 200 day moving average of $13.20, changing hands as high as $13.24 per share. American Realty Capital Properties Inc shares are currently trading up about 0.4% on the day. The chart below shows the one year performance of ARCP shares, versus its 200 day moving average:
Looking at the chart above, ARCP's low point in its 52 week range is $11.76 per share, with $14.96 as the 52 week high point - that compares with a last trade of $13.23.
According to the ETF Finder at ETF Channel, ARCP makes up 569.02% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Thursday.
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, ARCP makes up 569.02% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Thursday. American Realty Capital Properties Inc shares are currently trading up about 0.4% on the day. The chart below shows the one year performance of ARCP shares, versus its 200 day moving average: Looking at the chart above, ARCP's low point in its 52 week range is $11.76 per share, with $14.96 as the 52 week high point - that compares with a last trade of $13.23.
|
According to the ETF Finder at ETF Channel, ARCP makes up 569.02% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Thursday. In trading on Thursday, shares of American Realty Capital Properties Inc (Symbol: ARCP) crossed above their 200 day moving average of $13.20, changing hands as high as $13.24 per share. The chart below shows the one year performance of ARCP shares, versus its 200 day moving average: Looking at the chart above, ARCP's low point in its 52 week range is $11.76 per share, with $14.96 as the 52 week high point - that compares with a last trade of $13.23.
|
According to the ETF Finder at ETF Channel, ARCP makes up 569.02% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Thursday. In trading on Thursday, shares of American Realty Capital Properties Inc (Symbol: ARCP) crossed above their 200 day moving average of $13.20, changing hands as high as $13.24 per share. The chart below shows the one year performance of ARCP shares, versus its 200 day moving average: Looking at the chart above, ARCP's low point in its 52 week range is $11.76 per share, with $14.96 as the 52 week high point - that compares with a last trade of $13.23.
|
According to the ETF Finder at ETF Channel, ARCP makes up 569.02% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Thursday. In trading on Thursday, shares of American Realty Capital Properties Inc (Symbol: ARCP) crossed above their 200 day moving average of $13.20, changing hands as high as $13.24 per share. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
fe514107-4a98-4e2d-a462-d8eb94a9b169
|
728458.0
|
2014-08-21 00:00:00 UTC
|
Bullish Two Hundred Day Moving Average Cross - CVBF
|
DES
|
https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-cvbf-2014-08-21
|
nan
|
nan
|
In trading on Thursday, shares of CVB Financial Corp. (Symbol: CVBF) crossed above their 200 day moving average of $15.52, changing hands as high as $15.63 per share. CVB Financial Corp. shares are currently trading up about 1.4% on the day. The chart below shows the one year performance of CVBF shares, versus its 200 day moving average:
Looking at the chart above, CVBF's low point in its 52 week range is $12.57 per share, with $17.48 as the 52 week high point - that compares with a last trade of $15.59.
According to the ETF Finder at ETF Channel, CVBF makes up 128.76% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading higher by about 0.3% on the day Thursday.
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, CVBF makes up 128.76% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading higher by about 0.3% on the day Thursday. In trading on Thursday, shares of CVB Financial Corp. (Symbol: CVBF) crossed above their 200 day moving average of $15.52, changing hands as high as $15.63 per share. The chart below shows the one year performance of CVBF shares, versus its 200 day moving average: Looking at the chart above, CVBF's low point in its 52 week range is $12.57 per share, with $17.48 as the 52 week high point - that compares with a last trade of $15.59.
|
According to the ETF Finder at ETF Channel, CVBF makes up 128.76% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading higher by about 0.3% on the day Thursday. In trading on Thursday, shares of CVB Financial Corp. (Symbol: CVBF) crossed above their 200 day moving average of $15.52, changing hands as high as $15.63 per share. The chart below shows the one year performance of CVBF shares, versus its 200 day moving average: Looking at the chart above, CVBF's low point in its 52 week range is $12.57 per share, with $17.48 as the 52 week high point - that compares with a last trade of $15.59.
|
According to the ETF Finder at ETF Channel, CVBF makes up 128.76% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading higher by about 0.3% on the day Thursday. In trading on Thursday, shares of CVB Financial Corp. (Symbol: CVBF) crossed above their 200 day moving average of $15.52, changing hands as high as $15.63 per share. The chart below shows the one year performance of CVBF shares, versus its 200 day moving average: Looking at the chart above, CVBF's low point in its 52 week range is $12.57 per share, with $17.48 as the 52 week high point - that compares with a last trade of $15.59.
|
According to the ETF Finder at ETF Channel, CVBF makes up 128.76% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading higher by about 0.3% on the day Thursday. In trading on Thursday, shares of CVB Financial Corp. (Symbol: CVBF) crossed above their 200 day moving average of $15.52, changing hands as high as $15.63 per share. Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
7bfffe42-5311-4557-96d7-1a4b03011173
|
728459.0
|
2014-08-19 00:00:00 UTC
|
Medtronic (MDT) Q1 Earnings, Revenues Beat; Margins Drop - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/medtronic-mdt-q1-earnings-revenues-beat-margins-drop-analyst-blog-2014-08-19
|
nan
|
nan
|
After adjusting for one-time items including costs related to the pending Covidien plc ( COV ) acquisition and certain restructuring charges, Medtronic Inc. 's ( MDT ) first-quarter fiscal 2015 adjusted earnings per share (EPS) came in at 93 cents, up 5.7% year over year. Also, the figure beat the Zacks Consensus Estimate by a penny.
However, the company's reported net income of $871 million or 87 cents a share were down 8.6% and 6.5%, respectively, on a year-over-year basis.
Medtronic, Inc - Earnings Surprise | FindTheBest
Revenues in the reported quarter grossed $4.273 billion, up 4.7% year over year (up 4% at constant exchange rates or CER). The results, also, remained marginally ahead of the Zacks Consensus Estimate of $4.249 billion. Following the announcement, the stock price experienced a marginal uptick in the pre-trading session.
International sales (generating 45% of total sales) grew 3% year over year (up 2% at CER) to $1.940 billion in the quarter. Based on Medtronic's focus on emerging markets, revenues from these regions experienced continued growth momentum and increased 9% (up 11% at CER) to $539 million. This region now accounts for 13% of the company's total revenue.
Segment Details
Medtronic generates revenues from two major groups - the Cardiac & Vascular Group and the Restorative Therapies Group. The former encompasses the Cardiac Rhythm & Heart Failure, Coronary & Structural Heart, and Aortic & Peripheral businesses; while the latter includes the Spine, Neuromodulation, and Surgical Technologies segments.
Cardiac Rhythm & Heart Failure sales were up 5% year over year (up 4% at CER) to $1.256 billion.On the other hand, revenues at High Power inched down 5% at CER to $627 million. However, the company is upbeat about therecent U.S. FDA approval of the company`s Viva XT CRT-D, to be used in combination with its AdaptiveCRT algorithm and Attain Performa quadripolar lead.
Meanwhile, Low Power revenues stood at $525 million, up 10% at CER on the strong global launch of the Reveal LINQ insertable cardiac monitor.AF & Other revenues were $104 million, up a substantial 59% year over year on the back of growth at Hospital Solutions and Cardiocom, partially offset by declines in High Power and Coronary.
Coronary revenues were down 2% at CER to $428 million. On the other hand, Structural Heart recorded revenue growth of 6% (to $338 million) at CER. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. Strong Structural Heart sales were supported by the U.S. launch of the CoreValve transcatheter aortic heart valve.
Notably, for Structural Heart, the year-over-year comparisons were tough as adjusting for the German customer advance purchases of CoreValve in the year-ago quarter in anticipation of the since resolved injunction, Structural Heart grew in the upper teens at CER.
At the Aortic & Peripheral segment, sales came in at $232 million, up 6% year over year and 5% at CER.The ongoing adoption of Endurant II and Valiant Captivia stent grafts globally contributed toward growth in the segment.In Peripheral, the IN.PACTAdmiral and Pacific drug-coated balloons continued to deliver strong growth.
The sluggish trend for Spine revenues persisted and translated into a 3% decline year over year (same at CER) along with drop in Core Spine (2% at CER) and bone morphogenetic protein or BMP (11%) offsetting growth in Interventional Spine (up 4%).
Meanwhile, Surgical Technologies revenues were $381 million (up 5% at CER), while revenues at Neuromodulation were $479 million (up 11%, same at CER) and at Diabetes, $416 million (up 12% at CER).
Margins
Gross margin during the reported quarter contracted 83 basis points (bps) to 74.1%. Adjusted operating margin contracted 123 bps year over year to 29.2%, with a 6.4% increase in selling, general and administrative expenses (to $1.506 billion); a 1.4% improvement in research and development expenses (to $365 million) and a 15.9% rise in Other expenses to $51 million.
Guidance
Medtronic reaffirmed its revenues and EPS outlook for fiscal 2015. The company still expects its full-year EPS in the range of $4.00−$4.10 (implying annualized growth of approximately 6−9%).The current Zacks Consensus Estimate for EPS stands at $4.02, close to the mid-point of the guided range.
Fiscal 2015 revenue growth outlook is expected to remain within 3−5% at CER. The current Zacks Consensus Estimate of $17.706 billion falls at the lower end of the guided range.
Our Take
Medtronic posted an impressive first-quarter 2015 with both EPS and the top line exceeding our expectations. However, the weak core segment performances remain a matter of concern. Also, margin pressure adds to the woes.
Moreover, headwinds such as unfavorable currency movement and global economic uncertainties remain. In addition, the legal settlement with Edwards Lifesciences ( EW ) required Medtronic to make a one-time payment of $750 million. Although the company expects this incident to be beneficial for focusing further on business expansion, the colossal litigation-related compensation is expected to weigh on the stock.
However, Medtronic is striving to return to growth and profitability. In an effort to offset the impact of high U.S. corporate tax rate by shifting its tax base overseas, in June, the company announced its plans to acquire Covidien. This is because the business tax rate in Ireland is a mere 12.5%, much lower than that of 35% in the U.S., the highest in the world.
The deal, valued at $42.9 billion, also marks a solid step toward establishing Medtronic as the world's leading medical technology and services company in over 150 countries. Post-acquisition, the combined entity would generate about $27 billion in total revenue, including $3.7 billion from emerging markets. It is also expected to prove accretive to cash earnings in 2016 and beyond.
Currently, Medtronic carries a Zacks Rank #3 (Hold). However, investors interested in the Medical Product sector can consider Abaxis, Inc. ( ABAX ) carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
ABAXIS INC (ABAX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The former encompasses the Cardiac Rhythm & Heart Failure, Coronary & Structural Heart, and Aortic & Peripheral businesses; while the latter includes the Spine, Neuromodulation, and Surgical Technologies segments. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. Based on Medtronic's focus on emerging markets, revenues from these regions experienced continued growth momentum and increased 9% (up 11% at CER) to $539 million.
|
The former encompasses the Cardiac Rhythm & Heart Failure, Coronary & Structural Heart, and Aortic & Peripheral businesses; while the latter includes the Spine, Neuromodulation, and Surgical Technologies segments. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. Based on Medtronic's focus on emerging markets, revenues from these regions experienced continued growth momentum and increased 9% (up 11% at CER) to $539 million.
|
The former encompasses the Cardiac Rhythm & Heart Failure, Coronary & Structural Heart, and Aortic & Peripheral businesses; while the latter includes the Spine, Neuromodulation, and Surgical Technologies segments. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. Meanwhile, Low Power revenues stood at $525 million, up 10% at CER on the strong global launch of the Reveal LINQ insertable cardiac monitor.AF & Other revenues were $104 million, up a substantial 59% year over year on the back of growth at Hospital Solutions and Cardiocom, partially offset by declines in High Power and Coronary.
|
The former encompasses the Cardiac Rhythm & Heart Failure, Coronary & Structural Heart, and Aortic & Peripheral businesses; while the latter includes the Spine, Neuromodulation, and Surgical Technologies segments. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. International sales (generating 45% of total sales) grew 3% year over year (up 2% at CER) to $1.940 billion in the quarter.
|
1872d1a8-b6bf-4167-bd69-1d9071366fc9
|
728460.0
|
2014-08-19 00:00:00 UTC
|
Diebold, Incorporated (DBD) Ex-Dividend Date Scheduled for August 20, 2014
|
DES
|
https://www.nasdaq.com/articles/diebold-incorporated-dbd-ex-dividend-date-scheduled-august-20-2014-2014-08-19
|
nan
|
nan
|
Diebold, Incorporated ( DBD ) will begin trading ex-dividend on August 20, 2014. A cash dividend payment of $0.2875 per share is scheduled to be paid on September 12, 2014. Shareholders who purchased DBD stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 7th quarter that DBD has paid the same dividend. At the current stock price of $37.47, the dividend yield is 3.07%.
The previous trading day's last sale of DBD was $37.47, representing a -9.6% decrease from the 52 week high of $41.45 and a 34.35% increase over the 52 week low of $27.89.
DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). DBD's current earnings per share, an indicator of a company's profitability, is -$.2. Zacks Investment Research reports DBD's forecasted earnings growth in 2014 as 30.88%, compared to an industry average of 9.6%.
For more information on the declaration, record and payment dates, visit the DBD Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to DBD through an Exchange Traded Fund [ETF]?
The following ETF(s) have DBD as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 2.1% over the last 100 days. It also has the highest percent weighting of DBD at 0.82%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 2.1% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). The top-performing ETF of this group is DES with an increase of 2.1% over the last 100 days.
|
DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Iron Mountain Incorporated ( IRM ). The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 2.1% over the last 100 days.
|
fb6c44e3-b15a-4ada-ade7-76bffe990d86
|
728461.0
|
2014-08-19 00:00:00 UTC
|
The Pros And Cons of Smart Beta ETFs
|
DES
|
https://www.nasdaq.com/articles/pros-and-cons-smart-beta-etfs-2014-08-19
|
nan
|
nan
|
Many investors have traded in their passive indexes for smart beta ETFs over the last five years as these innovative strategies have shown promising results. The allure of creating a “better investment strategy” is an admirable objective for these semi-active funds. However, investors need to fully understand how the index is constructed and how much more they will pay in fees before deciding to invest in this arena.
Charles Rotblut, Vice President of the American Association of Individual Investors, recently wrote an excellent article about how to define and categorize smart beta ETFs. His analysis centered on the fact that there is no central repository or classification system for these funds. Rather, each investor has to decide for themselves whether an index is truly making substantive changes to its holdings in response to shifting conditions or just an innovative strategy.
His analysis culled 59 ETFs from the universe of over 1,600 funds that were considered in his eyes to be smart beta. Although, I would argue that equal weight ETFs should probably not fall into this category because the only thing innovative about them is their allocation sizes. In addition, I found that he may have unintentionally missed some key smart beta sector funds from First Trust that could have rounded out this guide.
Ultimately we both agree that smart beta investing is a perceptive exercise that may take different forms and meanings to each individual. The most obvious examples generally include fundamental or performance-based characteristics that are evaluated on a regular basis to identify the top rated stocks in each category. These can include factors such as price momentum, balance sheet characteristics, dividend yield, or a combination of several traits.
For example, the First Trust Consumer Staples AlphaDEX Fund (FXG) is constructed of approximately 40 stocks in the consumer staples space that are chosen according to a variety of value and growth metrics. This includes price appreciation, book value, sales growth, cash flow, and return on assets. The end result is a unique portfolio of companies that varies significantly from the sector benchmark Consumer Staples Select Sector SPDR (XLP).
The combination of these factors has led to FXG outperforming XLP by a fair margin on 1, 3, and 5-year time frames as of the last fiscal quarter. Much of that alpha has been driven by exposure to small and mid-cap companies that have outperformed their large-cap peers during this most recent bull market. It’s conceivable that during a protracted downtrend, these smaller companies may lead on the downside and cause a wave of underperformance in similar smart beta funds.
In addition, it’s worth noting that many smart beta funds have significantly higher expense ratios than their passive counterparts. In the aforementioned example, FXG charges expenses of 0.70% compared to 0.16% for XLP. Over the last several years, that premium cost has been worth paying to achieve a markedly stronger performance gain. However, it may lead to additional angst during the next slow growth cycle.
The suite of iShares factor ETFs that focus on momentum, volatility, value, and quality are probably the lowest cost smart beta funds with expenses of just 0.15% annually. As an example, the iShares MSCI USA Quality Factor ETF (QUAL) selects 125 stocks with that are exhibiting positive balance sheet fundamentals. Holdings in the index are then reevaluated and rebalanced quarterly.
WisdomTree has been a smart beta pioneer for many years now and has popularized fundamental security selection based on high dividend paying stocks. The WisdomTree Small Cap Dividend Fund (DES) has now been in existence for more than five years and shown to be a worthy competitor to a passive index such as the iShares Russell 2000 ETF (IWM). The focus on selecting holdings and weighting them according to dividend payouts is a concept that has been embraced by yield-hungry investors.
There is no doubt that smart beta strategies are here to stay and additional concepts will be introduced that continue to push the envelope for alpha-seeking investors. One key to successfully integrating these ETFs in your portfolio is to regularly monitor updates to their holdings to ensure they stay in line with your risk tolerance and investment objectives. In doing so, you will have a better understanding of how the funds adapt to various circumstances and how they perform versus passive benchmarks.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The WisdomTree Small Cap Dividend Fund (DES) has now been in existence for more than five years and shown to be a worthy competitor to a passive index such as the iShares Russell 2000 ETF (IWM). This includes price appreciation, book value, sales growth, cash flow, and return on assets. Charles Rotblut, Vice President of the American Association of Individual Investors, recently wrote an excellent article about how to define and categorize smart beta ETFs.
|
This includes price appreciation, book value, sales growth, cash flow, and return on assets. The WisdomTree Small Cap Dividend Fund (DES) has now been in existence for more than five years and shown to be a worthy competitor to a passive index such as the iShares Russell 2000 ETF (IWM). These can include factors such as price momentum, balance sheet characteristics, dividend yield, or a combination of several traits.
|
This includes price appreciation, book value, sales growth, cash flow, and return on assets. The WisdomTree Small Cap Dividend Fund (DES) has now been in existence for more than five years and shown to be a worthy competitor to a passive index such as the iShares Russell 2000 ETF (IWM). Many investors have traded in their passive indexes for smart beta ETFs over the last five years as these innovative strategies have shown promising results.
|
This includes price appreciation, book value, sales growth, cash flow, and return on assets. The WisdomTree Small Cap Dividend Fund (DES) has now been in existence for more than five years and shown to be a worthy competitor to a passive index such as the iShares Russell 2000 ETF (IWM). Many investors have traded in their passive indexes for smart beta ETFs over the last five years as these innovative strategies have shown promising results.
|
5faa5155-5fdd-4c83-9ff3-a1b74ce52b84
|
728462.0
|
2014-08-12 00:00:00 UTC
|
Notable Two Hundred Day Moving Average Cross - SBGI
|
DES
|
https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-sbgi-2014-08-12
|
nan
|
nan
|
In trading on Tuesday, shares of Sinclair Broadcast Group, Inc. (Symbol: SBGI) crossed below their 200 day moving average of $30.94, changing hands as low as $30.88 per share. Sinclair Broadcast Group, Inc. shares are currently trading off about 4.3% on the day. The chart below shows the one year performance of SBGI shares, versus its 200 day moving average:
Looking at the chart above, SBGI's low point in its 52 week range is $23.28 per share, with $37.50 as the 52 week high point - that compares with a last trade of $30.80.
According to the ETF Finder at ETF Channel, SBGI makes up 404.25% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Tuesday.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, SBGI makes up 404.25% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Tuesday. In trading on Tuesday, shares of Sinclair Broadcast Group, Inc. (Symbol: SBGI) crossed below their 200 day moving average of $30.94, changing hands as low as $30.88 per share. The chart below shows the one year performance of SBGI shares, versus its 200 day moving average: Looking at the chart above, SBGI's low point in its 52 week range is $23.28 per share, with $37.50 as the 52 week high point - that compares with a last trade of $30.80.
|
According to the ETF Finder at ETF Channel, SBGI makes up 404.25% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Tuesday. In trading on Tuesday, shares of Sinclair Broadcast Group, Inc. (Symbol: SBGI) crossed below their 200 day moving average of $30.94, changing hands as low as $30.88 per share. The chart below shows the one year performance of SBGI shares, versus its 200 day moving average: Looking at the chart above, SBGI's low point in its 52 week range is $23.28 per share, with $37.50 as the 52 week high point - that compares with a last trade of $30.80.
|
According to the ETF Finder at ETF Channel, SBGI makes up 404.25% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Tuesday. In trading on Tuesday, shares of Sinclair Broadcast Group, Inc. (Symbol: SBGI) crossed below their 200 day moving average of $30.94, changing hands as low as $30.88 per share. The chart below shows the one year performance of SBGI shares, versus its 200 day moving average: Looking at the chart above, SBGI's low point in its 52 week range is $23.28 per share, with $37.50 as the 52 week high point - that compares with a last trade of $30.80.
|
According to the ETF Finder at ETF Channel, SBGI makes up 404.25% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Tuesday. In trading on Tuesday, shares of Sinclair Broadcast Group, Inc. (Symbol: SBGI) crossed below their 200 day moving average of $30.94, changing hands as low as $30.88 per share. Click here to find out which 9 other stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
3ab5e90d-e1c9-4769-98ad-d8675bec6af5
|
728463.0
|
2014-08-12 00:00:00 UTC
|
EVR Breaks Above 2% Yield Territory
|
DES
|
https://www.nasdaq.com/articles/evr-breaks-above-2-yield-territory-2014-08-12
|
nan
|
nan
|
Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of Evercore Partners Incorporated (Symbol: EVR) were yielding above the 2% mark based on its quarterly dividend (annualized to $1.00), with the stock changing hands as low as $49.98 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the iShares Russell 3000 ETF ( IWV ) back on 5/31/2000 - you would have paid $78.27 per share. Fast forward to 5/31/2012 and each share was worth $77.79 on that date, a loss of $0.48 or 0.6% decrease over twelve years. But now consider that you collected a whopping $10.77 per share in dividends over the same period, increasing your return to 13.15%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.0%; so by comparison collecting a yield above 2% would appear considerably attractive if that yield is sustainable. Evercore Partners Incorporated (Symbol: EVR) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Evercore Partners Incorporated, looking at the history chart for EVR below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield.
According to the ETF Finder at ETF Channel, EVR makes up 92.41% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Tuesday.
Click here to find out which 9 other dividend stocks just recently went on sale »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, EVR makes up 92.41% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Tuesday. Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of Evercore Partners Incorporated (Symbol: EVR) were yielding above the 2% mark based on its quarterly dividend (annualized to $1.00), with the stock changing hands as low as $49.98 on the day. Evercore Partners Incorporated (Symbol: EVR) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets.
|
According to the ETF Finder at ETF Channel, EVR makes up 92.41% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Tuesday. Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of Evercore Partners Incorporated (Symbol: EVR) were yielding above the 2% mark based on its quarterly dividend (annualized to $1.00), with the stock changing hands as low as $49.98 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
|
According to the ETF Finder at ETF Channel, EVR makes up 92.41% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Tuesday. Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of Evercore Partners Incorporated (Symbol: EVR) were yielding above the 2% mark based on its quarterly dividend (annualized to $1.00), with the stock changing hands as low as $49.98 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return.
|
According to the ETF Finder at ETF Channel, EVR makes up 92.41% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading relatively unchanged on the day Tuesday. Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of Evercore Partners Incorporated (Symbol: EVR) were yielding above the 2% mark based on its quarterly dividend (annualized to $1.00), with the stock changing hands as low as $49.98 on the day. Even with dividends reinvested, that only amounts to an average annual total return of about 1.0%; so by comparison collecting a yield above 2% would appear considerably attractive if that yield is sustainable.
|
d0972621-c1be-47f6-a3a7-5604ed27a5e2
|
728464.0
|
2014-08-07 00:00:00 UTC
|
Oversold Conditions For Kindred Healthcare (KND)
|
DES
|
https://www.nasdaq.com/articles/oversold-conditions-kindred-healthcare-knd-2014-08-07
|
nan
|
nan
|
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Thursday, shares of Kindred Healthcare Inc (Symbol: KND) entered into oversold territory, hitting an RSI reading of 28.9, after changing hands as low as $21.67 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 32.9. A bullish investor could look at KND's 28.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of KND shares:
Looking at the chart above, KND's low point in its 52 week range is $12.95 per share, with $26.81 as the 52 week high point - that compares with a last trade of $21.84.
According to the ETF Finder at ETF Channel, KND makes up 298.48% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday.
Find out what 9 other oversold stocks you need to know about »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, KND makes up 298.48% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday. In trading on Thursday, shares of Kindred Healthcare Inc (Symbol: KND) entered into oversold territory, hitting an RSI reading of 28.9, after changing hands as low as $21.67 per share. A bullish investor could look at KND's 28.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side.
|
According to the ETF Finder at ETF Channel, KND makes up 298.48% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday. The chart below shows the one year performance of KND shares: Looking at the chart above, KND's low point in its 52 week range is $12.95 per share, with $26.81 as the 52 week high point - that compares with a last trade of $21.84. Find out what 9 other oversold stocks you need to know about » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, KND makes up 298.48% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday. In trading on Thursday, shares of Kindred Healthcare Inc (Symbol: KND) entered into oversold territory, hitting an RSI reading of 28.9, after changing hands as low as $21.67 per share. The chart below shows the one year performance of KND shares: Looking at the chart above, KND's low point in its 52 week range is $12.95 per share, with $26.81 as the 52 week high point - that compares with a last trade of $21.84.
|
According to the ETF Finder at ETF Channel, KND makes up 298.48% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.2% on the day Thursday. In trading on Thursday, shares of Kindred Healthcare Inc (Symbol: KND) entered into oversold territory, hitting an RSI reading of 28.9, after changing hands as low as $21.67 per share. Find out what 9 other oversold stocks you need to know about » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
508cb9c7-ca8b-4e35-bf54-ab356c1ba9b6
|
728465.0
|
2014-08-07 00:00:00 UTC
|
New Jersey Resources (NJR) Shares Cross Below 200 DMA
|
DES
|
https://www.nasdaq.com/articles/new-jersey-resources-njr-shares-cross-below-200-dma-2014-08-07
|
nan
|
nan
|
In trading on Thursday, shares of New Jersey Resources Corp (Symbol: NJR) crossed below their 200 day moving average of $48.80, changing hands as low as $48.63 per share. New Jersey Resources Corp shares are currently trading up about 0.2% on the day. The chart below shows the one year performance of NJR shares, versus its 200 day moving average:
Looking at the chart above, NJR's low point in its 52 week range is $41.44 per share, with $57.79 as the 52 week high point - that compares with a last trade of $49.06.
According to the ETF Finder at ETF Channel, NJR makes up 739.71% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Thursday.
Click here to find out which 9 other energy stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, NJR makes up 739.71% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Thursday. In trading on Thursday, shares of New Jersey Resources Corp (Symbol: NJR) crossed below their 200 day moving average of $48.80, changing hands as low as $48.63 per share. The chart below shows the one year performance of NJR shares, versus its 200 day moving average: Looking at the chart above, NJR's low point in its 52 week range is $41.44 per share, with $57.79 as the 52 week high point - that compares with a last trade of $49.06.
|
According to the ETF Finder at ETF Channel, NJR makes up 739.71% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Thursday. In trading on Thursday, shares of New Jersey Resources Corp (Symbol: NJR) crossed below their 200 day moving average of $48.80, changing hands as low as $48.63 per share. The chart below shows the one year performance of NJR shares, versus its 200 day moving average: Looking at the chart above, NJR's low point in its 52 week range is $41.44 per share, with $57.79 as the 52 week high point - that compares with a last trade of $49.06.
|
According to the ETF Finder at ETF Channel, NJR makes up 739.71% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Thursday. In trading on Thursday, shares of New Jersey Resources Corp (Symbol: NJR) crossed below their 200 day moving average of $48.80, changing hands as low as $48.63 per share. The chart below shows the one year performance of NJR shares, versus its 200 day moving average: Looking at the chart above, NJR's low point in its 52 week range is $41.44 per share, with $57.79 as the 52 week high point - that compares with a last trade of $49.06.
|
According to the ETF Finder at ETF Channel, NJR makes up 739.71% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.3% on the day Thursday. In trading on Thursday, shares of New Jersey Resources Corp (Symbol: NJR) crossed below their 200 day moving average of $48.80, changing hands as low as $48.63 per share. Click here to find out which 9 other energy stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
5ec58fa9-4ebd-4889-a2dc-b5609d0530c7
|
728466.0
|
2014-07-21 00:00:00 UTC
|
Will Boston Scientific (BSX) Surprise this Earnings Season? - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/will-boston-scientific-bsx-surprise-this-earnings-season-analyst-blog-2014-07-21
|
nan
|
nan
|
Boston Scientific Corporation ( BSX ) is scheduled to report its second-quarter 2014 results before the opening bell on Jul 24. Last quarter, the company had posted a positive earnings surprise of 11.11%. Moreover, the four-quarter trailing average beat is pegged at 10.10%. Let's see how things are shaping up for this announcement.
Factors at Play
Amid challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific posted mixed first-quarter 2014 results beating on earnings but missing revenues.
At the same time, the company also provided its outlook for the second quarter. Boston Sientific expects adjusted earnings to remain in the band of 18-20 cents per share while revenues are projected in the range of $1.84-$1.89 billion. In addition, gross margin will likely remain in the range of 70−71%. Selling, general and administrative as well as research and development expense margins are expected to be within 36.5%−37.5%, and 11.5%−12%, respectively, resulting in a targeted operating margin of 19% to 20%.
Despite several initiatives undertaken by Boston Scientific to revive its top line, we remain cautious as core segments like Cardiac Rhythm Management (CRM) and drug-eluting stents (DES) continue to witness several headwinds. The current challenging scenario fails to give any assurance that the size of the CRM and DES markets will increase above existing levels or the company will be able to increase its market share or net sales in these segments in the near term.
Meanwhile, Boston Scientific is resorting to all available means in order to return to growth. To revive its top line, the company is focusing on strategic initiatives to drive growth and profitability. These include the recently announced restructuring initiatives, strengthening of the company's portfolio, targeting suitable acquisitions in areas of unmet medical needs, and focusing on emerging markets.
Boston Scientific has a strong pipeline of products under development, the launch of which should drive the top line. We are also encouraged by the focus on emerging markets, especially India and China.
Earnings Whispers?
Our proven model does not conclusively show that Boston Scientific is likely to beat earnings this quarter. It is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. That is not the case here as you will see below.
Zacks ESP: Boston Scientific's Earnings ESP is 0.00%, since both the Most Accurate estimate and the Zacks Consensus Estimate stand at 20 cents.
Zacks Rank: Boston Scientific's Zacks Rank #3 (Hold) when combined with a 0.00% ESP makes surprise prediction difficult.
We caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revision momentum.
Other Stocks to Consider
Here are three companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Wright Medical Group Inc. ( WMGI ) has an earnings ESP of +2.22% and a Zacks Rank #1 (Strong Buy). Wright Medical will be reporting second-quarter earnings on Aug 5.
Hospira Inc. ( HSP ) has an earnings ESP of +1.79% and a Zacks Rank #2 (Buy). Hospira will report second-quarter earnings on Jul 30.
Community Health Systems, Inc. ( CYH ) has an earnings ESP of +2.94% and a Zacks Rank #3 (Hold). Community Health will be reporting second-quarter earnings on Aug 1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
HOSPIRA INC (HSP): Free Stock Analysis Report
WRIGHT MEDICAL (WMGI): Free Stock Analysis Report
COMMNTY HLTH SY (CYH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Despite several initiatives undertaken by Boston Scientific to revive its top line, we remain cautious as core segments like Cardiac Rhythm Management (CRM) and drug-eluting stents (DES) continue to witness several headwinds. The current challenging scenario fails to give any assurance that the size of the CRM and DES markets will increase above existing levels or the company will be able to increase its market share or net sales in these segments in the near term. Factors at Play Amid challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific posted mixed first-quarter 2014 results beating on earnings but missing revenues.
|
Despite several initiatives undertaken by Boston Scientific to revive its top line, we remain cautious as core segments like Cardiac Rhythm Management (CRM) and drug-eluting stents (DES) continue to witness several headwinds. The current challenging scenario fails to give any assurance that the size of the CRM and DES markets will increase above existing levels or the company will be able to increase its market share or net sales in these segments in the near term. Zacks Rank: Boston Scientific's Zacks Rank #3 (Hold) when combined with a 0.00% ESP makes surprise prediction difficult.
|
Despite several initiatives undertaken by Boston Scientific to revive its top line, we remain cautious as core segments like Cardiac Rhythm Management (CRM) and drug-eluting stents (DES) continue to witness several headwinds. The current challenging scenario fails to give any assurance that the size of the CRM and DES markets will increase above existing levels or the company will be able to increase its market share or net sales in these segments in the near term. Zacks ESP: Boston Scientific's Earnings ESP is 0.00%, since both the Most Accurate estimate and the Zacks Consensus Estimate stand at 20 cents.
|
Despite several initiatives undertaken by Boston Scientific to revive its top line, we remain cautious as core segments like Cardiac Rhythm Management (CRM) and drug-eluting stents (DES) continue to witness several headwinds. The current challenging scenario fails to give any assurance that the size of the CRM and DES markets will increase above existing levels or the company will be able to increase its market share or net sales in these segments in the near term. We caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revision momentum.
|
f0cf63c3-ba31-4711-898b-bb554dc20e91
|
728467.0
|
2014-07-07 00:00:00 UTC
|
WGL Holdings Inc (WGL) Ex-Dividend Date Scheduled for July 08, 2014
|
DES
|
https://www.nasdaq.com/articles/wgl-holdings-inc-wgl-ex-dividend-date-scheduled-july-08-2014-2014-07-07
|
nan
|
nan
|
WGL Holdings Inc ( WGL ) will begin trading ex-dividend on July 08, 2014. A cash dividend payment of $0.44 per share is scheduled to be paid on August 01, 2014. Shareholders who purchased WGL stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 4.76% increase over the same period a year ago. At the current stock price of $41.94, the dividend yield is 4.2%.
The previous trading day's last sale of WGL was $41.94, representing a -10.69% decrease from the 52 week high of $46.96 and a 18.63% increase over the 52 week low of $35.36.
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). WGL's current earnings per share, an indicator of a company's profitability, is $.35. Zacks Investment Research reports WGL's forecasted earnings growth in 2014 as 6.58%, compared to an industry average of 10.8%.
For more information on the declaration, record and payment dates, visit the WGL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to WGL through an Exchange Traded Fund [ETF]?
The following ETF(s) have WGL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 10.3% over the last 100 days. It also has the highest percent weighting of WGL at 0.89%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 10.3% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The top-performing ETF of this group is DES with an increase of 10.3% over the last 100 days.
|
WGL is a part of the Public Utilities sector, which includes companies such as Cheniere Energy, Inc. ( LNG ) and Ultrapar Participacoes S.A. ( UGP ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 10.3% over the last 100 days.
|
48a09b8a-584a-4c82-89a0-1e671f575d5f
|
728468.0
|
2014-07-02 00:00:00 UTC
|
Soaring Indian Coronary Stent Market Puts These Stocks in Focus - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/soaring-indian-coronary-stent-market-puts-these-stocks-in-focus-analyst-blog-2014-07-02
|
nan
|
nan
|
The recently published report on the Indian coronary stent market by market research firm Ace Business and Market Research Group (ABMRG) comes as a vital cue reminding medical device mammoths of the lucrative potential residing in emerging markets.
Research by ABMRG revealed that the Indian coronary stent market has grown at a robust 22% during 2005-2012 to reach a worthwhile $450 million. This growth came primarily on the back of cardiovascular diseases (CVD) reflecting a rising trend, which in turn, led to a surge in demand for PCIs (Percutaneous Coronary Intervention). Further impetus came from improved healthcare infrastructure and services, and growing disposable income. Added to that, more than 90% penetration rate of drug-eluting stents (DES) acted as a prime stimulus.
Moving on, mushrooming of a bunch of new private hospitals with increasing number of interventional cardiologists; government initiatives for the betterment of healthcare access; improving healthcare insurance coverage and increasing use of high value bioabsorbable stents are expected to pace up growth of the coronary stent market in the country down the line.
While stents are still not covered under health insurance translating into limitation in market demand, stalwarts should be upbeat about the fact that large numbers of below-poverty-line patients in this developing nation are sponsored either by state government healthcare insurance or by insurance under public and private partnerships. Researchers believe although a ceiling has been imposed on stent pricing by some state governments within the country, which may reduce profitability; in the long run, it will definitely increase the penetration of stents in this untapped market.
In addition, ABMRG anticipates that an aging population, improved life expectancy, and increasing lifestyle diseases accompanied by complications like diabetes, hypertension and obesity, should further fuel growth in the Indian market.
Companies like Abbott Laboratories ( ABT ), Boston Scientific Corporation ( BSX ), Medtronic Inc . ( MDT ) and other players like Biotronik, Sahajanand Medical Technologies, Meril Life Sciences and Translumina Therapeutics are all vying to expand their presence in India through investments in the coronary stent market. It is worth noting in this regard that Johnson and Johnson 's ( JNJ ) Cordis stopped selling its stents in 2011, leaving the market to be grabbed by the likes of Abbott, Medtronic and other players.
How the Behemoths are Faring in the Emerging Nations?
Abbott Laboratories continues to lead the investment trend in emerging nations with about 50% of sales coming in from this market. The company expects this contribution to climb to 60% by 2015. We believe that Abbott is extremely diversified with its presence well established in the nutrition, medical devices, diagnostics and branded generic pharmaceuticals markets. The diversification should enable the company to penetrate into these markets and capture incremental market share. Growth rates in the emerging markets are expected to continue higher compared to the developed countries.
Amid the backdrop of flattening or declining sales growth in developed markets like the U.S. and Europe, Boston Scientific Corporationis gradually strengthening its presence in the emerging nations with Brazil, Russia, India and China (BRIC) recordinga robust 22% growth rate in the last reported quarter.Boston Scientific is currently targeting its emerging market revenue contribution to increase from 8% of sales in 2013 to 15% in 2017. According to the company, PCI volume in the U.S. market is likely to be in the low single digits, and is likely to be offset by robust growth in the international markets, especially in the emerging ones.
For Medtronic, the emerging market demonstrated a robust 14% growth in the last reported quarter, representing more than 12% of the company's total sales mix. The recent data shows that emerging nations, on a whole for Medtronic, represent a $5 billion annual opportunity in margins compared to developed markets. Management is targeting 20% of its revenues from the emerging market eyeing incremental revenues of $2.5 billion over the next 5 years.
Similarly, Johnson & Johnson has registered 13% growth in the BRIC nations and is currently working to increase its presence in these regions. The company has already set up manufacturing and R&D centers in India, Brazil and China and expects to expand further in China on the back of the Synthes acquisition.
Becton, Dickinson and Company ( BDX ), with about 58% of its revenues from international markets, witnessed double-digit sales growth in the emerging geographies during the last reported quarter with China growing over 25% at constant exchange rate (CER).
In the same vein, Thermo Fisher Scientific, Inc. ( TMO ) is also expanding its presence in the emerging nations. It expects to garner 25% of total revenue from the high-growth Asia-Pacific region and emerging markets by 2016, up from 19% in 2011. According to the company, particularly China, with its rapid industrialization, increasing focus on healthcare, new BioPharma R&D centers and government-sponsored research, holds robust growth potential.
The Bottom Line
For the past few years, large-cap medical device makers have been witnessing low-single-digit growth rate in the developed and mature markets like the U.S., Europe and Japan. To reverse this trend, they are now turning their focus to high-growth emerging regions, specifically in economies like Brazil, Russia, India and China.
According to researchers, the lifestyles of Asian people are undergoing a dynamic change due to a shift in preference toward the West. As a result, Asians are now more prone to being affected by heart-related diseases prevalent in the western countries.
We believe, India as the second most densely-populated country in the world with favorable demography, infrastructure and government initiatives, is an ideal investment package for the medical device stalwarts.
Nonetheless, there exist hitches like the presence of numerous local players and price competition from mid-sized European companies which offer stents at almost half the price of popular brands. To add to the woes, the recent reimbursement rates reduction under the Central Government Health Scheme (CGHS) might further force these companies to reduce their prices.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
THERMO FISHER (TMO): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Added to that, more than 90% penetration rate of drug-eluting stents (DES) acted as a prime stimulus. In addition, ABMRG anticipates that an aging population, improved life expectancy, and increasing lifestyle diseases accompanied by complications like diabetes, hypertension and obesity, should further fuel growth in the Indian market. ( MDT ) and other players like Biotronik, Sahajanand Medical Technologies, Meril Life Sciences and Translumina Therapeutics are all vying to expand their presence in India through investments in the coronary stent market.
|
Added to that, more than 90% penetration rate of drug-eluting stents (DES) acted as a prime stimulus. Companies like Abbott Laboratories ( ABT ), Boston Scientific Corporation ( BSX ), Medtronic Inc . Amid the backdrop of flattening or declining sales growth in developed markets like the U.S. and Europe, Boston Scientific Corporationis gradually strengthening its presence in the emerging nations with Brazil, Russia, India and China (BRIC) recordinga robust 22% growth rate in the last reported quarter.Boston Scientific is currently targeting its emerging market revenue contribution to increase from 8% of sales in 2013 to 15% in 2017.
|
Added to that, more than 90% penetration rate of drug-eluting stents (DES) acted as a prime stimulus. The recently published report on the Indian coronary stent market by market research firm Ace Business and Market Research Group (ABMRG) comes as a vital cue reminding medical device mammoths of the lucrative potential residing in emerging markets. Amid the backdrop of flattening or declining sales growth in developed markets like the U.S. and Europe, Boston Scientific Corporationis gradually strengthening its presence in the emerging nations with Brazil, Russia, India and China (BRIC) recordinga robust 22% growth rate in the last reported quarter.Boston Scientific is currently targeting its emerging market revenue contribution to increase from 8% of sales in 2013 to 15% in 2017.
|
Added to that, more than 90% penetration rate of drug-eluting stents (DES) acted as a prime stimulus. Moving on, mushrooming of a bunch of new private hospitals with increasing number of interventional cardiologists; government initiatives for the betterment of healthcare access; improving healthcare insurance coverage and increasing use of high value bioabsorbable stents are expected to pace up growth of the coronary stent market in the country down the line. Researchers believe although a ceiling has been imposed on stent pricing by some state governments within the country, which may reduce profitability; in the long run, it will definitely increase the penetration of stents in this untapped market.
|
bd20ac5c-e16b-4e33-8364-89bcf41746bf
|
728469.0
|
2014-06-27 00:00:00 UTC
|
NICE Guidelines to Boost Boston Scientific's Rhythm Management - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/nice-guidelines-to-boost-boston-scientifics-rhythm-management-analyst-blog-2014-06-27
|
nan
|
nan
|
The new guidance released by the National Institute for Health and Care Excellence (NICE) - a public body of the Department of Health in the U.K. - on use of cardiac technologies for arrhythmias and heart failure is expected to boost Boston Scientific Corporation 's ( BSX ) Rhythm Management business in Europe. Accordingly, the company has come forward to welcome this updated guidance and expects to work with the National Health Service (NHS) to implement its guidelines.
This updated guidance stated two major specifics. Firstly, implantable cardioverter defibrillators (ICDs) can be used as a treatment option in prevention of cardiac arrest in patients with ventricular arrhythmias (an irregular heart beat in the ventricles) as well as those who have already survived a life-threatening arrhythmia. Secondly, cardiac resynchronisation therapy (CRT) can improve life expectancy and quality of life in heart failure patients.
NICE expands its recommendations on ICDs and CRT (CRT-P with pacing or CRT-D with pacing and defibrillation) for heart failure patients who have left ventricular dysfunction with an LVEF (left ventricular ejection fraction) of 35% or less.
Each year almost 75,000 people suffer from heart failure and a further 1 million are affected by cardiac arrhythmia in the U.K. This number is only expected to grow with an ageing population. Added to that, heart failure accounts for one of the biggest hospitalization cost components in the U.K. which contributes over 5% of emergency admissions and 2% of all NHS inpatient bed days. Accordingly, with this new set of guidelines, Boston Scientific is upbeat about the fact that more patients will be eligible for the use of the company's ICD and CRT, thereby boosting the prospects of these core segments in the U.K. health care market.
According to Boston Scientific, its current product portfolio features the world's longest-lasting ICDs and CRT-Ds, with real-world longevity projections of nine to 13 years, and the world's smallest and thinnest ICDs.
For quite a long time, the U.S. defibrillator and stent markets have remained as major overhangs. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - ICD and Drug Eluting Stent (DES) are still taking a toll on the numbers. Meanwhile, Boston Scientific is resorting to all available means in order to return to growth. To revive its top line, the company is focusing on strategic initiatives to drive growth and profitability. These include the recently announced restructuring initiatives, strengthening of the company's portfolio, targeting suitable acquisitions in areas of unmet medical needs, and focus on the international market. We believe this new guidance by NICE will also prove itself as a material positive for Boston Scientific's core segments in Europe.
Currently, Boston Scientific retains a Zacks Rank #3 (Hold). Some of the better-placed Medical stocks are ICU Medical, Inc. ( ICUI ), Cardica Inc. ( CRDC ) and NeuroMetrix Inc. ( NURO ), all carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
NEUROMETRIX INC (NURO): Get Free Report
CARDICA INC (CRDC): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - ICD and Drug Eluting Stent (DES) are still taking a toll on the numbers. Accordingly, with this new set of guidelines, Boston Scientific is upbeat about the fact that more patients will be eligible for the use of the company's ICD and CRT, thereby boosting the prospects of these core segments in the U.K. health care market. These include the recently announced restructuring initiatives, strengthening of the company's portfolio, targeting suitable acquisitions in areas of unmet medical needs, and focus on the international market.
|
Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - ICD and Drug Eluting Stent (DES) are still taking a toll on the numbers. NICE expands its recommendations on ICDs and CRT (CRT-P with pacing or CRT-D with pacing and defibrillation) for heart failure patients who have left ventricular dysfunction with an LVEF (left ventricular ejection fraction) of 35% or less. Some of the better-placed Medical stocks are ICU Medical, Inc. ( ICUI ), Cardica Inc. ( CRDC ) and NeuroMetrix Inc. ( NURO ), all carrying a Zacks Rank #2 (Buy).
|
Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - ICD and Drug Eluting Stent (DES) are still taking a toll on the numbers. The new guidance released by the National Institute for Health and Care Excellence (NICE) - a public body of the Department of Health in the U.K. - on use of cardiac technologies for arrhythmias and heart failure is expected to boost Boston Scientific Corporation 's ( BSX ) Rhythm Management business in Europe. Accordingly, with this new set of guidelines, Boston Scientific is upbeat about the fact that more patients will be eligible for the use of the company's ICD and CRT, thereby boosting the prospects of these core segments in the U.K. health care market.
|
Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - ICD and Drug Eluting Stent (DES) are still taking a toll on the numbers. Each year almost 75,000 people suffer from heart failure and a further 1 million are affected by cardiac arrhythmia in the U.K. To revive its top line, the company is focusing on strategic initiatives to drive growth and profitability.
|
14a9649d-2a4b-40d0-8713-3eca44a1eb58
|
728470.0
|
2014-06-20 00:00:00 UTC
|
Covanta Holding Corporation (CVA) Ex-Dividend Date Scheduled for June 23, 2014
|
DES
|
https://www.nasdaq.com/articles/covanta-holding-corporation-cva-ex-dividend-date-scheduled-june-23-2014-2014-06-20
|
nan
|
nan
|
Covanta Holding Corporation ( CVA ) will begin trading ex-dividend on June 23, 2014. A cash dividend payment of $0.18 per share is scheduled to be paid on July 02, 2014. Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 9.09% increase over the same period a year ago. At the current stock price of $20.34, the dividend yield is 3.54%.
The previous trading day's last sale of CVA was $20.34, representing a -7.08% decrease from the 52 week high of $21.89 and a 23.87% increase over the 52 week low of $16.42.
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). CVA's current earnings per share, an indicator of a company's profitability, is $.07. Zacks Investment Research reports CVA's forecasted earnings growth in 2014 as 12.28%, compared to an industry average of 27.9%.
For more information on the declaration, record and payment dates, visit the CVA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CVA through an Exchange Traded Fund [ETF]?
The following ETF(s) have CVA as a top-10 holding:
iShares S&P Global Clean Energy Index Fund ( ICLN )
First Trust RBA American Industrial Renaissance ETF ( AIRR )
Market Vectors Environment Index ETF Fund ( EVX )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is ICLN with an increase of 16.29% over the last 100 days. It also has the highest percent weighting of CVA at 5.17%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ).
|
The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have CVA as a top-10 holding: iShares S&P Global Clean Energy Index Fund ( ICLN ) First Trust RBA American Industrial Renaissance ETF ( AIRR ) Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
82d5f76d-9783-4a56-99c7-09ae3ff0ca64
|
728471.0
|
2014-06-20 00:00:00 UTC
|
Portland General Electric Company (POR) Ex-Dividend Date Scheduled for June 23, 2014
|
DES
|
https://www.nasdaq.com/articles/portland-general-electric-company-por-ex-dividend-date-scheduled-june-23-2014-2014-06-20
|
nan
|
nan
|
Portland General Electric Company ( POR ) will begin trading ex-dividend on June 23, 2014. A cash dividend payment of $0.28 per share is scheduled to be paid on July 15, 2014. Shareholders who purchased POR stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 1.82% increase over the prior quarter. At the current stock price of $33.78, the dividend yield is 3.32%.
The previous trading day's last sale of POR was $33.78, representing a -0.41% decrease from the 52 week high of $33.92 and a 22.52% increase over the 52 week low of $27.57.
POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). POR's current earnings per share, an indicator of a company's profitability, is $1.43. Zacks Investment Research reports POR's forecasted earnings growth in 2014 as 4.6%, compared to an industry average of 1.3%.
For more information on the declaration, record and payment dates, visit the POR Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to POR through an Exchange Traded Fund [ETF]?
The following ETF(s) have POR as a top-10 holding:
SPDR Russell 2000 Low Volatility ( SMLV )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 6.86% over the last 100 days. SMLV has the highest percent weighting of POR at 1.9%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have POR as a top-10 holding: SPDR Russell 2000 Low Volatility ( SMLV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 6.86% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have POR as a top-10 holding: SPDR Russell 2000 Low Volatility ( SMLV ) WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have POR as a top-10 holding: SPDR Russell 2000 Low Volatility ( SMLV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an increase of 6.86% over the last 100 days.
|
The following ETF(s) have POR as a top-10 holding: SPDR Russell 2000 Low Volatility ( SMLV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an increase of 6.86% over the last 100 days.
|
c81dac3a-e84c-448a-8c1e-a6d582a4d308
|
728472.0
|
2014-06-11 00:00:00 UTC
|
UIL Holdings Corporation (UIL) Ex-Dividend Date Scheduled for June 12, 2014
|
DES
|
https://www.nasdaq.com/articles/uil-holdings-corporation-uil-ex-dividend-date-scheduled-june-12-2014-2014-06-11
|
nan
|
nan
|
UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on June 12, 2014. A cash dividend payment of $0.432 per share is scheduled to be paid on July 01, 2014. Shareholders who purchased UIL stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 32nd quarter that UIL has paid the same dividend. At the current stock price of $36.65, the dividend yield is 4.71%.
The previous trading day's last sale of UIL was $36.65, representing a -11.96% decrease from the 52 week high of $41.63 and a 6.63% increase over the 52 week low of $34.37.
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). UIL's current earnings per share, an indicator of a company's profitability, is $2.15. Zacks Investment Research reports UIL's forecasted earnings growth in 2014 as -4.6%, compared to an industry average of 1.3%.
For more information on the declaration, record and payment dates, visit the UIL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to UIL through an Exchange Traded Fund [ETF]?
The following ETF(s) have UIL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES )
iShares Small Cap 600/BARRA Value Index Fund ( IJS ).
The top-performing ETF of this group is IJS with an increase of 3.33% over the last 100 days. DES has the highest percent weighting of UIL at 0.91%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) iShares Small Cap 600/BARRA Value Index Fund ( IJS ). DES has the highest percent weighting of UIL at 0.91%.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) iShares Small Cap 600/BARRA Value Index Fund ( IJS ).
|
The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) iShares Small Cap 600/BARRA Value Index Fund ( IJS ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). DES has the highest percent weighting of UIL at 0.91%.
|
The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) iShares Small Cap 600/BARRA Value Index Fund ( IJS ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). DES has the highest percent weighting of UIL at 0.91%.
|
0024742e-e317-4c39-9acb-bd1835d8f018
|
728473.0
|
2014-05-30 00:00:00 UTC
|
Compuware Corporation (CPWR) Ex-Dividend Date Scheduled for June 02, 2014
|
DES
|
https://www.nasdaq.com/articles/compuware-corporation-cpwr-ex-dividend-date-scheduled-june-02-2014-2014-05-30
|
nan
|
nan
|
Compuware Corporation ( CPWR ) will begin trading ex-dividend on June 02, 2014. A cash dividend payment of $0.125 per share is scheduled to be paid on June 18, 2014. Shareholders who purchased CPWR stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 5th quarter that CPWR has paid the same dividend. At the current stock price of $9.85, the dividend yield is 5.08%.
The previous trading day's last sale of CPWR was $9.85, representing a -15.96% decrease from the 52 week high of $11.72 and a 1.97% increase over the 52 week low of $9.66.
CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). CPWR's current earnings per share, an indicator of a company's profitability, is $.32. Zacks Investment Research reports CPWR's forecasted earnings growth in 2015 as -15%, compared to an industry average of 3.9%.
For more information on the declaration, record and payment dates, visit the CPWR Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CPWR through an Exchange Traded Fund [ETF]?
The following ETF(s) have CPWR as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 0.85% over the last 100 days. It also has the highest percent weighting of CPWR at 0.94%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). The following ETF(s) have CPWR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 0.85% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). The following ETF(s) have CPWR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have CPWR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). The top-performing ETF of this group is DES with an increase of 0.85% over the last 100 days.
|
CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). The following ETF(s) have CPWR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 0.85% over the last 100 days.
|
9029335d-41b8-4a67-9007-2cdb955555a6
|
728474.0
|
2014-05-27 00:00:00 UTC
|
Lexmark International, Inc. (LXK) Ex-Dividend Date Scheduled for May 28, 2014
|
DES
|
https://www.nasdaq.com/articles/lexmark-international-inc-lxk-ex-dividend-date-scheduled-may-28-2014-2014-05-27
|
nan
|
nan
|
Lexmark International, Inc. ( LXK ) will begin trading ex-dividend on May 28, 2014. A cash dividend payment of $0.36 per share is scheduled to be paid on June 13, 2014. Shareholders who purchased LXK stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 20% increase over the prior quarter. At the current stock price of $43.61, the dividend yield is 3.3%.
The previous trading day's last sale of LXK was $43.61, representing a -9.11% decrease from the 52 week high of $47.98 and a 48.48% increase over the 52 week low of $29.37.
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). LXK's current earnings per share, an indicator of a company's profitability, is $3.94. Zacks Investment Research reports LXK's forecasted earnings growth in 2014 as -6.63%, compared to an industry average of -.5%.
For more information on the declaration, record and payment dates, visit the LXK Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to LXK through an Exchange Traded Fund [ETF]?
The following ETF(s) have LXK as a top-10 holding:
First Trust Industrials AlphaDEX ( FXR )
Guggenheim Insider ETF ( NFO )
First Trust Mid Cap Value AlphaDEX Fund ( FNK )
WisdomTree Trust SmallCap Dividend Fund ( DES )
First Trust Mid Cap Core AlphaDEX ( FNX ).
The top-performing ETF of this group is FXR with an increase of 5.09% over the last 100 days. It also has the highest percent weighting of LXK at 1.7%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: First Trust Industrials AlphaDEX ( FXR ) Guggenheim Insider ETF ( NFO ) First Trust Mid Cap Value AlphaDEX Fund ( FNK ) WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust Mid Cap Core AlphaDEX ( FNX ). Shareholders who purchased LXK stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
The following ETF(s) have LXK as a top-10 holding: First Trust Industrials AlphaDEX ( FXR ) Guggenheim Insider ETF ( NFO ) First Trust Mid Cap Value AlphaDEX Fund ( FNK ) WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust Mid Cap Core AlphaDEX ( FNX ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ).
|
The following ETF(s) have LXK as a top-10 holding: First Trust Industrials AlphaDEX ( FXR ) Guggenheim Insider ETF ( NFO ) First Trust Mid Cap Value AlphaDEX Fund ( FNK ) WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust Mid Cap Core AlphaDEX ( FNX ). LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). Shareholders who purchased LXK stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: First Trust Industrials AlphaDEX ( FXR ) Guggenheim Insider ETF ( NFO ) First Trust Mid Cap Value AlphaDEX Fund ( FNK ) WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust Mid Cap Core AlphaDEX ( FNX ). Lexmark International, Inc. ( LXK ) will begin trading ex-dividend on May 28, 2014.
|
34412bf8-d51f-476e-949d-70117d1276ae
|
728475.0
|
2014-05-20 00:00:00 UTC
|
Medtronic Posts In-Line Earnings, Settles with Edwards - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/medtronic-posts-in-line-earnings-settles-with-edwards-analyst-blog-2014-05-20
|
nan
|
nan
|
After adjusting for certain one-time items like litigation charges primarily related to the company`s global patent agreement with Edwards Lifesciences Corporation ( EW ) and the company`s INFUSE product liability settlement, Medtronic Inc. 's ( MDT ) fourth-quarter fiscal 2014 adjusted earnings per share (EPS) came in at $1.12, up 2% year over year but in line with the Zacks Consensus Estimate.
However, without any one-time adjustments, the company reported net income of $448 million or 44 cents a share, both down 54% on a year-over-year basis. For the full year, adjusted EPS came in at $3.82 which was up 2% from the previous year and in line with the Zacks Consensus Estimate.
Revenues in the reported quarter grossed $4.566 billion, up 2% year over year (up 3% at constant exchange rates or CER). The result, however, remained marginally below the Zacks Consensus Estimate of $4.575 billion. Fiscal 2014 revenues reached $17.005 billion,up 3% from the previous year (up 4% at constant exchange rate or CER). However, following the news, the stock price remained almost flat in the pre-trading session.
International sales (generating 47% of total sales) grew 3% year over year (up 5% at CER) to $2.145 billion in the quarter. Based on Medtronic's focus on emerging markets, revenues from these regions experienced continued growth momentum and increased 10% (up 14% at CER) to $571 million. This region now represents 13% of the company's total revenue.
Segment Details
Medtronic earns revenues from two major groups - the Cardiac & Vascular Group and the Restorative Therapies Group. The former encompasses the Cardiac Rhythm Disease Management (CRDM), Coronary, Structural Heart and Endovascular businesses; while the latter includes the Spine, Neuromodulation, Diabetes and Surgical Technologies businesses.
CRDM sales were up 1% year over year (up 2% at CER) to $1.346 billion.Revenues from Implantable Cardioverter Defibrillators (ICD) were down 2% at CER to $734 million. However, in the international market, this business showed strong adoption of the Viva(TM) XT CRT-D, with its AdaptivCRT(TM) algorithm and Attain Performa quadripolar lead. Notably, in the reported quarter, the company launched the first full-body MRI-compatible ICD system, Evera MRI in Europe.
Pacing system revenues came in flat year over year at $503 million. AF solutions on the other hand, grew 20% at CER primarily due to a stupendous improvement in the Arctic Front CryoAblation System and the fourth-quarter international launch of PVAC Gold.
Coronary revenues were down 2% at CER to $446 million. On the other hand, Structural Heart and Endovascular recorded growth of 9% (to $337 million) and 3% (to $240 million), respectively, at CER. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. However, this was offset by declines in bare-metal stents and renal denervation.
Strong Structural Heart sales were driven by the U.S. launch of the self-expanding transcatheter CoreValve System. On the other hand, higher Endovascular sales came on the back of strong procedure growth in abdominal aortic aneurysms and thoracic aortic diseases. The ongoing adoption of Endurant II and Valiant Captivia stent grafts globally also contributed toward growth.
Spine revenues maintained the sluggish trend and fell 3% year over year (down 2% at CER) along with flat Core Spine revenue sales of $662 million. Excluding sales of balloon kyphoplasty, Core Spine grew in low single digits, globally.
Moreover, BMP (bone morphogenetic protein) revenues declined 11% at CER to $124 milliondue to difficult comparisons following the resolution of a supply disruption in the previous year. According to Medtronic, after showinglow-single digit market growth last quarter, the global and U.S. spine markets were relatively flat this time on a year-over-year basis.
Meanwhile, Surgical Technologies revenues were $438 million (up 8% year over year and up 9% at CER), while revenues at Neuromodulation were $513 million (up 4%, same at CER) and at Diabetes, $460 million (up 13%, same at CER).
Margins
Gross margin during the reported quarter contracted 21 basis points (bps) to 74.4%. Adjusted operating margin contracted 166 bps year over year to 30.9%, with a 4.3% increase in selling, general and administrative expenses (to $1.539 billion); a 5.8% decline in research and development expenses (to $385 million) and a huge increase in Other expenses to $59 million from $12 million of Other income in the year-ago quarter.
Guidance
Medtronic provided its revenues and EPS outlook for fiscal 2015. The company expects full-year EPS in the range of $4.00−$4.10 (implying annualized growth of approximately 6%−9%).The current Zacks Consensus Estimate for EPS stands at $4.09, close to the upper end of the guided range.
Fiscal 2015 revenue growth outlook is expected to remain within 3%−5% at CER. The current Zacks Consensus Estimate of $17.615 billion, which implies annualized growth of 3.6%, falls within the guided range.
Our Take
Medtronic posted an ordinary fiscal fourth quarter with in-line EPS and a top-line miss. The still sluggish CRDM sales with poor ICD and pacing revenues remain a matter of concern. Margin pressure too poses a major cause of worry. However, Medtronic is trying every means to boost growth. This includes penetration into the international markets, and expansion of portfolio and restructuring initiatives, which should benefit the company over the long term.
Furthermore, the company also announced that, under the terms of the cross-license settlement agreement, Medtronic has settled all the pending litigation matters and patent office actions with Edwards Lifesciences. In this process, Medtronic has to pay Edwards a one-time payment of $750 million, and ongoing royalty payments through April 2022 based on a share of CoreValve sales, in payments not less than $40 million annually.
Currently, Medtronic retains a Zacks Rank #3 (Hold). Medical device companies such as Mead Johnson Nutrition Co. ( MJN ) and ICU Medical, Inc. ( ICUI ) are also expected to do well. Both the stocks hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
MEAD JOHNSON NU (MJN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
The former encompasses the Cardiac Rhythm Disease Management (CRDM), Coronary, Structural Heart and Endovascular businesses; while the latter includes the Spine, Neuromodulation, Diabetes and Surgical Technologies businesses. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. This includes penetration into the international markets, and expansion of portfolio and restructuring initiatives, which should benefit the company over the long term.
|
The former encompasses the Cardiac Rhythm Disease Management (CRDM), Coronary, Structural Heart and Endovascular businesses; while the latter includes the Spine, Neuromodulation, Diabetes and Surgical Technologies businesses. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. This includes penetration into the international markets, and expansion of portfolio and restructuring initiatives, which should benefit the company over the long term.
|
The former encompasses the Cardiac Rhythm Disease Management (CRDM), Coronary, Structural Heart and Endovascular businesses; while the latter includes the Spine, Neuromodulation, Diabetes and Surgical Technologies businesses. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. This includes penetration into the international markets, and expansion of portfolio and restructuring initiatives, which should benefit the company over the long term.
|
The former encompasses the Cardiac Rhythm Disease Management (CRDM), Coronary, Structural Heart and Endovascular businesses; while the latter includes the Spine, Neuromodulation, Diabetes and Surgical Technologies businesses. The company is benefiting from the sales of the drug eluting stent (DES), which grew 2% at CER driven by significant share gains of the Resolute Integrity drug-eluting stent worldwide. This includes penetration into the international markets, and expansion of portfolio and restructuring initiatives, which should benefit the company over the long term.
|
100671ff-3503-4ae1-8246-5ed6a7566500
|
728476.0
|
2014-05-13 00:00:00 UTC
|
Diebold, Incorporated (DBD) Ex-Dividend Date Scheduled for May 14, 2014
|
DES
|
https://www.nasdaq.com/articles/diebold-incorporated-dbd-ex-dividend-date-scheduled-may-14-2014-2014-05-13
|
nan
|
nan
|
Diebold, Incorporated ( DBD ) will begin trading ex-dividend on May 14, 2014. A cash dividend payment of $0.2875 per share is scheduled to be paid on June 06, 2014. Shareholders who purchased DBD stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 6th quarter that DBD has paid the same dividend. At the current stock price of $37.75, the dividend yield is 3.05%.
The previous trading day's last sale of DBD was $37.75, representing a -8.93% decrease from the 52 week high of $41.45 and a 35.35% increase over the 52 week low of $27.89.
DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Pitney Bowes Inc. ( PBI ). DBD's current earnings per share, an indicator of a company's profitability, is -$2.49. Zacks Investment Research reports DBD's forecasted earnings growth in 2014 as 29.96%, compared to an industry average of 5.9%.
For more information on the declaration, record and payment dates, visit the DBD Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to DBD through an Exchange Traded Fund [ETF]?
The following ETF(s) have DBD as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 3.11% over the last 100 days. It also has the highest percent weighting of DBD at 0.84%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Pitney Bowes Inc. ( PBI ). The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 3.11% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Pitney Bowes Inc. ( PBI ). The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Pitney Bowes Inc. ( PBI ). The top-performing ETF of this group is DES with an increase of 3.11% over the last 100 days.
|
DBD is a part of the Miscellaneous sector, which includes companies such as W.W. Grainger, Inc. ( GWW ) and Pitney Bowes Inc. ( PBI ). The following ETF(s) have DBD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 3.11% over the last 100 days.
|
21f38d63-a90b-4d83-a7e0-6d1a8382bbeb
|
728477.0
|
2014-04-29 00:00:00 UTC
|
Boston Scientific Earnings Top, Revs Miss - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/boston-scientific-earnings-top-revs-miss-analyst-blog-2014-04-29
|
nan
|
nan
|
BostonScientific ( BSX ) reported adjusted earnings per share (after considering certain one-time adjustments other than amortization expense) of 13 cents in the first quarter of 2014, 3 cents ahead of the year-ago adjusted EPS figure.
However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 20 cents, 25% ahead of the year-ago adjusted number. This also exceeded the company's adjusted EPS guidance range of 16-18 cents and the Zacks Consensus Estimate of 18 cents.
Without these adjustments, the company reported net income of $133 million or 10 cents per share in the quarter, a huge increase from the year-ago net loss of $354 million or loss of 26 cents a share, respectively.
Revenues in the first quarter registered a 1% increase year over year (up 4% at constant exchange rate or CER, excluding divested business) to $1.774 billion. The figure missed the Zacks Consensus Estimate of $1.793 billion by a sliver, but remained within the company-provided guidance range of $1.755-$1.805 billion.
Segment Analysis
Boston Scientific currently has three global reportable segments comprising Cardiovascular, Rhythm Management and MedSurg.
The company generates maximum revenues from Cardiovascular, which comprises Interventional Cardiology and Peripheral Interventions. Sales in these sub-segments were $497 million (up 1% year over year at CER) and $203 million (up 5% at CER), respectively, during the quarter.
Global sales of coronary stent system (within Interventional Cardiology) were $289 million, down 6.8%. The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 5.5% to $276 million, and bare-metal stents that plunged 27.8% to $13 million.
The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. CRM reflected a sales decline of 2% to $466 million at CER.
Worldwide sales from pacemakers (within CRM) edged down 1% to $127 million, while defibrillators declined 3.1% to $339 million. Electrophysiology sales, on the other hand, improved 68% year over year to $58 million.
Over the recent past, the company has been targeting new product launches to revive the sales of the beleaguered Interventional Cardiology and CRM segments. However, the dismal performance of Interventional Cardiology and CRM during the reported quarter proved beyond doubt that the measures have not been enough to counter the ongoing challenges.
Other segments like Endoscopy, Urology/Women's Health and Neuromodulation (coming under the MedSurg broader group) recorded sales of $314 million (up 5% at CER), $125 million (up 8%) and $109 million (up 23%), respectively.
Margins
Gross margin grew 255 basis points (bps) year over year to 69.7%. Adjusted operating margin expanded 173 bps to 19.2% in the quarter. During the reported quarter, selling, general and administrative expenses increased 5.5% to $666 million, research and development expenses dropped 6.4% to $191 million and royalty expense was down by 2.4% to $40 million.
Balance Sheet
Boston Scientific exited the first quarter with cash and cash equivalents of $191 million, up from $217 million at the end of fiscal 2013, and had long-term debt of $4.24 billion. The company generated operating cash flow of $198 million and repurchased 10 million shares for $125 million in the quarter under the existing share repurchase program.
Guidance
Boston Scientific increased its 2014 adjusted EPS guidance in the range of 77-82 cents from earlier 75-80 cents (considering all one-time items including amortized expense). Revenues are expected to remain in the range of $7.30-$7.50 billion. The current Zacks Consensus Estimate for EPS of 78 cents and revenues of $7.41 billion coincide with the company's outlook.
For the second quarter of 2014, adjusted earnings are expected to remain in the band of 18-20 cents per share while the company predicts revenues within $1.84-$1.89 billion. The Zacks Consensus Estimate for EPS stands at 20 cents, while that for revenues is $1.87 billion.
Our Take
Amid challenging economic conditions, competitive environment, pressure on core segments and currency headwind, Boston Scientific posted a mixed first quarter with earnings beat and revenue miss.
For quite a long time, the US defibrillator and stent markets have remained as major overhangs. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and DES are still taking a toll on the numbers.
Nonetheless, we are also looking forward to the emerging market performance of the company.During the quarter, the company achieved 8% international growth on the back of 22% growth in emerging markets, which represented 9% of total company sales.
Moreover, Boston Scientific has managed to successfully move on with its strong pipeline of products. It is also focusing on strategic initiatives to drive growth and profitability. These include restructuring initiatives for 2014, targeting suitable acquisitions in areas of unmet medical needs and focus on emerging markets.
Currently, Boston Scientific retains a Zacks Rank #3 (Hold). Some of the better-placed Medical stocks are Cardinal Health, Inc. ( CAH ), Hologic Inc. ( HOLX ) and The Cooper Companies Inc. ( COO ), all carrying a Zacks Rank #2 (Buy).
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
CARDINAL HEALTH (CAH): Free Stock Analysis Report
COOPER COS (COO): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and DES are still taking a toll on the numbers. The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 5.5% to $276 million, and bare-metal stents that plunged 27.8% to $13 million. The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.
|
The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 5.5% to $276 million, and bare-metal stents that plunged 27.8% to $13 million. The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and DES are still taking a toll on the numbers.
|
The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 5.5% to $276 million, and bare-metal stents that plunged 27.8% to $13 million. The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and DES are still taking a toll on the numbers.
|
The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 5.5% to $276 million, and bare-metal stents that plunged 27.8% to $13 million. The next biggest contributor to Boston Scientific's top line was Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and DES are still taking a toll on the numbers.
|
7cea1bc7-2965-46b8-b638-72d65f777733
|
728478.0
|
2014-04-28 00:00:00 UTC
|
Will Boston Scientific (BSX) Beat Earnings This Quarter? - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/will-boston-scientific-bsx-beat-earnings-this-quarter-analyst-blog-2014-04-28
|
nan
|
nan
|
Boston Scientific Corporation ( BSX ) is scheduled to report its first-quarter 2014 results before the opening bell on Apr 29. Last quarter, Boston Scientific posted a positive earnings surprise of 10.53% while the four-quarter trailing average beat is pegged at 9.76%. Let's see how things are shaping up for this announcement.
Factors at Play
Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific has managed to successfully move on with its strong pipeline of products. The company has begun the year 2014 on an encouraging note with the launch of the OffRoad Re-Entry Catheter System in the U.S and the receipt of CE mark in Europe for its WallFlex Esophageal Stent in February.
Soon after, Boston Scientific obtained CE mark for its REBEL Platinum Chromium Coronary Stent System and Ingevity MRI Pacing Leads in March. Moving on, earlier this month, the company won the U.S. Food and Drug Administration (FDA) approval for a bunch of defibrillators and heart failure devices. Also, it won the U.S. Food and Drug Administration (FDA) and CE mark approval for the Expect Slimline (SL) Needle which will be used for Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) procedures.
Besides, the company is focusing on strategic initiatives like restructuring actions which include the 2014 restructuring plan, emerging markets expansion and share repurchases.
However, for quite a long time, the US defibrillator and stent markets remain as major overhangs.Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and drug-eluting stent (DES) are still taking a toll on the numbers.
Earnings Whispers?
Our proven model does not conclusively show that Boston Scientific is likely to beat earnings this quarter. It is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) and a Zacks Rank #1, 2 or 3 for this to happen. That is not the case here as you will see below.
Zacks ESP: BostonScientific's earnings ESP is 0.00%, as the Most Accurate estimate and the Zacks Consensus Estimate both stand at $0.18.
Zacks Rank: BostonScientific's Zacks Rank #3 (Hold) when combined with a 0.00% ESP makes surprise prediction difficult. We caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing a negative estimate revision momentum.
Other Stocks to Consider
Here are two companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Myriad Genetics Inc. ( MYGN ) has an earnings ESP of +10.87% and sports a Zacks Rank #1 (Strong Buy). Myriad Genetics will be reporting first-quarter earnings on May 6.
Cardinal Health, Inc. ( CAH ) has an earnings ESP of +1.00% and holds a Zacks Rank #2 (Buy). Cardinal Health will report third-quarter fiscal 2014 earnings on May 1.
We note that, Align Technology Inc. ( ALGN ) which surpassed its first-quarter 2014 earnings on Apr 23, had an earnings ESP of +13.89% and carried a Zacks Rank #1 (Strong Buy).
ALIGN TECH INC (ALGN): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
CARDINAL HEALTH (CAH): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Factors at Play Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific has managed to successfully move on with its strong pipeline of products. Besides, the company is focusing on strategic initiatives like restructuring actions which include the 2014 restructuring plan, emerging markets expansion and share repurchases. However, for quite a long time, the US defibrillator and stent markets remain as major overhangs.Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and drug-eluting stent (DES) are still taking a toll on the numbers.
|
Factors at Play Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific has managed to successfully move on with its strong pipeline of products. Besides, the company is focusing on strategic initiatives like restructuring actions which include the 2014 restructuring plan, emerging markets expansion and share repurchases. However, for quite a long time, the US defibrillator and stent markets remain as major overhangs.Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and drug-eluting stent (DES) are still taking a toll on the numbers.
|
Factors at Play Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific has managed to successfully move on with its strong pipeline of products. Besides, the company is focusing on strategic initiatives like restructuring actions which include the 2014 restructuring plan, emerging markets expansion and share repurchases. However, for quite a long time, the US defibrillator and stent markets remain as major overhangs.Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and drug-eluting stent (DES) are still taking a toll on the numbers.
|
Factors at Play Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific has managed to successfully move on with its strong pipeline of products. Besides, the company is focusing on strategic initiatives like restructuring actions which include the 2014 restructuring plan, emerging markets expansion and share repurchases. However, for quite a long time, the US defibrillator and stent markets remain as major overhangs.Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and drug-eluting stent (DES) are still taking a toll on the numbers.
|
a2a58f67-ae7a-4f44-89a0-684908845342
|
728479.0
|
2014-04-07 00:00:00 UTC
|
WGL Holdings Inc (WGL) Ex-Dividend Date Scheduled for April 08, 2014
|
DES
|
https://www.nasdaq.com/articles/wgl-holdings-inc-wgl-ex-dividend-date-scheduled-april-08-2014-2014-04-07
|
nan
|
nan
|
WGL Holdings Inc ( WGL ) will begin trading ex-dividend on April 08, 2014. A cash dividend payment of $0.44 per share is scheduled to be paid on May 01, 2014. Shareholders who purchased WGL stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 4.76% increase over the prior quarter. At the current stock price of $39.56, the dividend yield is 4.45%.
The previous trading day's last sale of WGL was $39.56, representing a -15.76% decrease from the 52 week high of $46.96 and a 11.89% increase over the 52 week low of $35.36.
WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). WGL's current earnings per share, an indicator of a company's profitability, is $.9. Zacks Investment Research reports WGL's forecasted earnings growth in 2014 as -.68%, compared to an industry average of 8.5%.
For more information on the declaration, record and payment dates, visit the WGL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to WGL through an Exchange Traded Fund [ETF]?
The following ETF(s) have WGL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 4.52% over the last 100 days. It also has the highest percent weighting of WGL at 0.82%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 4.52% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). The top-performing ETF of this group is DES with an increase of 4.52% over the last 100 days.
|
WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). The following ETF(s) have WGL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 4.52% over the last 100 days.
|
e2bb0cf7-39a6-4d43-a1ac-37487c71d9cb
|
728480.0
|
2014-03-21 00:00:00 UTC
|
Covanta Holding Corporation (CVA) Ex-Dividend Date Scheduled for March 24, 2014
|
DES
|
https://www.nasdaq.com/articles/covanta-holding-corporation-cva-ex-dividend-date-scheduled-march-24-2014-2014-03-21
|
nan
|
nan
|
Covanta Holding Corporation ( CVA ) will begin trading ex-dividend on March 24, 2014. A cash dividend payment of $0.18 per share is scheduled to be paid on April 02, 2014. Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 9.09% increase over the prior quarter.
The previous trading day's last sale of CVA was $16.8, representing a -23.25% decrease from the 52 week high of $21.89 and a 0.6% increase over the 52 week low of $16.70.
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). CVA's current earnings per share, an indicator of a company's profitability, is -$.05. Zacks Investment Research reports CVA's forecasted earnings growth in 2014 as 2.63%, compared to an industry average of 29.2%.
For more information on the declaration, record and payment dates, visit the CVA Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CVA through an Exchange Traded Fund [ETF]?
The following ETF(s) have CVA as a top-10 holding:
Market Vectors Environment Index ETF Fund ( EVX )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is EVX with an increase of 4.57% over the last 100 days. It also has the highest percent weighting of CVA at 2.57%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have CVA as a top-10 holding: Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have CVA as a top-10 holding: Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have CVA as a top-10 holding: Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). Shareholders who purchased CVA stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
CVA is a part of the Basic Industries sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have CVA as a top-10 holding: Market Vectors Environment Index ETF Fund ( EVX ) WisdomTree Trust SmallCap Dividend Fund ( DES ). A cash dividend payment of $0.18 per share is scheduled to be paid on April 02, 2014.
|
6edf5ee5-2003-465e-9ac5-f3d036b9fa1d
|
728481.0
|
2014-03-20 00:00:00 UTC
|
Portland General Electric Company (POR) Ex-Dividend Date Scheduled for March 21, 2014
|
DES
|
https://www.nasdaq.com/articles/portland-general-electric-company-por-ex-dividend-date-scheduled-march-21-2014-2014-03-20
|
nan
|
nan
|
Portland General Electric Company ( POR ) will begin trading ex-dividend on March 21, 2014. A cash dividend payment of $0.275 per share is scheduled to be paid on April 15, 2014. Shareholders who purchased POR stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that POR has paid the same dividend.
The previous trading day's last sale of POR was $32.16, representing a -3.31% decrease from the 52 week high of $33.26 and a 16.65% increase over the 52 week low of $27.57.
POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). POR's current earnings per share, an indicator of a company's profitability, is $1.35. Zacks Investment Research reports POR's forecasted earnings growth in 2014 as 2.22%, compared to an industry average of 1.1%.
For more information on the declaration, record and payment dates, visit the POR Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to POR through an Exchange Traded Fund [ETF]?
The following ETF(s) have POR as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 3.33% over the last 100 days. It also has the highest percent weighting of POR at 0.79%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have POR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 3.33% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have POR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have POR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an increase of 3.33% over the last 100 days.
|
The following ETF(s) have POR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). POR is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an increase of 3.33% over the last 100 days.
|
6c0c795c-7f95-4d60-a52d-0716b3210b35
|
728482.0
|
2014-03-17 00:00:00 UTC
|
Vector Group Ltd. (VGR) Ex-Dividend Date Scheduled for March 18, 2014
|
DES
|
https://www.nasdaq.com/articles/vector-group-ltd-vgr-ex-dividend-date-scheduled-march-18-2014-2014-03-17
|
nan
|
nan
|
Vector Group Ltd. ( VGR ) will begin trading ex-dividend on March 18, 2014. A cash dividend payment of $0.4 per share is scheduled to be paid on March 28, 2014. Shareholders who purchased VGR stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 44th quarter that VGR has paid the same dividend.
The previous trading day's last sale of VGR was $21.43, representing a -1.43% decrease from the 52 week high of $21.74 and a 46.69% increase over the 52 week low of $14.61.
VGR is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and British American Tobacco p.l.c. ( BTI ). VGR's current earnings per share, an indicator of a company's profitability, is $.33.
For more information on the declaration, record and payment dates, visit the VGR Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to VGR through an Exchange Traded Fund [ETF]?
The following ETF(s) have VGR as a top-10 holding:
PowerShares High Yield Equity Dividend Achievers Portfolio ( PEY )
SPDR Russell 2000 Low Volatility ( SMLV )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is SMLV with an increase of 7.24% over the last 100 days. PEY has the highest percent weighting of VGR at 4.06%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
VGR is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and British American Tobacco p.l.c. The following ETF(s) have VGR as a top-10 holding: PowerShares High Yield Equity Dividend Achievers Portfolio ( PEY ) SPDR Russell 2000 Low Volatility ( SMLV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). Shareholders who purchased VGR stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. VGR is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and British American Tobacco p.l.c. The following ETF(s) have VGR as a top-10 holding: PowerShares High Yield Equity Dividend Achievers Portfolio ( PEY ) SPDR Russell 2000 Low Volatility ( SMLV ) WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have VGR as a top-10 holding: PowerShares High Yield Equity Dividend Achievers Portfolio ( PEY ) SPDR Russell 2000 Low Volatility ( SMLV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). VGR is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and British American Tobacco p.l.c. Shareholders who purchased VGR stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
VGR is a part of the Consumer Non-Durables sector, which includes companies such as Philip Morris International Inc ( PM ) and British American Tobacco p.l.c. The following ETF(s) have VGR as a top-10 holding: PowerShares High Yield Equity Dividend Achievers Portfolio ( PEY ) SPDR Russell 2000 Low Volatility ( SMLV ) WisdomTree Trust SmallCap Dividend Fund ( DES ). A cash dividend payment of $0.4 per share is scheduled to be paid on March 28, 2014.
|
8d197802-a79e-407b-8eb1-37f184f8ba98
|
728483.0
|
2014-03-06 00:00:00 UTC
|
CPWR Crosses Below Key Moving Average Level
|
DES
|
https://www.nasdaq.com/articles/cpwr-crosses-below-key-moving-average-level-2014-03-06
|
nan
|
nan
|
In trading on Thursday, shares of CompuWare Corp. (Symbol: CPWR) crossed below their 200 day moving average of $10.84, changing hands as low as $10.79 per share. CompuWare Corp. shares are currently trading up about 1.1% on the day. The chart below shows the one year performance of CPWR shares, versus its 200 day moving average:
Looking at the chart above, CPWR's low point in its 52 week range is $9.66 per share, with $12.62 as the 52 week high point - that compares with a last trade of $10.88.
According to the ETF Finder at ETF Channel, CPWR makes up 1.00% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Thursday.
Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
According to the ETF Finder at ETF Channel, CPWR makes up 1.00% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Thursday. In trading on Thursday, shares of CompuWare Corp. (Symbol: CPWR) crossed below their 200 day moving average of $10.84, changing hands as low as $10.79 per share. The chart below shows the one year performance of CPWR shares, versus its 200 day moving average: Looking at the chart above, CPWR's low point in its 52 week range is $9.66 per share, with $12.62 as the 52 week high point - that compares with a last trade of $10.88.
|
According to the ETF Finder at ETF Channel, CPWR makes up 1.00% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Thursday. In trading on Thursday, shares of CompuWare Corp. (Symbol: CPWR) crossed below their 200 day moving average of $10.84, changing hands as low as $10.79 per share. The chart below shows the one year performance of CPWR shares, versus its 200 day moving average: Looking at the chart above, CPWR's low point in its 52 week range is $9.66 per share, with $12.62 as the 52 week high point - that compares with a last trade of $10.88.
|
According to the ETF Finder at ETF Channel, CPWR makes up 1.00% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Thursday. In trading on Thursday, shares of CompuWare Corp. (Symbol: CPWR) crossed below their 200 day moving average of $10.84, changing hands as low as $10.79 per share. The chart below shows the one year performance of CPWR shares, versus its 200 day moving average: Looking at the chart above, CPWR's low point in its 52 week range is $9.66 per share, with $12.62 as the 52 week high point - that compares with a last trade of $10.88.
|
According to the ETF Finder at ETF Channel, CPWR makes up 1.00% of the WisdomTree SmallCap Dividend Fund ETF (Symbol: DES) which is trading lower by about 0.1% on the day Thursday. In trading on Thursday, shares of CompuWare Corp. (Symbol: CPWR) crossed below their 200 day moving average of $10.84, changing hands as low as $10.79 per share. Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
4b0fd651-f08c-4a50-8060-5b372fe80d69
|
728484.0
|
2014-03-05 00:00:00 UTC
|
UIL Holdings Corporation (UIL) Ex-Dividend Date Scheduled for March 06, 2014
|
DES
|
https://www.nasdaq.com/articles/uil-holdings-corporation-uil-ex-dividend-date-scheduled-march-06-2014-2014-03-05
|
nan
|
nan
|
UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on March 06, 2014. A cash dividend payment of $0.432 per share is scheduled to be paid on April 01, 2014. Shareholders who purchased UIL stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 31st quarter that UIL has paid the same dividend.
The previous trading day's last sale of UIL was $36.38, representing a -13.67% decrease from the 52 week high of $42.14 and a 0.66% increase over the 52 week low of $36.14.
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). UIL's current earnings per share, an indicator of a company's profitability, is $2.19. Zacks Investment Research reports UIL's forecasted earnings growth in 2014 as -4.52%, compared to an industry average of -1%.
For more information on the declaration, record and payment dates, visit the UIL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to UIL through an Exchange Traded Fund [ETF]?
The following ETF(s) have UIL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 11.55% over the last 100 days. It also has the highest percent weighting of UIL at 0.93%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 11.55% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an increase of 11.55% over the last 100 days.
|
The following ETF(s) have UIL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). UIL is a part of the Public Utilities sector, which includes companies such as NextEra Energy, Inc. ( NEE ) and Dominion Resources, Inc. ( D ). The top-performing ETF of this group is DES with an increase of 11.55% over the last 100 days.
|
594c71d1-292c-4607-b311-dd4f13c2031a
|
728485.0
|
2014-03-05 00:00:00 UTC
|
Compuware Corporation (CPWR) Ex-Dividend Date Scheduled for March 06, 2014
|
DES
|
https://www.nasdaq.com/articles/compuware-corporation-cpwr-ex-dividend-date-scheduled-march-06-2014-2014-03-05
|
nan
|
nan
|
Compuware Corporation ( CPWR ) will begin trading ex-dividend on March 06, 2014. A cash dividend payment of $0.125 per share is scheduled to be paid on March 24, 2014. Shareholders who purchased CPWR stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that CPWR has paid the same dividend.
The previous trading day's last sale of CPWR was $11.01, representing a -12.76% decrease from the 52 week high of $12.62 and a 13.98% increase over the 52 week low of $9.66.
CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). CPWR's current earnings per share, an indicator of a company's profitability, is -$.07. Zacks Investment Research reports CPWR's forecasted earnings growth in 2014 as 25.93%, compared to an industry average of 1.8%.
For more information on the declaration, record and payment dates, visit the CPWR Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CPWR through an Exchange Traded Fund [ETF]?
The following ETF(s) have CPWR as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 11.55% over the last 100 days. It also has the highest percent weighting of CPWR at 0.98%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). The following ETF(s) have CPWR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 11.55% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). The following ETF(s) have CPWR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have CPWR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). The top-performing ETF of this group is DES with an increase of 11.55% over the last 100 days.
|
The following ETF(s) have CPWR as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). CPWR is a part of the Technology sector, which includes companies such as Microsoft Corporation ( MSFT ) and Oracle Corporation ( ORCL ). The top-performing ETF of this group is DES with an increase of 11.55% over the last 100 days.
|
c6f1736d-307c-4a65-b74a-16954ff2b5f3
|
728486.0
|
2014-03-04 00:00:00 UTC
|
Balanced View Retained for Boston Scientific - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/balanced-view-retained-for-boston-scientific-analyst-blog-2014-03-04
|
nan
|
nan
|
On Mar 04, 2014, we issued an updated research report on Boston Scientific Corporation ( BSX ), a leading medical devices company. Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to post healthy fourth-quarter 2013 results handily beating both revenues and earnings.
We are also optimistic about the recent update on the company's growth objective and its 2014 restructuring plan announced last October that convey significant new additions . The stock currently carries a Zacks Rank #3 (Hold).
Boston Scientific's fourth-quarter 2013 adjusted EPS of 21 cents beat the year-ago figure by 16.7% and also exceeded the company's guided range. The bottom line also exceeded the Zacks Consensus Estimate by a couple of cents. Revenues went up 5% at CER to $1.838 billion, ahead of the Zacks Consensus Estimate of $1.829 billion as well as the guided range of $1.780−$1.830 billion.
However, for quite a long time, the US defibrillator and stent markets have remained as major overhangs. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - Cardiac Rhythm Management (CRM) and Drug-Eluting Stent (DES) (contributing a total of 43% of sales in 2013) - are still taking a toll on the numbers. According to the company, the challenging scenario at present fails to betray any assurance that the size of the CRM and DES markets will increase above existing levels or that the company will be able to increase its market share or net sales in these segments in the near term.
Meanwhile, Boston Scientific is resorting to all available means in order to return to growth. To revive its top line, the company is focusing on strategic initiatives to drive growth and profitability. The company has a strong pipeline of products under development, the launch of which should boost the top line. We are encouraged by the focus on emerging markets, especially India and China. Boston Scientific plans to invest approximately $150 million in China over the next 5 years to build a local manufacturing operation.
Other Stocks to Consider
Some better-ranked medical devices stocks that are worth a look include Covidien plc ( COV ), NuVasive, Inc. ( NUVA ) and Stryker Corporation ( SYK ). All of these three stocks carry a Zacks Rank #2 (Buy).
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis Report
STRYKER CORP (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to post healthy fourth-quarter 2013 results handily beating both revenues and earnings. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - Cardiac Rhythm Management (CRM) and Drug-Eluting Stent (DES) (contributing a total of 43% of sales in 2013) - are still taking a toll on the numbers. According to the company, the challenging scenario at present fails to betray any assurance that the size of the CRM and DES markets will increase above existing levels or that the company will be able to increase its market share or net sales in these segments in the near term.
|
Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to post healthy fourth-quarter 2013 results handily beating both revenues and earnings. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - Cardiac Rhythm Management (CRM) and Drug-Eluting Stent (DES) (contributing a total of 43% of sales in 2013) - are still taking a toll on the numbers. According to the company, the challenging scenario at present fails to betray any assurance that the size of the CRM and DES markets will increase above existing levels or that the company will be able to increase its market share or net sales in these segments in the near term.
|
Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - Cardiac Rhythm Management (CRM) and Drug-Eluting Stent (DES) (contributing a total of 43% of sales in 2013) - are still taking a toll on the numbers. According to the company, the challenging scenario at present fails to betray any assurance that the size of the CRM and DES markets will increase above existing levels or that the company will be able to increase its market share or net sales in these segments in the near term. Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to post healthy fourth-quarter 2013 results handily beating both revenues and earnings.
|
Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - Cardiac Rhythm Management (CRM) and Drug-Eluting Stent (DES) (contributing a total of 43% of sales in 2013) - are still taking a toll on the numbers. Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to post healthy fourth-quarter 2013 results handily beating both revenues and earnings. According to the company, the challenging scenario at present fails to betray any assurance that the size of the CRM and DES markets will increase above existing levels or that the company will be able to increase its market share or net sales in these segments in the near term.
|
4cced4e8-d254-4017-b1a1-680995df1d1b
|
728487.0
|
2014-02-26 00:00:00 UTC
|
TAL International Group, Inc. (TAL) Ex-Dividend Date Scheduled for February 27, 2014
|
DES
|
https://www.nasdaq.com/articles/tal-international-group-inc-tal-ex-dividend-date-scheduled-february-27-2014-2014-02-26
|
nan
|
nan
|
TAL International Group, Inc. ( TAL ) will begin trading ex-dividend on February 27, 2014. A cash dividend payment of $0.72 per share is scheduled to be paid on March 24, 2014. Shareholders who purchased TAL stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 2.86% increase over the prior quarter.
The previous trading day's last sale of TAL was $44.57, representing a -22.92% decrease from the 52 week high of $57.82 and a 15.77% increase over the 52 week low of $38.50.
TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and United Rentals, Inc. ( URI ). TAL's current earnings per share, an indicator of a company's profitability, is $4.25. Zacks Investment Research reports TAL's forecasted earnings growth in 2014 as -1.73%, compared to an industry average of 17.4%.
For more information on the declaration, record and payment dates, visit the TAL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to TAL through an Exchange Traded Fund [ETF]?
The following ETF(s) have TAL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 5.31% over the last 100 days. It also has the highest percent weighting of TAL at 0.75%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and United Rentals, Inc. ( URI ). The following ETF(s) have TAL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 5.31% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and United Rentals, Inc. ( URI ). The following ETF(s) have TAL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and United Rentals, Inc. ( URI ). The following ETF(s) have TAL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 5.31% over the last 100 days.
|
The top-performing ETF of this group is DES with an increase of 5.31% over the last 100 days. TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and United Rentals, Inc. ( URI ). The following ETF(s) have TAL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
1af709c4-cfda-47bb-9893-da621ccfc3fe
|
728488.0
|
2014-02-26 00:00:00 UTC
|
Lexmark International, Inc. (LXK) Ex-Dividend Date Scheduled for February 27, 2014
|
DES
|
https://www.nasdaq.com/articles/lexmark-international-inc-lxk-ex-dividend-date-scheduled-february-27-2014-2014-02-26
|
nan
|
nan
|
Lexmark International, Inc. ( LXK ) will begin trading ex-dividend on February 27, 2014. A cash dividend payment of $0.3 per share is scheduled to be paid on March 14, 2014. Shareholders who purchased LXK stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 8th quarter that LXK has paid the same dividend.
The previous trading day's last sale of LXK was $42.73, representing a -0.51% decrease from the 52 week high of $42.95 and a 97.37% increase over the 52 week low of $21.65.
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). LXK's current earnings per share, an indicator of a company's profitability, is $4.1. Zacks Investment Research reports LXK's forecasted earnings growth in 2014 as -6.59%, compared to an industry average of .7%.
For more information on the declaration, record and payment dates, visit the LXK Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to LXK through an Exchange Traded Fund [ETF]?
The following ETF(s) have LXK as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 5.31% over the last 100 days. It also has the highest percent weighting of LXK at 0.77%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 5.31% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The top-performing ETF of this group is DES with an increase of 5.31% over the last 100 days.
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The top-performing ETF of this group is DES with an increase of 5.31% over the last 100 days.
|
d061a36d-c022-4014-b1eb-300dded07a67
|
728489.0
|
2014-02-25 00:00:00 UTC
|
Compass Minerals International, Inc. (CMP) Ex-Dividend Date Scheduled for February 26, 2014
|
DES
|
https://www.nasdaq.com/articles/compass-minerals-international-inc-cmp-ex-dividend-date-scheduled-february-26-2014-2014-02
|
nan
|
nan
|
Compass Minerals International, Inc. ( CMP ) will begin trading ex-dividend on February 26, 2014. A cash dividend payment of $0.6 per share is scheduled to be paid on March 14, 2014. Shareholders who purchased CMP stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 10.09% increase over the prior quarter.
The previous trading day's last sale of CMP was $83.75, representing a -8.85% decrease from the 52 week high of $91.88 and a 30.37% increase over the 52 week low of $64.24.
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ). CMP's current earnings per share, an indicator of a company's profitability, is $3.89. Zacks Investment Research reports CMP's forecasted earnings growth in 2014 as 1.16%, compared to an industry average of 6.2%.
For more information on the declaration, record and payment dates, visit the CMP Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to CMP through an Exchange Traded Fund [ETF]?
The following ETF(s) have CMP as a top-10 holding:
Market Vectors Wide Moat ETF ( MOAT )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 6.24% over the last 100 days. MOAT has the highest percent weighting of CMP at 5.35%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ). The following ETF(s) have CMP as a top-10 holding: Market Vectors Wide Moat ETF ( MOAT ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 6.24% over the last 100 days.
|
The following ETF(s) have CMP as a top-10 holding: Market Vectors Wide Moat ETF ( MOAT ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ).
|
The following ETF(s) have CMP as a top-10 holding: Market Vectors Wide Moat ETF ( MOAT ) WisdomTree Trust SmallCap Dividend Fund ( DES ). CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ). The top-performing ETF of this group is DES with an increase of 6.24% over the last 100 days.
|
The following ETF(s) have CMP as a top-10 holding: Market Vectors Wide Moat ETF ( MOAT ) WisdomTree Trust SmallCap Dividend Fund ( DES ). CMP is a part of the Basic Industries sector, which includes companies such as Teck Resources Ltd ( TCK ) and Vulcan Materials Company ( VMC ). The top-performing ETF of this group is DES with an increase of 6.24% over the last 100 days.
|
ce54f1fb-03bd-4095-bc73-f3ddacacac67
|
728490.0
|
2014-02-18 00:00:00 UTC
|
In-Line Earnings, Tighter Outlook at Medtronic - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/in-line-earnings-tighter-outlook-at-medtronic-analyst-blog-2014-02-18
|
nan
|
nan
|
Medtronic Inc. 's ( MDT ) third-quarter fiscal 2014 adjusted earnings per share (EPS) came in at 91 cents, down 2% year over year but in line with the Zacks Consensus estimate. The year-over-year decline was primarily due to the non-renewal, this year, of a benefit of 3 cents from the extension of the U.S. R&D tax credit.
Also, high interest expense and the U.S. medical device excise tax lowered the bottom line in the reported quarter. However, without any one-time adjustments, the company reported net income of $762 million or 75 cents a share, both down 23% on year-over-year bases.
Revenues in the reported quarter were $4.163 billion, up 3% year over year (up 4% at constant exchange rates or CER). The result remained marginally above the Zacks Consensus Estimate of $4.155 billion.
International
|
The year-over-year decline was primarily due to the non-renewal, this year, of a benefit of 3 cents from the extension of the U.S. R&D tax credit. Also, high interest expense and the U.S. medical device excise tax lowered the bottom line in the reported quarter. However, without any one-time adjustments, the company reported net income of $762 million or 75 cents a share, both down 23% on year-over-year bases.
|
Medtronic Inc. 's ( MDT ) third-quarter fiscal 2014 adjusted earnings per share (EPS) came in at 91 cents, down 2% year over year but in line with the Zacks Consensus estimate. Revenues in the reported quarter were $4.163 billion, up 3% year over year (up 4% at constant exchange rates or CER). The result remained marginally above the Zacks Consensus Estimate of $4.155 billion.
|
Medtronic Inc. 's ( MDT ) third-quarter fiscal 2014 adjusted earnings per share (EPS) came in at 91 cents, down 2% year over year but in line with the Zacks Consensus estimate. Revenues in the reported quarter were $4.163 billion, up 3% year over year (up 4% at constant exchange rates or CER). International
|
Medtronic Inc. 's ( MDT ) third-quarter fiscal 2014 adjusted earnings per share (EPS) came in at 91 cents, down 2% year over year but in line with the Zacks Consensus estimate. The year-over-year decline was primarily due to the non-renewal, this year, of a benefit of 3 cents from the extension of the U.S. R&D tax credit. Also, high interest expense and the U.S. medical device excise tax lowered the bottom line in the reported quarter.
|
70198df5-296e-4e32-9d0a-8ec35b065184
|
728491.0
|
2014-02-04 00:00:00 UTC
|
Boston Scientific Beats on Q4 Earnings, Revs - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/boston-scientific-beats-on-q4-earnings-revs-analyst-blog-2014-02-04
|
nan
|
nan
|
Boston Scientific ( BSX ) reported adjusted earnings per share (after considering certain one-time adjustments other than amortization expense) of 13 cents in the fourth quarter of 2013, 2 cents ahead of the year-ago adjusted EPS figure.
However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 21 cents, 16.7% ahead of the year-ago adjusted EPS. This also exceeded the company's adjusted EPS guidance range of 18-20 cents and the Zacks Consensus Estimate of 19 cents.
However, without these adjustments, the company reported net income of $108 million or 8 cents per share in the quarter, an 80% or 100% jump from the year-ago net income of $60 million or 4 cents a share, respectively.
For the full year, adjusted EPS (including amortized expense adjustments) reached 73 cents, up 10.6% from the prior-year figure surpassing the Zacks Consensus Estimate by 2 cents.
Revenues in the fourth quarter registered a 1% increase year over year (up 5% at constant exchange rate or CER, excluding divested business) to $1.838 billion. The figure exceeded the Zacks Consensus Estimate of $1.829 billion, as well as the company-provided guidance range of $1.780−$1.830 billion. For the full year, the company reported revenues of $7.143 billion, representing 1% decline on reported basis (up 1% at CER).
Segment Analysis
Boston Scientific currently has three global reportable segments comprising Cardiovascular, Rhythm Management and MedSurg.
The company generates maximum revenues from Cardiovascular, which comprises Interventional Cardiology and Peripheral Interventions. Sales in these sub-segments were $500 million (down 3% year over year at CER) and $205 million (up 7% at CER), respectively, during the quarter.
Global sales of coronary stent system (within Interventional Cardiology) were $287 million, down 13.8%. The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 12.8% to $272 million, and bare-metal stents that plunged 28.5% to $15 million.
The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. CRM continued to remain sluggish with 2% revenue growth to $468 million on a year-over-year basis (up 3% at CER).
After several quarters of drag, worldwide sales from pacemakers (within CRM) showed improvement of 6.3% to $135 million, while defibrillators edged up 0.9% to $333 million. Electrophysiology sales improved 33% year over year (up 35% at CER) to $50 million.
Over the recent past, the company has been targeting new product launches to revive the sales of the beleaguered Interventional Cardiology and CRM segments. Although, CRM is gradually coming back to growth, the dismal performance of Interventional Cardiology during the reported quarter proved beyond doubt that the measures have not been enough to counter the ongoing challenges.
Other segments like Endoscopy, Urology/Women's Health and Neuromodulation (coming under the MedSurg broader group) recorded sales of $343 million (up 8% at CER), $132 million (up 5%) and $138 million (up 33%), respectively.
Margins
Gross margin grew 182 basis points (bps) year over year to 69.8%. Adjusted operating margin however contracted 88 bps to 17.4% in the quarter. During the reported quarter, selling, general and administrative expenses increased 13.3% to $724 million, research and development expenses dropped 9.6% to $216 million and royalty expense was slashed by 14.3% to $24 million.
Balance Sheet
Boston Scientific exited the year 2013 with cash and cash equivalents of $217 million, up from $207 million at the end of fiscal 2012, and had long-term debt of $4.24 billion. The company generated operating cash flow of $1.078 billion and repurchased 51.4 million shares during 2013 under the existing share repurchase program.
Guidance
Boston Scientific provided its full year 2014 guidance.The company expects to report adjusted EPS of 75-80 cents (considering all one-time items including amortized expense) on revenues of $7.380-$7.500 billion. The current Zacks Consensus Estimate for EPS of 78 cents and revenues of $7.400 billion coincide with the company's outlook.
For the first quarter of 2014, adjusted earnings are expected to remain in the band of 16 cents-18 cents per share while the company predicts revenues within $1.755-$1.805 billion.The Zacks Consensus Estimate for EPS stands at 20 cents, while that for revenues is $1.799 billion.
Our Take
Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to beat estimates in the fourth quarter of 2013 and exited the year on a positive note.
We are also looking forward to the recently completed acquisition of electrophysiology business of C.R. Bard, Inc. ( BCR ). We believe this to add further traction to Boston Scientific's growing electrophysiology business in the coming months. Also, pacing business is gradually coming back to the growth trajectory, which is an encouraging sign.
However, for quite a long time, the US defibrillator and stent markets have remained as major overhangs. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and DES are still taking a toll on the numbers.
The DES business in the U.S. has been witnessing challenges due to pricing pressure, lower procedural volume, lower penetration rates and share losses from the launch of Medtronic Inc. 's ( MDT ) Resolute Integrity stent.
To revive its top line, Boston Scientific is focusing on strategic initiatives to drive growth and profitability. These include the recently announced restructuring initiatives for 2014, strengthening of its portfolio, targeting suitable acquisitions in areas of unmet medical needs, and focus on emerging markets. However, near-term visibility of these initiatives remains a matter of question.
Currently, Boston Scientific retains a Zacks Rank #4 (Sell). Among the better-ranked medical product companies, Stryker Corp. ( SYK ) which carries a Zacks Rank #2 (Buy), is worth considering.
BARD C R INC (BCR): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
STRYKER CORP (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Our Take Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to beat estimates in the fourth quarter of 2013 and exited the year on a positive note. Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments - implantable cardioverter defibrillator and DES are still taking a toll on the numbers. The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 12.8% to $272 million, and bare-metal stents that plunged 28.5% to $15 million.
|
The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 12.8% to $272 million, and bare-metal stents that plunged 28.5% to $15 million. The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. Our Take Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to beat estimates in the fourth quarter of 2013 and exited the year on a positive note.
|
The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 12.8% to $272 million, and bare-metal stents that plunged 28.5% to $15 million. The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. Our Take Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to beat estimates in the fourth quarter of 2013 and exited the year on a positive note.
|
The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 12.8% to $272 million, and bare-metal stents that plunged 28.5% to $15 million. The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. Our Take Despite challenging economic conditions, competitive environment, pressure on core segments and a larger-than-expected currency headwind, Boston Scientific managed to beat estimates in the fourth quarter of 2013 and exited the year on a positive note.
|
bcef3ded-43fe-446b-830e-0f70ecfe99cc
|
728492.0
|
2014-01-07 00:00:00 UTC
|
WGL Holdings Inc (WGL) Ex-Dividend Date Scheduled for January 08, 2014
|
DES
|
https://www.nasdaq.com/articles/wgl-holdings-inc-wgl-ex-dividend-date-scheduled-january-08-2014-2014-01-07
|
nan
|
nan
|
WGL Holdings Inc ( WGL ) will begin trading ex-dividend on January 08, 2014. A cash dividend payment of $0.42 per share is scheduled to be paid on February 01, 2014. Shareholders who purchased WGL stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that WGL has paid the same dividend.
The previous trading day's last sale of WGL was $39.31, representing a -16.29% decrease from the 52 week high of $46.96 and a 3.56% increase over the 52 week low of $37.96.
WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). WGL's current earnings per share, an indicator of a company's profitability, is $1.55. Zacks Investment Research reports WGL's forecasted earnings growth in 2014 as -3.03%, compared to an industry average of -.2%.
For more information on the declaration, record and payment dates, visit the WGL Dividend History page. Our
|
WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). Shareholders who purchased WGL stock prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports WGL's forecasted earnings growth in 2014 as -3.03%, compared to an industry average of -.2%.
|
WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). A cash dividend payment of $0.42 per share is scheduled to be paid on February 01, 2014. Shareholders who purchased WGL stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). WGL Holdings Inc ( WGL ) will begin trading ex-dividend on January 08, 2014. Shareholders who purchased WGL stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
WGL is a part of the Public Utilities sector, which includes companies such as Ultrapar Participacoes S.A. ( UGP ) and Cheniere Energy, Inc. ( LNG ). A cash dividend payment of $0.42 per share is scheduled to be paid on February 01, 2014. Shareholders who purchased WGL stock prior to the ex-dividend date are eligible for the cash dividend payment.
|
a300c0e2-1cff-4d5f-8903-a19cf96dacff
|
728493.0
|
2013-12-13 00:00:00 UTC
|
UIL Holdings Corporation (UIL) Ex-Dividend Date Scheduled for December 16, 2013
|
DES
|
https://www.nasdaq.com/articles/uil-holdings-corporation-uil-ex-dividend-date-scheduled-december-16-2013-2013-12-13
|
nan
|
nan
|
UIL Holdings Corporation ( UIL ) will begin trading ex-dividend on December 16, 2013. A cash dividend payment of $0.432 per share is scheduled to be paid on January 02, 2014. Shareholders who purchased UIL stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 30th quarter that UIL has paid the same dividend. At the current stock price of $37.04, the dividend yield is 4.67%.
The previous trading day's last sale of UIL was $37.04, representing a -12.1% decrease from the 52 week high of $42.14 and a 6.04% increase over the 52 week low of $34.93.
UIL is a part of the Public Utilities sector, which includes companies such as Dominion Resources, Inc. ( D ) and NextEra Energy, Inc. ( NEE ). UIL's current earnings per share, an indicator of a company's profitability, is $2.02. Zacks Investment Research reports UIL's forecasted earnings growth in 2013 as 6.88%, compared to an industry average of .1%.
For more information on the declaration, record and payment dates, visit the UIL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to UIL through an Exchange Traded Fund [ETF]?
The following ETF(s) have UIL as a top-10 holding:
PowerShares S&P SmallCap Utilities Portfolio ( PSCU )
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 3.88% over the last 100 days. PSCU has the highest percent weighting of UIL at 8.25%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
UIL is a part of the Public Utilities sector, which includes companies such as Dominion Resources, Inc. ( D ) and NextEra Energy, Inc. ( NEE ). The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 3.88% over the last 100 days.
|
The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. UIL is a part of the Public Utilities sector, which includes companies such as Dominion Resources, Inc. ( D ) and NextEra Energy, Inc. ( NEE ).
|
The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). UIL is a part of the Public Utilities sector, which includes companies such as Dominion Resources, Inc. ( D ) and NextEra Energy, Inc. ( NEE ). The top-performing ETF of this group is DES with an increase of 3.88% over the last 100 days.
|
The following ETF(s) have UIL as a top-10 holding: PowerShares S&P SmallCap Utilities Portfolio ( PSCU ) WisdomTree Trust SmallCap Dividend Fund ( DES ). UIL is a part of the Public Utilities sector, which includes companies such as Dominion Resources, Inc. ( D ) and NextEra Energy, Inc. ( NEE ). The top-performing ETF of this group is DES with an increase of 3.88% over the last 100 days.
|
948805f8-74cf-412c-a810-7537cd0fd67d
|
728494.0
|
2013-12-02 00:00:00 UTC
|
PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for December 03, 2013
|
DES
|
https://www.nasdaq.com/articles/pdl-biopharma-inc-pdli-ex-dividend-date-scheduled-december-03-2013-2013-12-02
|
nan
|
nan
|
PDL BioPharma, Inc. ( PDLI ) will begin trading ex-dividend on December 03, 2013. A cash dividend payment of $0.15 per share is scheduled to be paid on December 12, 2013. Shareholders who purchased PDLI stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 12th quarter that PDLI has paid the same dividend. At the current stock price of $9.77, the dividend yield is 6.14%.
The previous trading day's last sale of PDLI was $9.77, representing a -0.91% decrease from the 52 week high of $9.86 and a 50.31% increase over the 52 week low of $6.50.
PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ). PDLI's current earnings per share, an indicator of a company's profitability, is $1.68. Zacks Investment Research reports PDLI's forecasted earnings growth in 2013 as 21.09%, compared to an industry average of 8.4%.
For more information on the declaration, record and payment dates, visit the PDLI Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to PDLI through an Exchange Traded Fund [ETF]?
The following ETF(s) have PDLI as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 10.14% over the last 100 days. It also has the highest percent weighting of PDLI at 0.82%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ). The following ETF(s) have PDLI as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 10.14% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ). The following ETF(s) have PDLI as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
The following ETF(s) have PDLI as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ). The top-performing ETF of this group is DES with an increase of 10.14% over the last 100 days.
|
PDLI is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Amgen Inc. ( AMGN ). The following ETF(s) have PDLI as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 10.14% over the last 100 days.
|
ddaf6860-862c-4841-8daa-fbc94da8b011
|
728495.0
|
2013-11-27 00:00:00 UTC
|
BSX' Promus PREMIER DES Gets FDA Nod - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/bsx-promus-premier-des-gets-fda-nod-analyst-blog-2013-11-27
|
nan
|
nan
|
Boston Scientific Corporation ( BSX ) made a major breakthrough with its receipt of the U.S. Food and Drug Administration's (FDA) go-ahead for its new drug-eluting stent (DES) system, designed to treat coronary heart diseases. Subsequent to the approval, this next-generation durable polymer drug-eluting stent, Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System was launched in the U.S.
The company also announced the first implantation of this stent, to be performed by Martin Leon, director at the Center for Interventional Vascular Therapy at Columbia University Medical Center in NY. In Feb 2013, Boston Scientific received the European CE mark approval for this system.
Coronary artery disease refers to the narrowing of blood vessels that supply blood and oxygen to the heart, leading to pain, shortness of breath, and fatigue to the extent of heart attack. Placement of a stent in the artery in this case helps keep it open allowing the blood to flow more freely. Recent, data shows that the market for coronary heart disease is growing at a steady pace.
While we are encouraged with the approval of Promus PREMIER in the U.S., Boston Scientific's Interventional Cardiology segment has been recording declining sales over the past few quarters, primarily owing to disappointing performance of the coronary stent franchise. This is significant as the company in the recently reported third quarter derived 16% of its total revenue from coronary stents.
During the quarter, global sales of the coronary stent system (within Interventional Cardiology) were $277 million, down 8.9% due to disappointing performances of drug-eluting stents that slipped 7.4% to $262 million as well as bare-metal stents that plunged 28.6% to $15 million.
Despite relatively stable U.S. DES share, both sequentially and year over year, sales in the U.S. market declined 13.8% year over year to $106 million during the quarter. DES sales in the international market dropped 2.5% to $156 million as growth in emerging markets was offset by loss of sales in Germany. We note that the negative impact of the OrbusNeich injunction hampered the company's sales in Germany during the quarter.
The company's DES business in the U.S. has been struggling due to several headwinds - lower pricing, softness in percutaneous interventional volume and share losses following the launch of Medtronic 's ( MDT ) Resolute Integrity stent.
Given the several headwinds currently at play, Boston Scientific continues to focus on strategic initiatives to drive growth and profitability. These include strengthening its portfolio, targeting suitable acquisitions in areas of unmet medical needs and focusing on emerging markets. We also note that the company is working on penetrating its Element platform in emerging markets, including India, Brazil and China, and expects this to continue to accelerate growth through the current fiscal. We expect these factors to benefit the company over the long term.
Boston Scientific now carries a Zacks Rank #2 (Buy). Other better-ranked medical device stocks include AngioDynamics Inc. ( ANGO ) and CryoLife Inc. ( CRY ). Both these stocks hold the same Zacks Rank as BSX.
ANGIODYNAMICS (ANGO): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
CRYOLIFE INC (CRY): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Boston Scientific Corporation ( BSX ) made a major breakthrough with its receipt of the U.S. Food and Drug Administration's (FDA) go-ahead for its new drug-eluting stent (DES) system, designed to treat coronary heart diseases. The company's DES business in the U.S. has been struggling due to several headwinds - lower pricing, softness in percutaneous interventional volume and share losses following the launch of Medtronic 's ( MDT ) Resolute Integrity stent. Despite relatively stable U.S. DES share, both sequentially and year over year, sales in the U.S. market declined 13.8% year over year to $106 million during the quarter.
|
Despite relatively stable U.S. DES share, both sequentially and year over year, sales in the U.S. market declined 13.8% year over year to $106 million during the quarter. Boston Scientific Corporation ( BSX ) made a major breakthrough with its receipt of the U.S. Food and Drug Administration's (FDA) go-ahead for its new drug-eluting stent (DES) system, designed to treat coronary heart diseases. DES sales in the international market dropped 2.5% to $156 million as growth in emerging markets was offset by loss of sales in Germany.
|
Boston Scientific Corporation ( BSX ) made a major breakthrough with its receipt of the U.S. Food and Drug Administration's (FDA) go-ahead for its new drug-eluting stent (DES) system, designed to treat coronary heart diseases. Despite relatively stable U.S. DES share, both sequentially and year over year, sales in the U.S. market declined 13.8% year over year to $106 million during the quarter. DES sales in the international market dropped 2.5% to $156 million as growth in emerging markets was offset by loss of sales in Germany.
|
DES sales in the international market dropped 2.5% to $156 million as growth in emerging markets was offset by loss of sales in Germany. Boston Scientific Corporation ( BSX ) made a major breakthrough with its receipt of the U.S. Food and Drug Administration's (FDA) go-ahead for its new drug-eluting stent (DES) system, designed to treat coronary heart diseases. Despite relatively stable U.S. DES share, both sequentially and year over year, sales in the U.S. market declined 13.8% year over year to $106 million during the quarter.
|
8fb16648-c296-458b-954a-7141347b9e60
|
728496.0
|
2013-11-26 00:00:00 UTC
|
TAL International Group, Inc. (TAL) Ex-Dividend Date Scheduled for November 27, 2013
|
DES
|
https://www.nasdaq.com/articles/tal-international-group-inc-tal-ex-dividend-date-scheduled-november-27-2013-2013-11-26
|
nan
|
nan
|
TAL International Group, Inc. ( TAL ) will begin trading ex-dividend on November 27, 2013. A cash dividend payment of $0.7 per share is scheduled to be paid on December 23, 2013. Shareholders who purchased TAL stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 2.94% increase over the prior quarter. At the current stock price of $55.56, the dividend yield is 5.04%.
The previous trading day's last sale of TAL was $55.56, representing a -0.13% decrease from the 52 week high of $55.63 and a 78.19% increase over the 52 week low of $31.18.
TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and ADT Corporation ( ADT ). TAL's current earnings per share, an indicator of a company's profitability, is $4.36. Zacks Investment Research reports TAL's forecasted earnings growth in 2013 as 6.51%, compared to an industry average of 6.9%.
For more information on the declaration, record and payment dates, visit the TAL Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to TAL through an Exchange Traded Fund [ETF]?
The following ETF(s) have TAL as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES ).
The top-performing ETF of this group is DES with an increase of 10.78% over the last 100 days. It also has the highest percent weighting of TAL at 1.01%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and ADT Corporation ( ADT ). The following ETF(s) have TAL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 10.78% over the last 100 days.
|
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and ADT Corporation ( ADT ). The following ETF(s) have TAL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and ADT Corporation ( ADT ). The following ETF(s) have TAL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ). The top-performing ETF of this group is DES with an increase of 10.78% over the last 100 days.
|
The top-performing ETF of this group is DES with an increase of 10.78% over the last 100 days. TAL is a part of the Technology sector, which includes companies such as Paychex, Inc. ( PAYX ) and ADT Corporation ( ADT ). The following ETF(s) have TAL as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ).
|
f103b7a7-47e8-41d6-9e24-aa323f73eb4a
|
728497.0
|
2013-11-25 00:00:00 UTC
|
Lexmark International, Inc. (LXK) Ex-Dividend Date Scheduled for November 26, 2013
|
DES
|
https://www.nasdaq.com/articles/lexmark-international-inc-lxk-ex-dividend-date-scheduled-november-26-2013-2013-11-25
|
nan
|
nan
|
Lexmark International, Inc. ( LXK ) will begin trading ex-dividend on November 26, 2013. A cash dividend payment of $0.3 per share is scheduled to be paid on December 13, 2013. Shareholders who purchased LXK stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 7th quarter that LXK has paid the same dividend. At the current stock price of $36.22, the dividend yield is 3.31%.
The previous trading day's last sale of LXK was $36.22, representing a -12.62% decrease from the 52 week high of $41.45 and a 67.3% increase over the 52 week low of $21.65.
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). LXK's current earnings per share, an indicator of a company's profitability, is $2.48. Zacks Investment Research reports LXK's forecasted earnings growth in 2013 as 10.34%, compared to an industry average of 1.3%.
For more information on the declaration, record and payment dates, visit the LXK Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to LXK through an Exchange Traded Fund [ETF]?
The following ETF(s) have LXK as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES )
First Trust Mid Cap Value AlphaDEX Fund ( FNK ).
The top-performing ETF of this group is FNK with an increase of 14.7% over the last 100 days. DES has the highest percent weighting of LXK at 1.05%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust Mid Cap Value AlphaDEX Fund ( FNK ). DES has the highest percent weighting of LXK at 1.05%.
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust Mid Cap Value AlphaDEX Fund ( FNK ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ).
|
The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust Mid Cap Value AlphaDEX Fund ( FNK ). LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). DES has the highest percent weighting of LXK at 1.05%.
|
LXK is a part of the Technology sector, which includes companies such as Apple Inc. ( AAPL ) and International Business Machines Corporation ( IBM ). The following ETF(s) have LXK as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust Mid Cap Value AlphaDEX Fund ( FNK ). DES has the highest percent weighting of LXK at 1.05%.
|
ffcd93e6-adc2-4596-8303-0364cb48e4fe
|
728498.0
|
2013-11-11 00:00:00 UTC
|
R.R. Donnelley & Sons Company (RRD) Ex-Dividend Date Scheduled for November 12, 2013
|
DES
|
https://www.nasdaq.com/articles/rr-donnelley-sons-company-rrd-ex-dividend-date-scheduled-november-12-2013-2013-11-11
|
nan
|
nan
|
R.R. Donnelley & Sons Company ( RRD ) will begin trading ex-dividend on November 12, 2013. A cash dividend payment of $0.26 per share is scheduled to be paid on December 02, 2013. Shareholders who purchased RRD stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 42nd quarter that RRD has paid the same dividend. At the current stock price of $17.02, the dividend yield is 6.11%.
The previous trading day's last sale of RRD was $17.02, representing a -12.34% decrease from the 52 week high of $19.42 and a 105.06% increase over the 52 week low of $8.30.
RRD is a part of the Miscellaneous sector, which includes companies such as Thomson Reuters Corp ( TRI ) and Reed Elsevier PLC ( RUK ). RRD's current earnings per share, an indicator of a company's profitability, is -$4.11. Zacks Investment Research reports RRD's forecasted earnings growth in 2013 as -14.52%, compared to an industry average of 20.6%.
For more information on the declaration, record and payment dates, visit the RRD Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to RRD through an Exchange Traded Fund [ETF]?
The following ETF(s) have RRD as a top-10 holding:
WisdomTree Trust SmallCap Dividend Fund ( DES )
First Trust DJ Global Select Dividend ( FGD ).
The top-performing ETF of this group is FGD with an increase of 11.21% over the last 100 days. DES has the highest percent weighting of RRD at 3.25%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
RRD is a part of the Miscellaneous sector, which includes companies such as Thomson Reuters Corp ( TRI ) and Reed Elsevier PLC ( RUK ). The following ETF(s) have RRD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust DJ Global Select Dividend ( FGD ). DES has the highest percent weighting of RRD at 3.25%.
|
The following ETF(s) have RRD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust DJ Global Select Dividend ( FGD ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. RRD is a part of the Miscellaneous sector, which includes companies such as Thomson Reuters Corp ( TRI ) and Reed Elsevier PLC ( RUK ).
|
The following ETF(s) have RRD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust DJ Global Select Dividend ( FGD ). RRD is a part of the Miscellaneous sector, which includes companies such as Thomson Reuters Corp ( TRI ) and Reed Elsevier PLC ( RUK ). DES has the highest percent weighting of RRD at 3.25%.
|
The following ETF(s) have RRD as a top-10 holding: WisdomTree Trust SmallCap Dividend Fund ( DES ) First Trust DJ Global Select Dividend ( FGD ). RRD is a part of the Miscellaneous sector, which includes companies such as Thomson Reuters Corp ( TRI ) and Reed Elsevier PLC ( RUK ). DES has the highest percent weighting of RRD at 3.25%.
|
89f2c308-3381-4bf6-9a3f-1a320c5000f9
|
728499.0
|
2013-10-24 00:00:00 UTC
|
BSX Posts In-Line Earnings, Narrows Guidance - Analyst Blog
|
DES
|
https://www.nasdaq.com/articles/bsx-posts-in-line-earnings-narrows-guidance-analyst-blog-2013-10-24
|
nan
|
nan
|
BostonScientific ( BSX ) reported adjusted earnings per share (after considering certain one-time adjustments other than amortization expense) of 10 cents in the third quarter of 2013, in line with the year-ago adjusted EPS figure.
However, considering amortized expense adjustments, the quarter's adjusted EPS came in at 17 cents, beating the year-ago adjusted EPS by a penny. This also exceeded the company's adjusted EPS guidance range of 14-16 cents. The Zacks Consensus Estimate for the reported quarter was 17 cents.
However, without these adjustments, the company reported net loss of $5 million, or break-even EPS in the quarter, comparing favorably with year-ago net loss of $663 million or a loss of 48 cents a share.
Revenues remained flat year over year (up 4% at constant exchange rate or CER, excluding divested business) at $1.735 billion. Although the figure exceeded the Zacks Consensus Estimate of $1.729 billion, it remained within the company-provided guidance range of $1.700−$1.860 billion. The company also presented an encouraging performance in the BRIC (Brazil, Russia, India and China) nations with 28% (29% at CER) year-over-year sales growth during the quarter.
Segment Analysis
Boston Scientific currently has three global reportable segments comprising Cardiovascular, Rhythm Management and MedSurg.
The company generates maximum revenues from Cardiovascular, which comprises Interventional Cardiology and Peripheral Interventions. Sales in these sub-segments were $472 million (down 2% year over year at CER) and $195 million (up 7% at CER), respectively, during the quarter.
Global sales of coronary stent system (within Interventional Cardiology) were $277 million, down 8.9%. The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 7.4% to $262 million, and bare-metal stents that plunged 28.6% to $15 million.
The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. This segment also continued to disappoint with flat third-quarter revenues of $498 million on a year-over-year basis (up 1% at CER). Worldwide CRM revenues remained flat at $464 million.
Sales from pacemakers were down 0.7% to $134 million, while defibrillators edged up 0.9% to $330 million. Electrophysiology sales deteriorated 3% year over year (down 1% at CER) to $34 million.
Over the recent past, the company has been targeting new product launches to revive the sales of the beleaguered Interventional Cardiology and CRM segments. However, the dismal performance of these segments during the reported quarter proved beyond doubt that these measures have not been enough to counter the ongoing challenges.
Other segments like Endoscopy, Urology/Women's Health and Neuromodulation (coming under the MedSurg broader group) recorded sales of $322 million (up 8% at CER), $131 million (up 8%) and $115 million (up 32%), respectively.
Margins
Gross margin grew 277 basis points (bps) year over year to 70.6%. Adjusted operating margin however contracted 98 bps to 18.6% in the quarter. During the reported quarter, selling, general and administrative expenses grew 11.7% to $658 million, research and development expenses dropped 1.4% to $217 million and royalty expense declined 3.4% to $28 million.
Balance Sheet
Boston Scientific exited the quarter with cash and cash equivalents of $571 million, up from $207 million at the end of fiscal 2012 and had long-term debt of $4.25 billion. The company generated operating cash flow of $250 million and repurchased 6.8 million shares during the quarter under the existing share repurchase program.
Guidance
Boston Scientific provided its fourth-quarter guidance and updated its fiscal 2013 outlook. In the upcoming quarter, the company expects to report adjusted EPS of 18-20 cents (considering amortized expense adjustments) on revenues of $1.780 to $1.830 billion. The current Zacks Consensus Estimate for EPS of 20 cents coincides with the higher end of the company's outlook, although the same for revenues of $1.819 billion falls within the company's guidance.
For full year 2013, the company tightened its revenue guidance to the band of $7.085−$7.135 billion (the earlier provided range being $7.050−$7.170 billion). Adjusted EPS was narrowed to the range of 69−71 cents from 67−71 cents guided previously. The Zacks Consensus Estimate for revenues stands at $7.120 billion, while that for EPS is 70 cents.
2014 Restructuring Initiative
During theearnings call Boston Scientific also announced a restructuring program for 2014. Major actions under this plan includes continued implementation of the company's ongoing Plant Network Optimization strategy, continued focus on driving operational efficiencies and current business and commercial model changes.
The company expects this plan to reduce gross annual pre-tax operating expenses by $150−$200 million by the end of 2015. It also plans to make savings through this restructuring program, to reinvest a part of it in strategic growth initiatives. According to BSX, this will lead to around 1,100−1,500 job cuts worldwide through attrition and targeted headcount reductions. The company expects this program to be brought into effect from the fourth quarter of 2013 through 2015.
CFO Transition
In a separate press release, Boston scientific also announced that its existing executive vice president and chief financial officer Jeffrey Capello will shed off his role effective Dec 31, 2013. Daniel Brennan, currently the company's senior vice president and corporate controller, will be taking up his position thereon.
Our Take
Boston Scientific managed to beat estimates in the third quarter of 2013. However, challenging economic conditions, competitive environment, pressure on core segments and currency fluctuations remain major headwinds.
Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments, implantable cardioverter defibrillator and DES continue to face challenges.
The US defibrillator market remains an overhang for Boston Scientific and its peers. The DES business in the U.S. has been witnessing challenges due to pricing pressure, lower procedural volume, lower penetration rates and share losses from the launch of Medtronic 's ( MDT ) Resolute Integrity stent.
However, to revive its top line, Boston Scientific is focusing on strategic initiatives to drive growth and profitability. These include the recently announced restructuring initiatives, strengthening of its portfolio, targeting suitable acquisitions in areas of unmet medical needs, and focus on emerging markets. However, near-term visibility of these initiatives remains a matter of question.
Currently, Boston Scientific retains a Zacks Rank #2 (Buy). MedTech companies such as Mindray Medical International Ltd ( MR ) and Bio-Rad Laboratories, Inc. ( BIO ), which carry a Zacks Rank #1 (Strong Buy), are also worth considering.
BIO-RAD LABS -A (BIO): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
MINDRAY MEDICAL (MR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
|
Despite several initiatives undertaken by the company to revive its top line, we remain cautious as its core segments, implantable cardioverter defibrillator and DES continue to face challenges. The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 7.4% to $262 million, and bare-metal stents that plunged 28.6% to $15 million. The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology.
|
The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 7.4% to $262 million, and bare-metal stents that plunged 28.6% to $15 million. The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. The current Zacks Consensus Estimate for EPS of 20 cents coincides with the higher end of the company's outlook, although the same for revenues of $1.819 billion falls within the company's guidance.
|
The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 7.4% to $262 million, and bare-metal stents that plunged 28.6% to $15 million. The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. The current Zacks Consensus Estimate for EPS of 20 cents coincides with the higher end of the company's outlook, although the same for revenues of $1.819 billion falls within the company's guidance.
|
The downfall was owing to a disappointing performance from drug-eluting stents (DES) that declined 7.4% to $262 million, and bare-metal stents that plunged 28.6% to $15 million. The next biggest contributor to Boston Scientific's top line is Rhythm Management, which includes Cardiac Rhythm Management (CRM) and Electrophysiology. The current Zacks Consensus Estimate for EPS of 20 cents coincides with the higher end of the company's outlook, although the same for revenues of $1.819 billion falls within the company's guidance.
|
b5c9b0f9-4054-4286-9768-25db01e47f4d
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.